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Abstract 
 
Chronic pain is one of the most significant medical and scientific challenges 
in western society today. As well as the emotional and physical effects on the 
individual it proves to be a significant financial burden to society. Studies 
have shown that chronic pain leads to central sensitisation that is partially 
regulated by release of proinflammatory molecules within the CNS. Most 
work has concentrated on the role of the spinal cord and little is known about 
changes in supraspinal regions. The CFA footpad model was used to 
investigate the expression of inflammatory mediators in the brain in persistent 
inflammatory pain. 
 
Using RT-PCR, gene expression of inflammatory mediators was measured in 
various brain regions. Consistent with previous reports at 7 and 14 days post-
injection IL1β expression was significantly elevated in the posterior of the 
brain (p<0.05), TNFα showed differential expression with a significant 
increase in the posterior ipsilateral brain region at 72 hours (p<0.05). The 
chemokine CXCL1 was significantly elevated at 6 hours post-injection 
(p<0.05) suggesting a role for this chemokine in regulation of the acute pain 
response. Contrary to evidence from the spinal cord, CX3CL1 and its 
receptor CX3CR1 were down regulated in the brain at 6 and 24 hours post-
injection. Differential expression of astrocyte activation was identified by 
GFAP immunochemistry. 
 
Hypoxia has been implicated in neurodegeneration, a process thought to play 
a role in chronic pain. Here Hypoxia inducible factor (Hif1α) mRNA 
expression within the brain was not altered in a CFA model of peripheral 
inflammation. Interestingly, using Hypoxyprobe immunohistochemistry, a 
higher level of hypoxia was identified in non-injected controls than in CFA 
treated animals.  
 
This is the first evidence of differential chemokine expression in the brain in 
persistent inflammatory pain and the first study to suggest a potential role for 
differential oxygenation within the brain in this condition. 
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Chapter 1 
 
1 Introduction: Pain Mechanisms 
 
Pain is defined by the International Association for the Study of Pain (IASP) 
as “An unpleasant sensory and emotional experience associated with actual 
or potential tissue damage, or described in terms of such damage.” (Merskey 
and Bogduk, 1994). This definition goes some way to describe the complexity 
of pain, it is not merely a physical response to tissue damage, and it is a 
complex experience involving both sensory and emotional systems. These 
two components of pain are termed “sensory-discriminative” and 
“motivational-affective”, the former being the sensory and temporally 
descriptive response and the latter the emotional psychological side of the 
pain response, the element that makes pain “unpleasant and not just another 
sensation" (Melzack and Casey, 1968). These two components are both 
required for a sensation to be felt as pain and one can significantly impact on 
the strength of the other. 
 
Although pain is useful, warning of potential damage or encouraging the 
protection of already damaged tissue to allow healing, it can also occur 
seemingly unnecessarily or persist long after damaged tissue has healed. 
The IASP definition of chronic pain is “Pain that persists beyond normal 
tissue healing time, which is assumed to be 3 months”. (Merskey and 
Bogduk, 1994). As well as conditions encompassed by this definition chronic 
pain can often result for no apparent reason. 
 
Chronic pain affects 17-40% of the general population at some time and 
about 90% of cancer patients (Elliott, Smith et al. 1999; Blyth, March et al. 
2001; Eriksen, Jensen et al. 2003; Jakobsson 2010). It therefore represents a 
significant medical and financial burden with many sufferers having to take a 
substantial amount of time off work. The existence of chronic pain and the 
significant differences between it and the acute pain response indicate the 
complexity of the somatosensory system. It is clear that nociception is not a 
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hardwired process, but a plastic one, wherein the nervous system can 
change and evolve in ways which are not always beneficial. 
 
The classical understanding of the pain pathway involves a single three 
neuron chain, it is now known that the system is more complicated than this 
and involves at least two pathways at each level. These pathways are 
thought to control two different pain responses, the “first pain” which is 
usually a sharp pain occurring almost immediately after the stimulus and the 
“second pain” which is felt more slowly and tends to be a burning and less 
specifically localised sensation. As stated above, these two physical 
sensations can be described in terms of the “sensory-discriminative” and 
“affective-motivational” responses and will be discussed in further detail in 
the following chapters. It has been suggested that pain is not a physical 
perception at all but more an affectation or motivation to act, to protect 
already damaged tissue or to remove oneself from a potentially dangerous 
situation; a finger in a candle flame will start to hurt some time before there is 
any physical damage to the tissue. 
 
1.1 PNS Processing of Noxious Stimuli 
 
1.1.1 Nociceptive Nerve Fibres 
 
Nerves make up the “communication system” within the mammalian body, 
they are defined as either afferent or efferent; the former carrying information 
from the body to the CNS and the latter from the CNS to the body. Nerves 
are composed of a bundle of axons of varying size and structure which are 
specialised in carrying specific types of information; motor neurons are 
examples of efferent fibres and sensory neurons of afferent. 
 
Primary afferent nerves which respond to painful or noxious stimuli are found 
throughout the body, particularly in the skin. These sensory afferents are 
known as nociceptors and activation of these receptors results in 
depolarisation of sensory neurons signalling damage to the CNS and 
resulting in a painful sensation. Nociceptive neurons differ from the accepted 
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physiology of a “normal” neuron in that they can send and receive impulses 
in both directions. A standard neuron receives input at the dendrite and 
transmits information from its biochemically distinct axon, whereas, a 
nociceptive neuron can send and receive messages at either the peripheral 
end or the central terminus within the spinal cord. Nociceptive neurons are 
also unusual in that the cell body is contained outwith the axon in the dorsal 
root ganglion (DRG) of the spinal cord (or the trigeminal ganglion in the case 
of the face), proteins synthesised here are transported to both the peripheral 
and central terminals of the nociceptor, see figure 1. This bi-directionality 
means that, although the peripheral terminal is typically excited by the 
external stimulus and then sends a message to the central spinal terminal; 
both axonal and dendritic terminals can be regulated by endogenous and 
exogenous modulators. 
 
Figure 1 Diagram comparing a basic sensory neuron (right) with a “textbook” 
neuron such as a motor neuron (left). The standard neuron is unidirectional, 
information is received by the dendrites and transmitted to the biochemically distinct 
axon terminus where proteins synthesised in the cell body are released. In contrast 
sensory neurons are bi-directional, receiving and transmitting information from either 
terminal. Proteins synthesised in the cell body, located in the DRG, can be released 
from either terminal. 
 
Nociceptors are made up of three types of axon; C-fibres with small diameter 
(0.2-1.5µm) unmyelinated axons which conduct nerve impulses relatively 
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slowly (<2m/s), medium diameter (5-30 µm) myelinated Aδ fibres conducting 
much faster at around 12 m/s, and finally large diameter (~10μm) Aβ fibres 
which are also myelinated and conduct at speeds of up to 80m/s, see figure 
2. 
 
Figure 2 The most common sensory fibres. Aβ fibres are large diameter (6-
12µm), myelinated axons carrying impulses at speeds of 35-75m/s, Aδ fibres are 
medium diameter neurons (5-30μm) carrying impulses at the slightly slower speed 
of 5-30m/s. These fibres are involved the faster first pain and mechanosensation. C-
fibres are much smaller in diameter (0.2-1.5μm) and transmit impulses at slower 
speeds (0.5-2m/s); they are associated with slow burning pain and itch. 
 
The term “nociceptors” is something of a misnomer since the fibres described 
above do not only regulate painful sensations, some are pruriceptors 
mediating itch, others respond to innocuous temperatures and, recently, a 
subgroup of C-fibres has been identified that appears to mediate pleasant 
touch (Johansson et al., 1988, Olausson et al., 2010). In tissue injury and 
chronic pain some of these fibres regulating innocuous touch become 
hypersensitive to a variety of stimuli and contribute to the pain sensation, this 
has led to the term “silent nociceptor”. 
 
Receptors exist for the transduction of many types of noxious stimuli; ion 
channels have been identified that open at specific temperatures or in 
response to mechanical or chemical stimulation. Nociceptors are polymodal; 
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they often express a variety of receptors and as such can respond to more 
than one stimulus. They also show heterogeneity in signalling mechanisms. 
Together this enables the encoding of multiple complex sensory stimuli into 
the incredible variety of sensations felt as pain. 
 
Early studies used pinch to locate the receptive fields of nociceptors. 
However this method resulted in a subset of nociceptive neurons being 
ignored since not all nociceptors are mechanosensitive and, of those that 
are, many have very high thresholds. More recent studies using electrical 
stimulation to identify nociceptive fields in the cutaneous skin of monkeys and 
rats have demonstrated that approximately 50% of Aδ fibres and 30% of C-
fibres are mechanically insensitive afferents (MIAs) (Meyer et al., 1991, 
Handwerker et al., 1991) where MIAs were unresponsive to mechanical 
stimuli under 600g/mm2.  
 
1.1.1.1 C-fibres 
 
C-fibres, which primarily mediate the sensation of burning pain, are an 
example of the polymodality of nociceptors most of them responding to both 
heat and a variety of chemical stimuli. These fibres are generally excited by 
temperatures in the range of 39-41ºC which corresponds to the human pain 
threshold to noxious heat (LaMotte and Campbell, 1978, Tillman et al., 1995) 
and the activation temperature of the transient receptor potential vanilloid 
cation channel 1 (TRPV1 see 1.1.4.1) receptor (Caterina et al., 1997) which 
is also activated by protons and the chemical capsaicin; TRPV1 and related 
receptors are discussed in more detail later in this chapter. 
 
A subset of MIA C-fibres have been demonstrated to be involved in the 
regulation of itch, a process which shares many of the same pathways as 
nociception, and are excited by histamine, resulting in the characteristic 
inflammatory “wheal and flare” response (Schmelz et al., 1997). There is 
significant evidence for an alternative subset of primary afferent pruriceptors 
since itch can be induced by mechanical and electrical stimulation (Ikoma et 
al., 2005, Von Frey, 1922, Shelley and Arthur, 1957) as well as in response 
 20 
to certain medications. Recently a seemingly non-inflammatory, itch 
mechanism has been identified where pruritogens, such as cowhage spicules 
from the Mucuna pruriens plant, directly activate C-fibres leading to an itch 
response with no flare (Schmelz, 2010, Johanek et al., 2008, Namer et al., 
2008). 
 
Another subset of C-fibres are activated by low-threshold mechanical 
stimulation which activate the insular, but not the somatosensory, cortex and 
are thought to be involved in mediating the sensation of pleasant touch 
(Johansson et al., 1988, Olausson et al., 2010). The discovery of these fibres 
is interesting as for many years mechanical stimulation was mainly 
considered to be mediated by Aβ-fibres and Aδ-fibres. The slow response of 
C-fibres and the activation of the insular cortex and limbic system by these 
mechanoreceptors indicates that they may have an affective/emotional role in 
the regulation of innocuous touch. It is possible that pleasant touch may have 
two functional responses as described for pain, via a sensory-discriminative 
and affective-motivational pathway (McGlone and Reilly, 2010). 
 
Although C-fibres appear to have a limited role in mechanical pain a subset 
of generally MIA C-fibres appear to develop a response to mechanical stimuli 
following persistent mechanical stimulation suggesting they may have a role 
in regulating pain in response to tonic pressure. As mentioned previously C-
fibres which only respond to very high pressures are also considered to be 
mechanically insensitive; such fibres may have a role in pain where their 
threshold of activation may be decreased by endogenous modulators 
(Basbaum et al., 2009). 
 
1.1.1.2 A-fibres 
 
A-fibres are generally considered to mediate the pricking and sharp pain felt 
immediately after peripheral insult. They provide a faster more precise signal 
than C-fibres and are also thought to contribute to aching pain (Slugg et al., 
2000). The A-fibres are divided into two groups; type-I and type-II. Briefly, 
type-I fibres are sensitive to mechanical and chemical stimuli as well as 
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noxious heat in the higher range of noxious temperature (>53°C) as 
regulated by TRPV2 (Caterina et al., 1999). Two types of fibre make up the 
type-I group, Aδ and Aβ fibres making this group the fastest conducting with 
speeds of 25-55m/s (McGlone and Reilly, 2010).  
 
Type II fibres lay undiscovered for some time due to the fact that most of 
them are MIAs. Using an electrical stimulus as opposed to a pinch test to 
locate afferents demonstrated that there are roughly equal numbers of Type I 
and II fibres in non-glabrous primate skin. Type I fibres have similar 
properties to C-fibres in that they have a similar response to heat and may 
express the TRPV1 receptor. Since they are only thinly myelinated, type II 
fibres have relatively low conduction velocities, around 15m/s, compared to 
their type I counterparts (Treede et al., 1995). 
 
1.1.2 Sensory Neurotransmitters 
 
The predominant excitatory neurotransmitter used by all primary afferent 
fibres including nociceptive neurons is glutamate, although other transmitters 
also have a role in transmission and modulating excitability. As well as 
delivering information from the periphery to the CNS, primary afferent 
neurons release neurotransmitters within their peripheral locality where they 
have a significant role in neurogenic inflammation via the release of 
substance P and calcitonin gene related peptide (CGRP). A significant 
number of small fibre neurons, thought to be C-fibres, release such 
neuropeptides, not only in the periphery but also centrally, within the dorsal 
horn on stimulation where their action on postsynaptic receptors plays a key 
role in setting the magnitude of response of second order neurons (Basbaum 
et al., 2009). 
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1.1.3 Ion Channels 
 
1.1.3.1 Voltage Gated Ion Channels 
 
Following detection of a sensation in the periphery the signal must be 
propagated along the axon to the spinal cord, this signal takes the form of an 
action potential which is mediated by voltage gated ion channels (VGCs). 
Such channels regulate nerve impulses throughout the PNS and CNS and 
although some are ubiquitous, others are specific to a certain kind of neuron 
of sensory modality. VGCs have been identified that are specific to and play 
significant roles in nociceptive neurons, providing a greater understanding of 
the mechanisms of pain regulation and potential targets for medication. 
 
1.1.3.2 Sodium Channels 
 
Nine different types of voltage sensitive sodium channel have been identified 
in mammals and sensory neurons express six of these at relatively high 
levels (Ekberg and Adams, 2006) Voltage gated sodium channels consist of 
a single α subunit made up of four membrane spanning domains which form 
the sodium specific pore; various β subunits and accessory proteins form the 
remainder of the channel and can contribute to its properties. It is by these α 
subunits that the nine classes of sodium channel are classified as Nav1.1 – 
Nav1.9 (Goldin et al., 2000). Sodium channels are also classified according to 
their susceptibility to blocking by the neurotoxin tetrodotoxin (TTX) with 
Nav1.5, Nav1.8 and Nav1.9 being TTX resistant while the remainder are 
irreversibly blocked following exposure. 
 
Using electrophysiology sensory neurons have been shown to express both 
TTX-sensitive and TTX-resistant Nav channels and the former have been 
demonstrated to be a prerequisite for action potential firing in most, if not all, 
of these neurons (Ritter and Mendell, 1992). 
 
The action potential of sensory neurons differs from the “standard” action 
potential shape by having an extended shoulder in the depolarising phase. 
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This alters the electrophysiological properties of the neuron, such that, the 
falling phase is extended and the neuron takes longer to repolarise, resulting 
in longer lasting irregular action potentials (Koltzenburg et al., 1997). Voltage 
gated sodium channels (VGSC) have been demonstrated to be significant in 
the regulation of this unusual action potential and specific channel isoforms 
are required for each phase of the response. 
 
Following immunohistochemical and electrophysiological analysis, the 
specific Nav channel subtypes necessary for nociceptive function have been 
identified. As mentioned above, TTX-sensitive fibres are essential for action 
potential generation in all sensory neurons in nociceptive fibres; the channels 
demonstrated to have a significant role are Nav1.6 in myelinated axons and 
Nav 1.7 in unmyelinated nerves. The TTX-resistant channels, although non-
essential for action potential generation, are vital in defining the specific 
electrophysiological properties of the nociceptive neuron (Caldwell et al., 
2000, Djouhri et al., 2003b). Of the TTX-resistant channels Nav1.8 and 
Nav1.9 have been demonstrated to be expressed in most, if not all 
nociceptors and Nav1.9 is specific to nociceptive neurons (Djouhri et al., 
2003a, Fang et al., 2002). 
 
The absence of specific antagonists for a large number of VGSCs and the 
ubiquitous nature of others has made their study difficult. However, gene 
deletion studies in mice have enabled the identification of three genes 
encoding for specific sodium channels which are expressed in sensory 
neurons. SCN10A and SCN11A are nociceptor specific genes encoding the 
Nav1.9 and Nav1.8 channel α subunits respectively. The third gene to be 
identified in nociceptors is SCN9A which encodes the Nav1.7 channel α 
subunit (Foulkes and Wood, 2008). 
 
The specific kinetic properties of Nav1.8 and Nav1.9 are the driving force 
behind the distinctive electrophysiological fingerprint of the nociceptive 
neuron. Nav1.9, unusually for a VGSC, opens at negative membrane 
potentials (~ -80mV) and remains open for a considerable time as the 
membrane potential increases then rapidly closes after the action potential 
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peak. This provides a small but persistent current at resting membrane 
potential enabling faster depolarisation of the neuron on stimulation (Herzog 
et al., 2001).  
 
Nav1.9 alone cannot explain the classical TTX-resistant current seen in 
sensory neurons as this is activated at a positive voltage and inactivates 
relatively slowly. This points to Nav1.8 as the other TTX-resistant VGSC 
expressed in nociceptors and indeed this channel has been demonstrated to 
be key in the nociceptive response following the generation of mice lacking 
Nav1.8 gene (Nav1.8 -/-) (Akopian et al., 1999). The sensory neurons from 
the DRG of these mice expressed only rapidly activating and inactivating 
TTX-resistant currents and no slow VGSC currents were seen in DRG 
neurons from these animals and although these mice displayed normal 
physical characteristics they had decreased behavioural responses to both 
mechanical and thermal noxious stimuli and a delayed response to 
inflammatory hyperalgesia induced by carrageenan injection. 
 
Sodium channels play a key role in setting neuronal excitability and their 
expression in peripheral nerves is often altered in pain states. Following 
experimental neuroma generation only 0.4% saphenous nerves from Nav1.8 
k.o. mice exhibited ectopic firing compared to 19% of wild type counterparts 
(Roza et al., 2003). The Nav1.8 k.o. mice also showed reduced 
mechanosensitivity in the early stages of the experiment (up to 10 days) 
which returned to normal by day 22 clearly implicating the Nav1.8 channel in 
the development and propagation of neuropathic pain. This demonstrates the 
plasticity of distribution of these channels and how trafficking of receptor and 
channel proteins may contribute to pain states. 
 
In neuropathic injury and chronic pain conditions abnormal trafficking of 
channel proteins may lead to accumulation of sodium channels not only in 
the affected nerve but also in healthy neighbouring neurons. This increase in 
excitatory sodium channels will lead to a decreased activation threshold of 
the nerves local to the damaged resulting in an increase in the likelihood of 
ectopic firing, this signal propagation may contribute to central sensitisation. 
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Sodium channels have also been implicated in human pain conditions. 
Perhaps the best understood of these is familial erythromelalgia, a disorder 
affecting the peripheral neurovasculature leading to inflammation and pain, 
which is caused by a gain of function mutation in the SCN9A gene which 
codes for the α-subunit of Nav1.7 (Cummins et al., 2004). Conversely a loss 
of function mutation in humans results in an apparently normal phenotype 
except that these individuals cannot feel pain, a condition that can lead to 
serious or even life threatening injury (Cox et al., 2006). Interestingly, global 
deletion of the SCN9A gene in mice causes them to die shortly after birth, 
apparently due to problems feeding, probably caused by loss of function of 
the sensory neurons (Nassar et al., 2004). 
 
1.1.3.3 Calcium Channels 
 
Voltage gated calcium channels (VGCCs) act as translators of a message 
from one cell to the next, they open following depolarisation of the membrane 
allowing a massive intracellular calcium influx. This influx results in the 
contraction of muscle or release of hormones, neurotransmitters or other 
ligands from neurons. VGCCs contribute to increased nociceptive input from 
the periphery in both neuropathic and inflammatory pain, their role in 
neurotransmitter release at the first synapse means they are vital in the 
transmission of pain information from the periphery to the CNS. As well as 
signalling information from the periphery to the CNS and local motor circuits 
calcium release is also involved in descending regulation from the brain, a 
process that will be discussed in greater detail in Chapter 2. 
 
There are a large variety of VGCCs, many of which have a significant role in 
neuronal function. They are divided into five subtypes; L, N, P, R and T, with 
N, P and R groups implicated in neurotransmission (Tsien et al., 1995). Of 
these N and P type channels are implicated in painful conditions, the former 
in severe persistent pain and the latter in migraine (Julius and Basbaum, 
2001). Subtype T VGCCs are also involved in neuronal function where they 
play a role in the electrophysical properties of neurons. The L-type VGCCs 
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regulate muscle contraction as well as neuronal plasticity and gene 
regulation (Basbaum et al., 2009). 
 
The individual subtypes of VGCC are differentially distributed throughout the 
body and N-type VGCC have been demonstrated to be critical for the 
majority of fast neurotransmission within sensory neurons (Gruner and Silva, 
1994). N-type VGCC are largely present in the PNS and play a less 
significant role in the CNS, within sensory neurons significantly more of them 
are found in the smaller sensory neurons which are likely to be nociceptors 
(Cardenas et al., 1995). This fairly specific distribution of N-type VGCCs 
makes them excellent targets for analgesic drugs. Inhibitors have been 
shown to relieve severe pain in humans, and to relieve allodynia in a rat 
neuropathic pain model, without having any effect on acute pain (Scott et al., 
2002). The analgesic effects of opiates are due to mu opioid receptor 
activation having an inhibitory effect on N-type VGCCs (Schroeder et al., 
1991). However, due to the presence of some N-type VGCCs in the CNS 
higher doses of drugs targeting these channels can have unpleasant side 
effects such as nausea, disorientation, hallucination and agitation, requiring 
dosage to be carefully monitored (Penn and Paice, 2000). 
 
1.1.3.4 Voltage Gated Potassium Channels 
 
Voltage-Gated Potassium Channels (VGKC) are not vital for the action 
potential in sensory neurons but play a role in the properties or “shape” of it. 
When opened, VGKC take the membrane potential towards that of 
potassium, resulting in a decrease in excitability, making them a potential 
regulator of hyperexcitability in hyperalgesia. There is a vast variety of VGKC 
but they can be loosely categorised according to the number of 
transmembrane domains they possess. The classic VGKC has 6 
transmembrane domains and it is in one of nine subgroups, these channels 
are often known as delayed rectifiers, as they alter the potassium current with 
a small delay after voltage activated opening (Gutman et al., 2003). Of 
particular interest in pain is Kv1.4 which has been shown, by 
immunohistochemistry, to be expressed in small diameter neurons that also 
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express NaV1.8 (Rasband et al., 2001). This evidence, in combination with 
electrical physiological properties of this channel, makes it a candidate for a 
delayed rectifier in nociceptive neurons. 
 
The two other structural classes of VGKCs have either two or four membrane 
domains, the former are inward rectifiers that are constitutively open and 
determine the resting membrane potential. Little is known about the four-
transmembrane VGKC, although, interestingly, there is some evidence for 
their regulation by acidity in the gut (Holzer, 2003); further research may 
show that these channels play a key role in nociception. 
 
There are also potassium channels that are gated by factors other than 
voltage. Within the six transmembrane groups, two channels have been 
documented that play a key role in excitability. These M and H channels 
regulate resting membrane potential in response to regulation by G-protein 
coupled receptors. M channels are present on sensory neurons where they 
can be opened via activation of muscarinic acetylcholine or peptide 
stimulated GPCRs (Jentsch, 2000) this suggests they may play a role in pain 
regulation an idea that has been supported by Passmore et al (2003) who 
demonstrated that inhibiting M channels leads to a significant decrease in 
hyperalgesia in rats following intraplantar carrageenan injection. 
 
1.1.4 Sensory Receptors 
 
1.1.4.1 Transient Receptor Potential Cation Channels 
 
A family of channels called transient receptor potential cation channels (TRP) 
includes many of the temperature sensitive channels that are all in the 
Vanilloid subgroup (TRPV). Perhaps the best documented of these channels 
is TRPV1, a cation specific channel expressed in sensor neurons and 
activated both by heat and capsaicin, a chemical found in hot chilli peppers. 
TRPV2 and TRPV4 have also been demonstrated to be activated at noxious 
temperatures (Tominaga and Caterina, 2004, Green, 2004). 
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There are also channels activated at cooler temperatures for example 
TRPM8 (the metastatin subgroup), which is also activated by menthol and 
TRPA1 (containing ankyrin repeats) a receptor sensitive to both cold and 
mechanical stimulation. Cold pain differs from pain caused by heat in that the 
threshold of cold nociceptors is much further from normal mammalian body 
temperature. All A-fibres respond to temperatures below 0°C and cold 
sensation is generally mediated by Aδ fibres that have a tonic baseline 
activity at room temperature and demonstrate a significant increase in firing 
on cooling (Tominaga and Caterina, 2004, Green, 2004).  
 
The TRPA1 receptor has an activation threshold of 17.5°C and has been 
found to colocalise with receptors responding to heat and capsaicin, 
suggesting a role for this receptor in the burning sensation associated with 
some cold pain (Story et al., 2003). Some TRP channels can also be 
regulated by endogenous mediators; TRPV1, for example, is activated by 
protons and TRPV2 and TRPV4 by cell volume. Along with capsaicin many 
other exogenous substances can modulate TRP channels leading to burning 
(e.g. alicin) or cooling sensations (e.g. menthol). The properties of the major 
TRP channels are summarised in Table 1.  
 
1.1.4.2 Acid-Sensing Ion Channels 
 
Acidosis is a common sign of tissue damage and inflammation and, as 
previously mentioned, TRPV1 can be activated by protons. However, the 
proton activation threshold of this channel is relatively high by which point 
irreparable damage may have occurred. Acid-sensing ion channels (ASIC) 
are activated at much lower proton concentrations and have been 
demonstrated to play a key role in pain sensation. ASICs are members of the 
voltage-insensitive, amelioride-sensitive epithelial Na+ channel/degenerin 
family of cation channels and are encoded by three different genes ASIC1, 
ASIC2 (BCN1) and ASIC3 (DRASIC) (Foulkes and Wood, 2008). An 
individual channel is formed by two subunits which may be hetero or 
homomeric, ASICs 1 and 2 have two splice variants each adding to the 
potential functional differences. 
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Channel Activation 
Temp 
Endogenous 
Modulators 
Exogenous 
Modulators 
Tissue  
Distribution 
TRPV1 
(VR1) 
>43°C Protons 
Anandamide 
 
Capsaicin (chilli) 
Allicin (garlic) 
Piperine 
(black pepper) 
Camphor 
Sensory neurons 
Bladder 
TRPV2 
(VRL-1) 
>52°C Cell volume  Sensory neurons 
Brain 
Bladder 
Spleen 
TRPV3 ~31-39°C  Eugenol  
Thymol  
Carvacrol 
Camphor 
Sensory neurons 
Hypothalamic 
neurons 
Keratinocytes 
TRPV4 >27°C Cell volume  Sensory neurons 
Kidney 
Keratinocytes 
Hypothalamus 
Hair cells 
Merkel Cells 
TRPM8 
(CMR1) 
~ 8-28°C  Menthol 
Eucalyptol 
Sensory neurons 
Prostate epithelia 
TRPA1 
ANKTM1 
<17°C   Isothiocyanates  
e.g.:  
Mustard oil 
Wasabi 
Horseradish 
Sensory neurons 
 
Table 1 A summary of the most widely studied TRP channels and their 
properties. For reviews see (Jordt et al., 2003) and (Tominaga and Caterina, 2004). 
 
At least 5 subtypes of ASIC have been described, ASIC 3 is expressed in 
large and medium diameter neurons where it has been shown to have a 
transient response to stimulation by relatively mild acidosis, there is mounting 
evidence for a role for this channel in mediating cardiac pain in ischaemic 
heart disease (Immke and McCleskey, 2001a). Under normal physiological 
conditions Ca2+ blocks the pore of ASIC3, lactate released in ischaemic 
muscle has been demonstrated to sensitise this channel to acid at higher pH 
by decreasing the extracellular Ca2+ concentration (Immke and McCleskey, 
2001b).  
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1.1.4.3 Mechanoceptors 
 
Sensory neurons also express receptors that are activated by mechanical 
stimulation leading to their physical distortion by bending or stretching. Such 
receptors are present in many areas throughout the body where they play 
key roles in maintaining homeostasis through regulation of skin contraction, 
distension of digestive tracts, blood vessels and the bladder as well as 
sensing both noxious and innocuous touch. Mechanoreceptors are 
unmyelinated axon branches populated with mechanosensitive ion channels 
which open in response to changes in membrane tension. Different classes 
of nociceptive neurons mediate different forms of mechanical stimulus; Aα 
fibres regulate proprioception, Aβ fibres touch and low pressure and Aδ and 
C strong mechanical. 
 
Skin is subjected to a large variety of stimuli, which can differ in mode and 
intensity, requiring a range of mechanoreceptors sensitive to different forms 
of energy. Electrophysiological methods have been highly effective in 
locating mechanoreceptors and identifying their properties. As well as an 
immediate response to a stimulus receptors also vary in the way in which 
they respond to persistent stimuli; receptors which respond quickly but stop 
firing even if the stimulus continues are described as rapidly adapting and 
those that maintain a response during a sustained stimulus are known as 
slowly adapting. 
 
The specific receptors involved in mechanosensation are difficult to identify 
but tests can be done on isolated neurons to identify their electrophysical 
properties in response to varying mechanical stimuli, which ultimately may 
lead to identification of specific receptors. Ion channels have been identified 
in Escherichia coli bacteria, which open in response to osmotic pressure 
causing stretching of the cell envelope (Sukharev et al., 1993), and 
potassium channels have been identified in mammalian cells that may play a 
similar role. 
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Finally, channels known primarily for their role in sensing chemical stimuli 
have also been implicated in regulating the response to mechanical 
stimulation. ASIC and TRP channels have been demonstrated to respond to 
specific mechanical stimuli in electrophysiological experiments. It is also 
likely that physical deformation of cell membranes will result in the release of 
chemical messengers such as ATP that can act on specific receptors and 
also modify the excitability of other receptors (Julius and Basbaum, 2001). 
 
1.1.5 Chemical Stimuli and Sensitisation 
 
Tissue injury leads to sensitivity as a protective mechanism to prevent further 
injury and allow healing; a similar response is seen following an infectious 
insult. This sensitivity is mediated by the release of factors from both 
neuronal and non-neuronal cells. This milieu of inflammatory mediators is 
often referred to as the “inflammatory soup” (Dray, 1995, Julius and 
Basbaum, 2001). The ligands within the inflammatory soup exert their effects 
by acting directly on ion channels or indirectly via second messenger 
systems, some such as 5HT and ATP can target both. 
 
The purpose of these substances is to provide protection to the damaged 
tissue and kill off any invading infectious particles. This is achieved by 
increasing blood flow to the region via vasodilation, by increasing the influx of 
macrophages and fibroblasts to the area by chemoattraction and by 
sensitising sensory neurons to encourage protection of the damaged region 
to allow time for healing. Of primary interest here, is the effect of this soup on 
the sensitivity of nociceptors and some of the key players are discussed 
below. 
 
C-fibre activation results in the release and retrograde transport of a variety 
of inflammatory substances, including CGRP and substance P, which 
contribute to increased neuronal excitability, vasodilation and capillary 
permeability. An increase in substance P and damage to tissue results in the 
release of further mediators including K+, H+, acetylcholine, histamine and 
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bradykinin (Bk) which in turn increase the sensitivity of high threshold 
mechanoreceptors. 
 
Endogenous inflammatory mediators can mediate the nociceptive response 
by direct action on nociceptors or activation of inflammatory cells, which in 
turn release nociceptor regulating substances such as cytokines, chemokines 
and nerve growth factors. Sensitisation of nociceptors can also result in an 
increased response to baseline levels of endogenous ligands leading to 
symptoms such as hyperalgesia and allodynia. 
 
The bidirectionality of sensory axons allows the rapid spread of neurogenic 
inflammation via nerve impulses and retrograde transport of substance P to 
the periphery. This can quickly sensitise non-injured/involved neurons 
contributing to primary and secondary hyperalgesia. 
 
1.1.5.1 ATP  
 
The nucleoside, adenosine and its derivatives adenosine monophosphate 
(AMP), adenosine diphosphate (ADP) and adenosine triphosphate (ATP) are 
often released from cells, particularly platelets, following tissue injury. 
Adenosine can directly activate nociceptors and administration of it and its 
phosphates has been demonstrated to cause pain in human and animal 
models, reviewed in Hamilton and McMahon (2000). ATP mediates its effects 
via purinoceptors (P2X) expressed on peripheral and DRG neurons 
 
ATP is released by damaged cells and activated nociceptors. Sensory 
neurons express several P2x receptors whose activation leads to increased 
activity and the subsequent release of more ATP resulting in a positive 
feedback loop. Of the P2x receptors expressed, P2x3 is the most studied as 
it is specifically expressed on small diameter neurons within the dorsal root 
and trigeminal ganglia (North, 2004). 
 33 
1.1.5.2-Hydroxytryptamine (5-HT) 
 
Serotonin (5-HT) can directly activate nociceptors and potentiate pain 
initiated peripherally. Following activation by inflammatory mediators mast 
cells release platelet activating factor, which in turn results in the release of 
5-HT from platelets. 
 
5-HT can depolarise sensory neurons via direct activation of the 5-HT3 
receptor, a ligand-gated ion channel. 5-HT3 has been shown to be expressed 
by both small non-peptidergic neurons in the periphery and Gabaergic 
neurons on the dorsal horn and spinal cord, indicating a significant role for 
this receptor in pain regulation. This suggestion has been borne out by 
evidence from gene knock-out studies where mice lacking 5-HT3 
demonstrated a significant decrease in persistent pain in the setting of tissue 
injury (Zeitz et al., 2002). Moreover the same authors demonstrated that this 
5-HT-mediated effect is not due to an involvement in inflammation or oedema 
but via direct activation of a specific subgroup of non-peptidergic sensory 
neurons and activation of neurons within the CNS. 
 
1.1.5.3 Protons 
 
Acidosis often results from tissue damage, ischaemia or inflammation and 
the degree of acidosis correlates with pain and discomfort. In cultures, DRG 
neurons demonstrate both transient and sustained excitatory responses 
when exposed to acidic solutions. In similar experiments, around 50% of 
isolated C-fibres produced sustained currents (Krishtal and Pidoplichko, 
1980, Reeh and Steen, 1996). As previously mentioned, several receptors 
are implicated in mediating responses to protons including TRPV1 and 
ASICs. The TRPV1 channel can be directly activated by protons and is likely 
to play a role in the burning pain associated with acid stimulation (Bevan and 
Geppetti, 1994, Caterina and Julius, 2001). Interestingly, protons can also act 
as allosteric regulators of TRPV1, decreasing the thermal activation threshold 
to below body temperature; this latter form of regulation may be significant in 
thermal hyperalgesia as a result of tissue damage (Tominaga et al., 1998). 
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Both electrophysiological and behavioural experiments support this idea; C-
fibres or DRG neurons cultured from mice in which the TRPV1 gene has 
been deleted demonstrate significantly decreased sustained activity at pH 5 
compared with wild type and TRPV1 knock-out animals do not develop 
thermal sensitivity following inflammatory insult (Caterina et al., 2000, Davis 
et al., 2000).  
 
1.1.6 Neuropathic pain  
 
Neuropathic pain differs from pain that is the result of tissue injury or 
inflammatory insult since it occurs as a result of injury to neurons within either 
the central or peripheral nervous systems. This kind of injury can be 
associated with sensory loss but, perhaps more significantly, often results in 
an increase in stimulus evoked and spontaneous pain. Spontaneous pain 
following peripheral nerve injury is thought to result from ectopic firing of 
these nerves leading to a barrage of firing within the spinal cord. This type of 
pain, which is difficult to treat and often becomes chronic, will be discussed in 
further detail in Chapter 2. 
 
1.1.7 Drugs in the periphery 
 
NSAIDs (non-steroidal anti-inflammatory drugs) are well known for their anti-
inflammatory action via inhibition of prostaglandins (PG); they are however 
ineffective in the treatment of neurogenic inflammation which acts via the 
distinct mechanism described above. Steroids have been shown to be 
effective in some cases of neurogenic pain, their mechanisms are unknown 
although there is evidence that they act on histamine, 5-HT, Bk and PG. 
 
Local anaesthetics may prevent higher sensitisation in neuropathic pain, 
suggesting they may have significant practical applications in the prevention 
of post-operative pain. Capsaicin has also been demonstrated to have some 
effect in the treatment of neuropathic pain as it depletes substance P from 
the nerve terminals decreasing sensitivity. This treatment has been 
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particularly effective in treating neuralgia where nerve pain occurs in the 
absence of nociceptor stimulation (Woolf and Chong, 1993). 
 
Peripheral nerve damage can result in ectopic firing, where a nerve fires 
spontaneously or abnormally. Anticonvulsant drugs such as carbamazepine 
which are traditionally used to treat abnormal firing in the brain in conditions 
such as epilepsy have been used with some success in treating neuropathic 
pain in conditions such as post hepatic and trigeminal neuralgia (Cross, 
1994). 
 
Burning pain that occurs as a result of C-fibre damage can be treated with 
low-dosage local anaesthetics. Such drugs act by inhibiting sodium channel 
activation and therefore decreasing firing, since C-fibres are unmyelinated 
they are susceptible to much lower doses of anaesthetic and their myelinated 
neighbours will remain unaffected (Stracke et al., 1992). 
 
1.1.8 Hyperalgesia and Allodynia 
 
Hyperalgesia and allodynia are symptoms of both acute and chronic pain; 
they describe an increased nociceptive response to sensory stimulation. 
Hyperalgesia is an increased response to stimuli that are normally painful, 
i.e. a reduced thermal threshold leading to a burning sensation at body 
temperature, and allodynia is a painful response to normally innocuous 
stimuli i.e. light brushing of the skin. Primary hyperalgesia affects the 
damaged tissue itself and secondary hyperalgesia is increased sensitivity in 
the surrounding area. In a normal acute pain response these symptoms 
encourage increased protection of the damaged tissue to allow healing 
without further damage; however, they can become problematic where they 
persist after healing or occur where there is no apparent injury. 
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1.1.8.1 Primary hyperalgesia 
 
Heat hyperalgesia occurs as a result of sensitisation of nociceptors, there is a 
correlation between subjective pain ratings of humans following a burn injury 
and recordings from monkey nociceptors following the same injury (LaMotte 
and Campbell, 1978). The type of sensitisation seen varies greatly depending 
on the injury, the tissue type and the nociceptors involved. Primary 
mechanical hyperalgesia is loosely divided into two categories, stroking 
hyperalgesia or allodynia, where stroking with a swab elicits a painful 
response, and punctate mechanical hyperalgesia, where a pin prick stimulus 
results in an increased pain response. Stroking hyperalgesia/allodynia occurs 
as a result of sensitisation of low threshold mechanoreceptors in A-fibres and 
an increased painful response to pin-prick stimulation occurs due to 
sensitisation of C-fibres. 
 
Progressive tactile hypersensitivity may be associated with inflammation 
where inflammatory mediators increase the excitability of neurons and 
receptors in their vicinity (Ma and Woolf, 1997, Ma and Woolf, 1996b). 
Hyperalgesia and allodynia are a significant example of the plasticity of the 
nervous system due to changes in the properties of neurons and their 
receptors. These changes can occur at all levels of the nervous system and 
are specific to the type and duration of insult. 
 
In the periphery, functional diversity occurs following tissue damage leading 
to an increase in painful responses. One way in which sensitivity might be 
increased is through lowered threshold of nociceptive nerves causing them to 
respond to lower level stimuli. Heat and mechanical injury do not directly 
decrease the threshold of activation but an inflammatory insult does and, 
depending on the type and extent of burn or mechanical injury, some 
secondary inflammation may occur and contribute to primary hyperalgesia 
(Davis et al., 1993). In some cases the increase in response of nociceptors is 
not due to a decreased threshold but an increased response to 
suprathreshold stimuli (Cooper et al., 1991). An increase in the receptive field 
of individual neurons also contributes to the hyperalgesic state by leading to 
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more frequent and less specific activation. Finally, there is evidence for 
ectopic firing in nerves within damaged tissue leading to increased 
spontaneous firing in the absence of any stimulus (Djouhri et al., 2006). 
 
Another significant contributor to hyperalgesia is a loss of central or 
descending inhibition from the brain and spinal cord. This will be discussed in 
the following section. 
 
1.2 CNS Processing of noxious stimuli 
 
Pain differs from other sensory modalities in that it is not merely a physical 
response to external events; it is an internal perception of tissue damage. In 
general, senses are exteroceptive, informing us of the nature of the 
environment we find ourselves in. Pain as a description of the location and 
‘type’ of pain is also exteroceptive, however, it can also be considered an 
interoceptive sense, such as thirst or hunger. Pain also differs from other 
senses in that it is considered to be real even in the absence of physical 
damage. This is not the case in vision, for example, where a response in the 
absence of a physical stimulus is considered to be a hallucination.  
 
1.2.1 First Pain Synapse and Spinal Cord 
 
First order primary afferents for innocuous touch and painful sensation 
synapse in different parts of the CNS. Tactile afferents for fine touch, 
vibration and proprioception travel up the spinal cord and synapse with 
second order neurons within the medulla. These secondary afferents cross to 
the contralateral side of the brainstem and form the medial lemniscus 
pathway to the thalamus.  
 
Primary afferent nociceptive and thermal sensory neurons from the periphery 
project to the spinal cord where neurons of different types synapse in distinct 
laminae; the Aδ fibres synapse in laminae I and V, Aβ fibres in laminae III, IV 
and V and C-fibres in laminae I (peptidergic) and II (non-peptidergic). The 
secondary afferents then decussate and ascend the spinal cord on the 
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contralateral side to the initial stimulus. Lamina II of the spinal cord contains 
a number of excitatory inter-neurons which are suggested to be involved in 
the development of chronic pain (Malmberg et al., 1997). 
 
 
Figure 3 The Primary ascending (left) and descending (right) pathways. 
 
In the ascending pathway activated primary afferent neurons synapse within distinct 
laminae of the dorsal horn of the spinal cord releasing glutamate and other 
excitatory modulators. The subsequently activated second order neurons cross to 
the contralateral side of the spinal cord where they terminate in the brainstem and 
thalamus synapsing with third order neurons projecting to higher brain areas.  
 
The descending pathway can be activated by external and internal modulators and 
motivational states. These pathways can be both excitatory (red) and inhibitory 
(green). The limbic system plays a key role in descending regulation with areas such 
as the anterior cingulate cortex (ACC), the hypothalamus (H) and the amygdala all 
synapsing in the periaqueductal grey (PAG) of the midbrain. Within in the PAG top 
down information is consolidated before transmission to the rostral ventral medulla 
(RVM) which then modulates pain messages from the dorsal horn. Messages within 
the RVM can also be modulated by 5-HT in a state-dependent manner. 
 
Diagrams taken from: Nature Reviews Neuroscience 5, 565-575 (2004) 
 
Ascending Pathways Descending Pathways 
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1.2.1.1 Dorsal Horn neurons 
 
The secondary neurons within the pain pathway have their cell bodies within 
the dorsal horn and axon terminating in the thalamus. They are broadly 
divided into two categories: Wide dynamic range (WDR) neurons which 
respond to gentle stimuli and increase in response when the stimulus 
increases and nociceptive specific neurons (NS) which only respond to 
noxious stimuli (Besson and Chaouch, 1987). 
 
Wide dynamic range neurons are in laminae IV, V and VI, where they receive 
input from Aδ and C fibres. Damage to neurons in the periphery leads to 
increased responses in these neurons, this is known as “wind-up” where a 
consistent peripheral stimulus will result in an increased response from the 
neurons of the DRG. If this continues the DRG neurons become over 
stimulated and themselves exhibit ectopic firing. WDR neurons also receive 
input from the viscera and play a key role in referred sensations (Fields, 
1987).  
 
The nociceptive specific neurons are primarily with lamina I of the spinal 
cord, where a significant amount of input is received from C and Aδ fibres, 
and are specific to the sensory-discriminative aspect of pain. Receiving only 
noxious input these neurons are also sensitised by repetitive stimulation. 
Complex neurons projecting from laminae VII and VIII receive convergent 
input from visceral receptors, often bilaterally. Within the DRG of the spinal 
cord a single cell body may receive input from more than one axon in the 
periphery and often from more than one nerve. This combined with the 
release of substance P in the area means more than one site may be 
excited. This increased sensitivity and excitation within the DRG contributes 
to secondary hyperalgesia and “wind-up” (Hunt et al., 1987). 
 40 
1.2.1.2 Ascending Pathways 
 
Both WDR and NS neurons decussate the spinal corn in the anterior white 
commissure and then ascend the anterolateral quadrant (ALQ) of the spinal 
cord. The ALQ comprises many ascending pathways including the 
spinothalamic tract (STT), which terminates in the thalamus, and the 
spinoreticular tract (SRT), which terminates in the dorsal horn.  
 
Of the STT neurons ascending to the thalamus approximately 50% comprise 
WDR neurons, 30% are NS and 10% are activated by deep tissue stimulation 
(Besson and Chaouch, 1987). Around 2% of ascending axons are thought to 
be activated by innocuous touch. Within the thalamus nociceptive STT 
terminate in two main regions, those from laminae I and V, which mediate the 
sensory-discriminative response, within the lateral nuclei and neurons from 
laminae I, IV and VI, which mediate the affective-motivation response, within 
the medial nuclei (Cross, 1994). 
 
SRT neurons ascend the ALQ to the reticular formation, a primitive part of 
the brain involved in the regulation of basic functions necessary for life, the 
bulbopontine group of neurons ascend to nuclei within the pons and medulla 
and the mesencephalic to the periaqueductal grey, superior coliculus and the 
nucleus cuneiformis. This primitive pathway is crucial to the affective 
motivational aspect of pain and is the origin of descending pathways (Besson 
and Chaouch, 1987, Cross, 1994). 
 
There are other smaller ascending pathways which contribute to pain 
perception and are likely to be involved in longer term persistent pain, 
including projections to SII and the insular cortex. These will be discussed 
further in the next chapter. 
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1.2.1.3 Segmental Modulation 
 
The pain signal from the two descending pathways is modulated in two 
different ways, segmental and descending modulation. The segmental 
modulation within the spinal cord is primarily inhibitory and occurs by two 
methods. The primary neurons for non-nociceptive sensation also have their 
cell bodies within the DRG and the secondary neurons in this pathway have 
an inhibitory effect on nociceptive activity, hence rubbing can help alleviate 
pain (Bini et al., 1984). Transcutaneous electrical nerve stimulation (TENS) is 
a commonly used method of pain relief which also works by stimulation of 
these non-nociceptive neurons leading to a decrease in pain sensation which 
can last for several hours (Johnson and Martinson, 2007). 
 
The second method of inhibition within the dorsal horn is via a network of 
inhibitory interneurons which may have their effect through endogenous 
opioid release as opioid receptors have been demonstrated in this region. 
Substance P receptors are also found here suggesting excitatory regulation 
may also occur in this region under certain circumstances contributing to 
wind-up and sensitisation (Basbaum and Fields, 1984). 
 
1.2.2 Thalamus 
 
The thalamus is commonly considered as a relay station for sensory 
information (Herrero et al., 2002). It receives input from both the peripheral 
and central nervous systems and its primary role is to integrate information 
for use by the higher cortices. 
 
The major nociceptive output from the spinal cord to the thalamus is from 
laminae I and V which contribute to the spinoreticulothalamic and 
spinothalamic tracts. The thalamus plays a key role in integrating information 
from all of the senses before it is transmitted to the cortex, collating both 
sensory and discriminative signals. The thalamus is not only an “information 
exchange” it has a significant effect on the regulation of pain symptoms, 
particularly the affective-motivational responses; lesions in this area lead to 
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chronic pain indicating that it may play a role in inhibitory regulation 
(McGlone and Reilly, 2010, Urban and Gebhart, 1999).  
 
Sensory information from the face and mouth is a slight exception to this rule 
as primary neurons from this region synapse at the trigeminal ganglion. 
Secondary neurons then decussate and synapse in the thalamus joining the 
same pathway as information from the rest of the body. 
 
1.2.2.1 Thalamocortical Projections 
 
Third order neurons make up the final stage of the ascending pathway 
projecting from the thalamus to the cortex (Besson and Chaouch, 1987). The 
lateral thalamic nuclei projects to SI and the intralaminar and medial nuclei to 
the anterior cingulate cortex (ACC). The former being involved in the 
representation of the pain or the sensory-discriminative aspect and the latter 
the affective-motivational response, the anterior cingulate cortex is also 
activated when it is apparent that other people are in pain and may be 
implicated in the empathetic response (Cross, 1994, Ohara et al., 2005). 
 
1.2.3 Cortical Regulation 
 
The primary sensory cortex, SI, is the most well-studied area in the brain 
relating to sensory perception. It is made up of a detailed map of the body 
known as the Penfield’s Homunculus (see Figure 10), specific regions 
correspond to specific body areas.  
 
In both animal and human studies of nociception the degree of SI activation 
is not as significant as might be expected. Other areas of the cortex are 
activated, often bilaterally, suggesting a role in the affective-motivational 
response as well as the sensory-discriminative (Ohara et al., 2005). 
 
In acute pain human studies, areas that are activated include, the anterior 
insular cortex, SII, associative parietal cortex, anterior cingulate and the 
prefrontal and supplementary motor cortices. Recent research suggests that 
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pain may be the result of the activation of several brain areas at once, the so 
called “pain matrix” or “association cortex” (Ohara et al., 2005). The areas of 
the brain activated and the order in which this happens may help differentiate 
between the wide variety of pain sensations experienced. 
 
The cingulate cortex is part of the limbic lobe, forming a collar around the 
corpus collosum, it is divided into the anterior and posterior cingulate 
cortices. There is little or no evidence for the involvement of this region in the 
discriminative-sensory response to nociception, but there is considerable 
evidence that it is involved in the affective-motivational response. As part of 
the limbic system the cingulate cortex is implicated in the regulation of 
emotional and empathetic responses, it receives significant input from the 
thalamus where nociceptive information is processed. 
 
Electrophysiological studies in animals have shown that the ACC receives 
nociceptive input to large receptive fields (Sikes and Vogt, 1992, Yamamura 
et al., 1996). The size of the fields further suggests that the role of the ACC is 
unlikely to be sensory-discriminative since they are too large to be precise. 
Abolishing activity in this region by application of opioids or creating a lesion 
has an anti-nociceptive effect in mice, whereas enhancing responses here 
using glutamate or electrical stimulation results in hyperalgesia. Moreover, 
these responses can be blocked by anaesthetising the rostroventrolateral 
medulla (RVLM). Experiments in the medial prefrontal cortex, which is rostral 
to the ACC, have demonstrated opposite effects, which also appear to be 
mediated by descending inhibitory pathways (Lee et al., 1999, Calejesan et 
al., 2000).  
 
Experiments using withdrawal responses and other measurements of 
hyperalgesia/allodynia do not directly measure effective-motivational 
responses. In a study using “place preference”, Johansen et al. (2001) found 
that formalin-treated rats with lesions of the ACC had no altered acute 
response to formalin, but had a reduced avoidance of the chamber in which 
the formalin injection was received. Injection of the cholinergic antagonist, 
scopolamine, into the ACC prior to a painful stimulus resulted in a decrease 
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in pain after the stimulus, however when the antagonist was given after the 
stimulus there was no decrease in nociception. This suggests that the ACC is 
significant in the “memory” of pain.  
 
1.2.4 Descending Regulation 
 
Nociception is not merely a “one way street” with information from the 
periphery terminating in the CNS and resulting in a sensation; descending 
regulation plays a key role in regulating nociception and can be both 
excitatory and inhibitory. The majority of descending regulation comes from 
the cortices, however, the spinal cord, dorsal root ganglia and periaqueductal 
grey (PAG) can also regulate pain responses without cortical modulation. 
Several neurotransmitters are known to regulate descending pathways 
including, adrenaline, NA, 5HT and opioids (Basbaum et al., 2009, Cross, 
1994, Ohara et al., 2005).  
 
The ventrolateral orbital (VLO) region of the frontal cortex is thought to be a 
significant part of the pain matrix as it is activated by cutaneous and visceral 
nociceptive stimuli. Morphine injection into the VLO increases initial tail flick 
latency and analgesia in neuropathic rats in a naloxone-reversible fashion, 
and similar effects are seen following application of anaesthetic or lesioning 
of the region (Al Amin et al., 2004). 
 
Studies on the rostral area of the insular cortex (RAIC) have demonstrated 
that this area can contribute to both increases and decreases in nociceptive 
thresholds. Increasing the levels of the inhibitory neurotransmitter, gamma-
aminobutyric acid (GABA), causes an increase in nociceptive thresholds, 
blocking descending inhibition abrogates this response. Interestingly, the 
RAIC can also mediate its effects without activation of the lower centres; if 
GABA is increased and the GABAB receptor subsequently blocked, there is a 
decrease in nociceptive threshold, an effect which is reversed by blocking 
activity in the amygdala. Of particular note is the fact that these areas of the 
limbic system can exert antinociceptive effects without activation of the 
descending inhibitory system (Ohara et al., 2005). 
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Descending projections from these higher centres terminate in the PAG 
where information is collated and then transmitted to the RVM. The RVM is 
rich in 5-HT and supplies a tonic inhibitory stimulus, as such a decrease in 5-
HT in this area may result in an increased pain response. Noradrenaline also 
contributes to tonic inhibition in a manner that is selective to dorsal horn 
nociceptive neurons. Intrathecal administration of noradrenaline acts via α-
adrenoceptors to have an analgesic effect. Stimulation of the nuclear raphe 
magnus within the RVM results in release of both 5-HT and noradrenaline. 
Acute stress can decrease the pain response via an increase in NA and 5-
HT. However, it is known that, in long-term stress and depression, pain can 
increase, and that this may be due to the depletion of these 
neurotransmitters. 
 
The locus coeruleus (LC) of the pons also projects noradrenaline-releasing 
neurons that synapse in the dorsal horn. The LC is stimulated by the 
hypothalamus resulting in inhibition of nociceptive transmission in the spinal 
cord. The LC can also exert negative feedback on the hypothalamus via the 
release of NA. 
 
These recent discoveries about the importance of monoamines in 
descending regulation of pain have led to the use of antidepressants such as 
amitriptyline HCL and selective serotonin re-uptake inhibitors in the treatment 
of chronic pain with varying degrees of success. Electrical stimulation by 
placement of electrodes in varying parts of the descending pathway is also a 
common treatment. 
 
Opioid receptors are also found in the periphery, dorsal horn and brain stem. 
The receptors of the brain stem are the primary targets for endogenous 
opioids and are important for the regulation of the internal antinociceptive 
system; lesions in the area can inhibit endogenous opioid effects. 
 
Within the PAG and ventromedial nucleus of the hypothalamus (VMN) there 
are two classes of descending neurons; excitatory or “on” neurons and 
inhibitory or “off” neurons. The former, directly or indirectly increase 
 46 
nociceptive transmission and are inhibited by both NA and opioids, whereas 
the latter, decrease nociceptive transmission and are excited by opioids. 
 
Descending inhibition is not the only form of endogenous analgesia. Recent 
research has brought to light the significance of inter-cortical regulation. 
Depending on the areas involved, this form of regulation can not only alter 
the degree of nociception but also the quality of the pain experience. For 
example, lesions of the frontal cortex do not decrease the sensory perception 
of a painful stimulus but can alter the amount of “unpleasantness” 
experienced (Talbot et al., 1995, Ploner et al., 1999). 
 
1.2.5 Psychological Symptoms 
 
As previously mentioned, pain is not merely a physical symptom, by its very 
definition it is “An unpleasant sensory and emotional experience” (Merskey 
and Bogduk, 1994) involving many complex psychological and social factors. 
 
Acute pain is not associated with many long-term psychological symptoms, a 
severe injury may be associated with psychological problems such as post-
traumatic stress disorder (PTSD), but in these cases the pain itself is not 
usually the cause of the issues. Chronic pain, however, can have a 
significant impact on the psychological health of sufferers and conversely, a 
person’s psychological state can make a huge contribution to the 
development of chronic pain conditions. There is a significant link between 
depression and chronic pain, particularly with conditions such as fibromyalgia 
(FM), complex regional pain syndrome (CRPS) and chronic fatigue syndrome 
(CFS). Anxiety is also a significant problem in chronic pain patients; this is 
unsurprising since anxiety and depression frequently go hand in hand. 
Anxiety can occur for many reasons, for example, patients may become 
afraid of going out or doing exercise for fear of making their condition worse.  
 
Pain can lead to disordered sleep and when a person’s sleep patterns have 
been significantly disrupted over a long period of time this can lead to longer-
term sleep problems. Lack of sleep is detrimental to physical and 
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psychological health, often resulting in a vicious downward spiral of 
symptoms. 
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Chapter 2 
 
2 Introduction: Chronic Pain 
 
The plastic nature of the nervous system allows for a non-dependable 
relationship between intensity of stimulus and perception of pain by 
alterations in neurons and receptors at all levels. Under normal conditions 
this plasticity is helpful, enabling the best response for the circumstances, for 
example an increase in sensitivity following tissue damage in order to allow 
the sensitive tissues to heal. Unfortunately this plasticity, the very thing that 
makes the nervous system so efficient, can also lead to inappropriate 
responses where pain is felt in response to innocuous stimuli or with no 
stimulus at all. As discussed earlier, chronic pain is usually defined as pain 
that does not result from disease or physical trauma, or that persists after 
physical symptoms have healed (Merskey and Bogduk, 1994). In practise the 
definition of pain as chronic depends very much on the condition involved 
and the expected healing time of said condition. There are also myriad 
chronic conditions in which pain is a predominant symptom, including, 
fibromyalgia (FM), complex regional pain syndrome (CRPS), arthritis, cancer, 
back pain, migraine, shingles and trigeminal neuralgia to name but a few. 
 
2.1 Chronic Pain Conditions 
 
The main physical symptoms of chronic pain, hyperalgesia (exaggerated 
response to normally painful stimuli), allodynia (painful response to normally 
non-painful touch) and spontaneous pain occur as a result of central 
sensitisation. In chronic pain the affective-motivational elements of the pain 
response become far more prevalent than in the acute response contributing 
to some of the most disturbing and intractable symptoms of chronic 
conditions. 
 
The effects of chronic pain are far reaching, not only is there a significant 
effect on the physical and emotional wellbeing of the individual sufferer, the 
financial burden of healthcare and employee absence has a major impact on 
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the western economy. Estimations of the prevalence of chronic pain in 
developed countries range from 17-46% of the general population (Elliott et 
al., 1999, Blyth et al., 2001, Eriksen et al., 2003, Jakobsson, 2010a). This 
apparently wide range can, in part, be explained by the differing 
classifications and methods used in individual studies, with those at the lower 
end of the spectrum only considering pain going on for six months or longer 
as chronic and using medical records or phone interviews versus, those at 
the higher end classifying as chronic pain lasting for three months or longer 
and using self-completed written questionnaires. Even taken at the absolute 
lowest estimate of 17% or the general population it is clear that chronic pain 
is a significant problem for a large proportion of people in the western world. 
Chronic pain patients are up to five times more likely to seek medical help 
than non-sufferers making it a significant drain on health service resources 
(Elliott et al., 1999). This combined with its impact on individual physical and 
psychological health, as well as socio-economic wellbeing, makes it a highly 
significant problem facing the community today. Chronic low back pain, for 
example, accounts for 12.5% of all sick days in the UK and cost over £11 
billion in 2000 (Frank, 1993, Maniadakis and Gray, 2000). 
 
More detailed examination of the epidemiological statistics of chronic pain 
has provided increasing evidence of the significant personal and economic 
burdens of this condition. Chronic pain has been demonstrated to correlate 
with increasing age although some studies have shown that it peaks in 
middle age (45-59) and then decreases slightly in later life (Blyth et al., 2001, 
Elliott et al., 1999, Eriksen et al., 2003, Jakobsson, 2010b). There is also 
significant evidence to suggest that women suffer more frequently with 
chronic pain than men do and this has been supported in animal studies of 
male and female sex hormones (Manson, 2010). It should also be taken into 
account, however, that women are more likely to report and seek help for 
pain and as such there may be some bias in the statistics. The financial 
impact of chronic pain on both the individual and the economy is also high, 
with the condition being significantly associated with sufferers taking disability 
benefit, being unemployed and requiring long term support from health care 
systems, indeed, one study demonstrated that chronic pain sufferers have 
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twice as many days off due to illness than non-suffering controls and are up 
to seven times more likely to quit their job due to ill health. There are also 
significant social factors relating to chronic pain, lower levels of completed 
education, rented versus owned accommodation, unemployment and receipt 
of government benefits have all been significantly associated with chronic 
pain (Eriksen et al., 2003, Jakobsson, 2010a, Elliott et al., 1999, Blyth et al., 
2001). 
 
2.1.1 Complex Regional Pain Syndrome (CRPS) 
 
Complex regional pain syndrome (CRPS) is a condition which results in 
abnormal swelling, hypersensitivity and a significant amount of pain in the 
affected part of the body. It usually begins in an individual limb and can be 
triggered by injury, stroke or surgery, however, it often appears for no 
apparent reason. The condition is divided into two subtypes CRPS type I, 
where there is no causative nerve damage and CRPS type II where the 
symptoms can be related to some obvious nerve lesion. Previously, CRPS 
has also been known as reflex sympathetic dystrophy (RSD) and causalgia; it 
is thought to be related to several disorders including fibromyalgia (FM) and 
chronic fatigue syndrome (CFS). 
 
The symptoms are many and varied but certain criteria have been developed 
for the diagnosis of the syndrome (Birklein, 2005). The most widely accepted 
criteria for diagnosis is that of the International Association for the Study of 
Pain (IASP) where symptoms must include; spontaneous pain and 
hyperalgesia, which is not limited to the territory of a single peripheral nerve 
and oedema, altered blood flow or abnormal sudomotor activity, although this 
is constantly evolving (Bruehl et al., 1999, Reinders et al., 2002, Stanton-
Hicks et al., 1995, van de Beek et al., 2002) and is widely considered to be 
too general for accurate diagnosis given the variety of other symptoms 
commonly associated with the disease including: 
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 Changes in skin temperature, which can differ greatly from the 
contralateral limb 
 Increased sweating 
 Changes in skin appearance, blotchiness, change in colour 
 Changes in hair and nail growth 
 Motor disability, problems moving the affected body part 
 
The order of presentation of symptoms and their relative severity varies from 
patient to patient but most report all of the above symptoms at some stage of 
their disease. Figure 4 shows examples of affected limbs demonstrating 
some of these symptoms. 
 
Figure 4 Examples of typical CRPS limbs. Note the extensive swelling and 
oedema in the affected limbs. The foot also shows increased sweating and 
alterations in skin texture and colour compared with the healthy limb 
 
More recently many unusual symptoms have come to light that are less 
physiological in nature and could in fact be considered to be psychological in 
their origin (Galer and Jensen, 1999, McCabe et al., 2003a, McCabe et al., 
2003b). For many years such symptoms have been ignored or gone 
unnoticed as they were thought to be completely unrelated to the condition. 
However it has now become apparent that such symptoms are part of the 
CRPS condition and affect the majority of patients at some time. These 
symptoms, which could be considered to be part of the affective-motivational 
pain response, include: 
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 Altered visuospatial awareness 
 Referred sensations  
 A feeling of alienation towards the affected limb/neglect like symptoms 
 Emotional labiality 
 Altered sleep and dreams 
 Problems with memory and concentration 
 
The body of research into these symptoms is growing and similarities 
between CRPS and other chronic pain conditions have become apparent 
(Forderreuther et al., 2004, Juottonen et al., 2002, Maihofner et al., 2006, 
McCabe et al., 2003a). 
 
2.1.2 Chronic Low Back Pain (CLBP) 
 
Low back pain is one of the most common chronic pain complaints in western 
society affecting 70-85% of adults at some point in their lifetime of these 
around 5% go on to develop long term pain with an estimated 30% of the 
population suffering from the chronic form of the condition at any given time 
(Andersson, 1997, Frank, 1993). 
 
Depression has been strongly linked with chronic low back pain (CLBP) 
(Meyer et al., 2007, Reid et al., 2003) and there may be many reasons for 
this, chronic pain is obviously a risk factor for depression, depression also 
tends to lead to a more sedentary life which, as mentioned above, has a 
negative effect on recovery from back pain. Furthermore, inflammation with 
the CNS has been linked with depression (Maes et al., 2009) and is also 
known to contribute to central sensitisation in chronic pain (see section 
2.2.1).  
 
MRI scans of CLBP sufferers are abnormal when compared with healthy 
controls and metabolic changes have been seen that are similar to those 
seen neurodegenerative disease (Grachev et al., 2000). 
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2.1.2.1 Treatment of low back pain 
 
Although previously rest was frequently prescribed for back pain recent 
evidence points towards early mobilisation along with effective analgesia as 
the treatment with the best potential outcome (Jasmin et al., 2003). One 
mechanism by which this may work is through inhibition of central 
sensitisation by analgesia. 
 
Using fMRI scanning and ratings of spontaneous pain fluctuations Baliki et al 
(2006) identified a pattern of activity specific to CLBP, two differing activation 
profiles were observed: when spontaneous pain was rapidly increasing the 
insula, anterior cingulate and parietal cortices along with the cerebellum were 
activated. When subjects rated spontaneous pain as high an increase in 
activity in the medial prefrontal cortex (mPFC) was observed while less 
activity was seen in the amygdala and ventral striatum. When comparing the 
response to an acute thermal stimulus no difference in pattern of activity was 
seen between CLBP sufferers and controls. This work shows a specific 
profile of activity in this chronic pain condition and demonstrates the 
importance of investigating brain activation in a symptom specific context and 
not only in response an acute nociceptive stimulus. 
 
Further analysis of the results of Baliki et al (2006) demonstrated a 
correlation between reported pain intensity and mPFC activation to the extent 
that greater than 80% of pain intensity can be accounted for by mPFC 
activity. Furthermore activity in insula cortex correlates with the number of 
years suffering from chronic pain. These results show that there is a specific 
matrix of activation seen in CLBP regardless of the initial cause of the 
condition. Since activity in the mPFC and dorsolateral prefrontal cortex 
(DLPFC) is normally inversely correlated, atrophy in the DLPFC is likely to 
contribute to the increase in activity seen in the mPFC. 
 
Acute pain results in a fairly consistent pattern of brain activation in both 
chronic pain sufferers and controls (Apkarian et al., 2005) whereas, individual 
chronic pain conditions have been demonstrated to show specific patterns of 
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activity with a significant increase in the prominence of the prefrontal cortex 
vs. acute pain (Furukawa and Gouaux, 2003).  
 
2.1.3 Fibromyalgia 
 
Mu-opioid binding has been shown to be decreased in fibromyalgia patients 
by PET binding studies (Harris et al., 2007) and altered dopamine release 
has also been demonstrated in this condition (Wood et al., 2007). 
 
Fibromyalgia is a relatively common condition with an incidence of 35/100000 
people. It primarily affects women over the age of 40 and has been linked to 
the menopause (Wolfe et al., 1997). Fibromyalgics present with a number of 
symptoms but the most widely accepted diagnostic criteria is that of the 
American College of Rheumatology (Wolfe et al., 1990) as listed below: 
 
 Widespread chronic pain for at least three months: 
In both sides of the body 
Above and below the waist including axial skeletal pain 
 Pain at eleven of eighteen specific tender points on digital palpitation 
with an approximate force of 4kg. 
 
Sufferers often report a wide variety of other symptoms including, severe 
fatigue, insomnia and cognitive problems such as impaired concentration and 
memory issues. 
 
2.1.3.1 Mechanisms of Fibromyalgia 
 
Wallace et al (2001) investigated the cytokine profile in the blood of 89 
fibromyalgia (FM) patients, 23 with a disease duration of under two years and 
33 diagnosed as chronic sufferers i.e. with a duration of two or more years. It 
has been suggested that there are two types of FM with 50% of patients 
diagnosed recovering within two years, whereas 95% of chronic patients 
show no significant recovery over a two year period (Wolfe et al., 1997). 
Serum levels of a number of cytokines and related factors were analysed 
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along with their stimulated versus spontaneous release from peripheral blood 
monocytes (PBMCs) using ELISA. 
 
Of all the factors measured, no significant difference in plasma levels of IL-
1β, IFNγ, SIL-2R, IL-10, TNFα, and IL-2 was demonstrated. However, FM 
sufferers had on average a 55% increase in serum levels IL-1Ra versus 
normal healthy controls and plasma levels of IL-8 were three times higher 
than those seen in controls, this effect was primarily due to levels in chronic 
sufferers. Spontaneous cytokine expression was measured after a 72 hour 
incubation of un-stimulated isolated PBMC, IL-6 and IL-1Ra expression was 
higher in FM PBMC than control but this effect was only significant in cells 
from chronic sufferers. Spontaneous IL-8 expression was low across all 
groups and no significant difference was seen in levels of this cytokine. 
 
Isolated PBMC were stimulated with Lipopolysaccharide (LPS) in the 
presence or absence of phorbol myristate acetate (PMA) which is known to 
stimulate T-cell activation. Without PMA, LPS induced similar levels of ILR-
1Ra, IL-6, IL-8 and IL-2 in FM PBMC to those seen in controls. However 
when 1ng/ml PMA was added along with the LPS, a significant increase in IL-
1Ra was seen in the chronic FM group compared with both the control and 
the acute FM group, IL-6 also showed a significant increase this time in both 
FM groups. 
 
These results, which are mediated by T-cell activation, demonstrate altered 
levels of circulating cytokines in FM, an affect that increases with duration of 
the disease. IL-6 is associated with many of the symptoms seen in FM 
including fatigue, hyperalgesia and depression, and IL-1Ra with stress 
(Pillemer et al., 1997, Sachs et al., 2002). The increased response to PMA 
and LPS seen in FM patients indicates a hypersensitivity of the immune 
system which may result in an excessive response to injury or infection 
leading to some of the symptoms seen in this condition. Ultimately, this may 
lead to a vicious cycle of increased pain, depression and stress resulting in 
elevated cytokine levels that in turn result in more pain. 
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Further support for this theory comes from the work of Uceyler et al (2006) 
who measured protein and mRNA levels of a wide spectrum of cytokines in 
the peripheral blood of 40 patients with chronic pain. 26 of these patients 
fulfilled the American College of Rheumatology (ACR) diagnostic criteria for 
FM. They found sufferers to have a significant decrease in both gene and 
protein expression of IL-4 and IL-10 relative to normal healthy controls. It has 
been suggested that these cytokines have anti-inflammatory and analgesic 
affects and IL-4 has been demonstrated to play an intrinsic role in switching 
the immune response from the cellular to the humoral response. In animal 
studies pre-treatment with this cytokine has been shown to decrease the 
writhing response to intraperitoneal (i.p.) acetic acid injection and allodynia 
following sciatic nerve ligation (Kanaan et al., 1998, Vale et al., 2003). This 
decrease in hyperalgesia may be due to the up-regulation of opioid receptors 
by IL-4.IL-10 has also been demonstrated to reduce hyperalgesia, although 
the mechanism by which this occurs is not yet known (Kanaan et al., 1998, 
Vale et al., 2003). 
 
A reduced level of circulating anti-inflammatory cytokines would lend support 
to the positive feedback theory suggested above. Although FM is almost 
certainly the result of dysregulation of many systems it seems likely that a 
disproportionate response from the immune system plays a significant role in 
this disease. 
 
2.1.4 Chronic Fatigue Syndrome 
 
Chronic fatigue syndrome (CFS) is characterised by long-term severe fatigue 
combined with myalgia, cognitive disturbances, low grade fever and 
disturbed sleep. There is a known link with CFS and depression and it was 
long considered to be psychological in origin. However many of these 
symptoms also point towards a possible immunological or neurological 
cause.  
Lange et al (1999) demonstrated significant abnormalities in the brains of a 
subset of CFS patients who had no history of psychiatric disorder but did 
demonstrate impaired cognitive functioning. The abnormalities were primarily 
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seen in the frontal lobes as small punctate hyper-intensitivities. These 
differences were seen in almost half of the patients (47.6%) with no 
psychiatric history. Of significant interest is that these differences were only 
evident when patients were divided according to psychiatric diagnosis, only 
16.7% of patients with diagnosed psychiatric disorders and 10.5% of healthy 
controls had abnormal scans of the frontal lobe. This leads to the suggestion 
that there may be two subgroups of CFS sufferers, those whose disease is in 
some way the result of a psychiatric disorder and those with a disease of 
organic origin. 
 
Building on this work, Natelson et al (2005) investigated cytokine and protein 
levels and the number of white blood cells in the cerebrospinal fluid (CSF) of 
44 CFS patients. They found 30% of patients to have abnormal protein levels 
and/or increased numbers of white blood cells when compared to laboratory 
standards, all controls demonstrated normal levels. This subgroup of patients 
had a lower rate of current depression than those with normal CSF providing 
some support for the suggestion that their illness is organic and not 
psychological in origin. Of the 19 cytokines investigated 11 were identified at 
some level in CSF and 3 were found to show significant differences between 
groups. Granulocyte macrophage colony stimulating factor (GM-CSF) was 
found to be lower in CSF subjects compared to control, IL-8 was higher in 
patients with sudden onset CSF than control or gradual onset patients and 
IL-10 was higher in patients with abnormal CSF when compared with other 
groups. GM-CSF is important in the regulation of macrophage and 
granulocyte populations and its down-regulation in the presence of IL-8 and 
IL-10 can lead to a decreased response to certain bacterial infections 
(Hamilton, 2002, Lee and Rikihisa, 1996). In addition IL-10 has been shown 
to inhibit GM-CSF dependent monocyte survival and macrophage generation 
(Hashimoto et al., 2001). Taken together these results provide support for the 
hypothesis that in some cases CFS is the result of a disorder of the immune 
system leading to neurological dysfunction.  
 
Stress is a known factor in the regulation of the immune response. The 
hypothalamo-pituitary-adrenal axis (HPA) is the central mechanism for 
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regulation of the stress response that ultimately controls circulating levels of 
steroid hormones such as cortisol. One suggestion is that the dysregulation 
of the immune response in conditions such as CFS may be the result of 
decreased activity of the HPA axis leading to increased cytokine release in 
stress. To investigate this possibility Gaab et al (Gaab et al., 2005)(Gaab, 
Rohleder, Heitz, Engert, Schad, Schurmeyer, & Ehlert 2005) tested to see if 
a period of psychosocial stress altered the immune response to challenge by 
LPS. Subjects were exposed to two stressors, a fake job interview and a 
mental arithmetic task, immediately after this, and at several subsequent time 
points, blood and saliva samples were taken. As a measure of HPA axis 
activity, blood and saliva levels of cortisol and ACTH were obtained. To 
investigate the immune response whole blood was incubated with LPS 
overnight and cytokine levels measured by ELISA. CFS subjects had 
significantly lower ACTH levels than controls, however, their stress response 
did follow the expected pattern and levels of cortisol released were not 
significantly different to those of controls. In response to the immune 
challenge, numbers of leucocytes increased in the blood of both groups and 
there were significant differences in the stimulated cytokine production.  
 
Contrary to initial expectations CFS patients showed decreased levels of 
both TNFα and IL-6 in the stimulated cytokine response following stress, 
exactly the opposite to the response seen in controls. There was no 
significant relationship between this difference and levels of cortisol 
suggesting that steroid regulation of cytokines was not the cause. These 
results lend further support to the theory that there is an altered immune 
response in CFS and also suggest a heightened sensitivity to glucocorticoid 
regulation in this condition. The immune system and the HPA axis are closely 
integrated and dysregulation of one often leads to problems with the other, 
these results suggest altered responsiveness of both systems in CFS. 
 
2.2 Mechanisms of Chronic Pain 
 
As previously mentioned, different pain modalities show differing patterns of 
activation within the peripheral and central nervous systems, this is true of 
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both acute and chronic pain. Chronic pain is thought to be the result of 
central sensitisation which can occur at the level of the spinal cord and higher 
up in the brain. Multiple mechanisms are thought to contribute to sensitisation 
including inflammation, cortical reorganisation and wind-up. 
 
The situation is further complicated by the fact that many chronic pain 
conditions contain several components, low back pain, for example, can 
result from muscle, nerve, joint, or bone injury or a combination of these 
things. Teasing out the precise cause or even the major contributing factor to 
many chronic pain conditions is often practically impossible. 
 
2.2.1 Inflammation in the CNS 
 
2.2.1.1 Cytokines 
 
Cytokines are chemical messengers of the immune response; they mediate 
inflammation and are released in response to injury or other physiological 
insult such as bacterial infection. They set off a cascade of events leading to 
inflammation, infiltration of macrophages and vasodilation. They are known to 
stimulate ‘sickness behaviour’, a group of symptoms including: fatigue, 
malaise, inability to focus, fever and decreased appetite. Following tissue 
damage, cytokines also stimulate growth and repair and as such they are 
vital for recovery and development. Until recently the CNS was considered to 
be protected from cytokines, and related molecules, by the blood brain 
barrier. It has been demonstrated however that glial cells within the CNS 
release a variety of cytokines in response to physiological insult (McMahon et 
al., 2005). 
 
The inflammatory cytokines are primarily known as mediators of the immune 
response via secondary messenger cascades in response to physiological 
insult. Recent work, however, has demonstrated an additional role for 
cytokines in the regulation of neuronal sensitivity and activity in response to 
tissue damage and inflammation (Hellstrom et al., 2005, Hoheisel et al., 
2005). This regulation manifests itself in several ways, including changes in 
 60 
response to stimulation, altered sensitivity to neuronal mediators and in some 
cases through direct stimulation of the nerve itself (i.e. by acting as a 
neurotransmitter). Several cytokines have been demonstrated to play a role 
in the development of allodynia and hyperalgesia in both chronic and acute 
pain and others have been shown to decrease these symptoms (Marchand et 
al., 2005, Covey et al., 2000, Ignatowski et al., 1999) 
 
Administration of cytokines stimulates hyperalgesia and allodynia in animal 
and human models (Covey et al., 2000, Turrin et al., 2001). Increased levels 
of circulating cytokines are seen in the blood and cerebral spinal fluid (CSF) 
of chronic pain sufferers and this had previously been demonstrated in FM, 
CFS and CRPS (Alexander et al., 2006, Alexander et al., 2005, Natelson et 
al., 2005, Uceyler et al., 2006, Wallace et al., 2001). In animal models of 
pain, increased levels of cytokines have been demonstrated in the brain and 
specifically within the hippocampus (Turrin et al., 2001). 
Intracerbroventricular (ICV) injection of cytokines causes increased pain 
behaviour in animals and subcutaneous injection stimulates hyperalgesia and 
allodynia in human subjects. 
 
How and why cytokines have these effects is of great interest at present. The 
fact that they are involved in the development of a heightened pain state 
(allodynia/hyperalgesia) during injury and healing can be easily explained as 
a protective response to tissue damage. What is more intriguing is that these 
mediators seem to also be released in chronic pain, where there is not 
always obvious injury or tissue damage. This leads to the suggestion that 
such cytokines may themselves be mediators of chronic pain conditions. 
Altered cytokine expression has been demonstrated in several conditions 
associated with chronic pain including, FM, chronic fatigue syndrome and 
CRPS (Alexander et al., 2006, Alexander et al., 2005, Uceyler et al., 2006, 
Wallace et al., 2001). 
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2.2.1.2 Cytokines in the Hippocampus 
 
The hippocampus is one of the most widely studied areas of the brain, it is 
known to be involved in learning, memory, spatial mapping and navigation, 
emotional responses and stress regulation. The hippocampus is also 
considered to be involved in the perception of pain and a role for cytokines in 
the regulation of hippocampal activity is suggested. 
  
Ignatowski et al (1999) used chronic constriction nerve injury (CCI) as a 
model of chronic neuropathic pain in rats and investigated TNF distribution 
within the brain, spinal cord and plasma using a WEHI-13 cytotoxicity assay. 
Levels of the cytokine were found to increase in both the spinal cord and 
hippocampus of CCI rats when compared with both control and sham 
operated animals. There was a significant increase in TNF concentration in 
the hippocampus from day 4 to day 6, post CCI. This increase correlated with 
the development of thermal hyperalgesia as measured by the hot plate test. 
This indicates a direct role for TNF in the development of neuropathic pain, 
a suggestion that is further supported by inhibition of hyperalgesia when 
antibodies to TNF are given four but not six days post CCI. 
 
Following on from this, these authors (Covey et al., 2000) performed a similar 
experiment where changes in TNF levels in relation to the noradrenergic 
response within the hippocampus were investigated. The 2 adrenergic 
receptor is an auto-inhibitory receptor and its activation is associated with 
modulation of pain (Kontinen et al., 1998, Schmitt et al., 1974) and regulation 
of hippocampal activity (Curet and De Montigny, 1988, Unnerstall et al., 
1984). As previously, levels of TNF were elevated in the brain and spinal 
cord of CCI animals, with most significant differences in the brain being within 
the locus coeruleus (LC) and hippocampus. Interestingly, levels within the LC 
increased by day four, whereas hippocampal levels were only significantly 
increased at day eight, again correlating with the development of 
hyperalgesia. Along with this increase in TNF, an increase in inhibition of 
stimulated noradrenaline (NA) release was demonstrated, this inhibition was 
 62 
stimulated by TNF and inhibited by idazoxan (an 2 adrenoreceptor 
antagonist). These results, combined with the fact that the hippocampus 
receives the majority of its adrenergic input from the LC, suggest that TNF 
mediates pain behaviour by modulation of the 2 adrenoreceptor activity 
within these areas. 
 
Further support for a modulatory effect of TNF on the 2 adrenergic 
receptor is provided by its role in regulating the effect of the tricyclic 
antidepressant desipramine (Ignatowski and Spengler, 1994). Desipramine is 
an NA reuptake inhibitor, in rats chronic (14 days) desipramine administration 
reversed TNF induced inhibition of NA release resulting in increased 
release. However, when the 2 receptor is blocked with idazoxan this 
reversal is attenuated such that the percentage inhibition is greater than that 
seen in idazoxan treated controls.  
 
These results suggest a role for TNFα in the regulation of adrenergic activity 
within the hippocampus via modulation of α2 receptor activity. The different 
effects seen over time and with desipramine administration suggest that long 
term exposure to altered cytokine levels may modify the NA response leading 
to altered processing of pain other cognitive input. This may explain some of 
the variances seen between acute and chronic pain states. 
 
2.2.1.3 Cytokines in CRPS 
 
Recent work (Alexander et al., 2005) has demonstrated an increase in the 
levels of cytokines in the CSF of CRPS patients when compared with non 
CRPS controls. The cytokines measured were IL-6, IL-1 and TNF using 
ELISA. As well as clear increases in levels, it was noted that there was a 
large variance in the levels of cytokines in the CRPS samples compared with 
controls. This suggests that there may be a change in the expression of 
these molecules over the duration of the disease and it would be interesting 
to see if this was linked to variations in physical symptoms and/or time 
course of disease. 
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In comparison to the above affects seen in the central nervous system (CNS) 
the innate cytokine profile within the blood of CRPS patients has been 
demonstrated to be normal both at ‘baseline’ and in response to stimulation 
by administration of LPS or thrombin (van de Beek et al., 2001). As would be 
expected due to the presence of excessive inflammation, an increase in 
cytokines is seen in the affected limb when compared with the unaffected 
limb (measured in blister fluid). It would also be interesting to see if there is a 
correlation between levels of cytokines and extent of inflammation, 
temperature changes and colour changes in the affected limb.  
 
Taken together these results suggest a role for altered cytokine expression in 
the development and maintenance of chronic pain conditions and their 
associated symptoms. 
 
2.2.1.4 Chemokines 
 
Chemokines are a family of over 50 proteins which play an important role in 
regulating inflammation in response to tissue injury, infection and tumour 
growth. Their name is derived from their function as chemotactic cytokines 
inducing leukocyte migration. The effects of chemokines are all mediated via 
G-protein-coupled receptors, this family of seven transmembrane receptors 
reacts to molecules outside the cell to activate signalling cascades within 
(Melik-Parsadaniantz and Rostene, 2008). 
 
Chemokines are, in general, promiscuous ligands binding to several different 
receptors. There are exceptions to this rule, notably the chemokine 
fractalkine (CX3CL1), which binds to one receptor only and this receptor, 
CX3CR1, binds only fractalkine making it a good potential target for specific 
intervention. Fractalkine was first identified in the CNS and was initially 
known as neurotactin (Trettel et al., 2008). Under normal conditions this 
molecule is highly expressed on the extracellular surface of neurons, 
attached by a membrane spanning mucin stalk. Strong excitation of the 
neuron results in cleavage of this stalk and release of the extracellular 
domain as a potent diffusible signal to surrounding neurons and glial cells. 
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Within the CNS the CX3CR1 receptor is primarily expressed on microglia 
however it has also been reported to be expressed by neurons of the 
hippocampus. Pain is a strong stimulus to neurons of the spinal cord and has 
been demonstrated to result in release of fractalkine from these neurons and 
to increase the expression of the chemokine receptor in pain related regions 
(Baliki et al., 2003, Clark et al., 2007, Axen and Porath, 1966). 
 
2.2.2. Neurodegeneration 
 
Apkarian et al (2004b) demonstrated, for the first time, that chronic pain is 
correlated with decreased grey matter in the brain, specifically within the 
prefrontal cortex and thalamus. This work supports the theory that chronic 
pain is a form of neurodegenerative disease in which alterations in brain 
structure and chemistry contribute significantly to both physical and 
emotional/psychological symptoms. 
 
2.2.2.1 Evidence from Animal Models 
 
As discussed in Chapter 1, of the ascending pain pathways, the 
spinothalamic tract (STT) is the well-documented, although there is evidence 
that the spinorecticular, spinomesencephalic, spinoparabrachial and 
spinohypothalamic tracts all transmit pain information to the higher centres of 
the brain. There is also growing evidence that some neurons project directly 
from the periphery to the brain. Recent studies have further broken down the 
type of information transmitted in the STT indicating that the lateral pathway 
is involved primarily in sensory discrimination and the medial, which projects 
primarily to the ACC in the PFC, in the affective motivational response to pain 
(Apkarian et al., 2005). This work has further contributed to the theory that 
higher brain centres play a highly significant role in the regulation of chronic 
pain. 
 
The evidence for anti-nociceptive descending modulation in acute pain is well 
documented (Basbaum and Fields, 1984). Interestingly, recent work has 
demonstrated the presence of descending pathways which have a pro-
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nociceptive effect (Lima and Almeida, 2002). Evidence for the role of 
descending pathways in maintaining neuropathic pain states comes from two 
recent studies; Vera-Portocarrero et al (2006) demonstrated a role for the 
ventromedial medulla in the maintenance of neuropathic pain in a spinal 
nerve ligation model. Ablation of mu-opioid expressing cells of the 
ventromedial medulla, prior to surgery, using dermorphin-saporin resulted in 
allodynia and activation of the ipsilateral dorsal horn only at day three and not 
days five and ten as was seen in neuropathic controls. Furthermore, both 
pro- and anti-nociceptive cells have been identified within the rostroventro 
medulla (Carlson et al., 2007), these cells, termed “on” and “off” cells by the 
authors, showed increased sensitivity allodynia-inducing stimulation when 
compared with sham and normal controls, no effect was seen on so-called 
“neutral cells”, which have no-response to thermal stimulation.  
 
2.2.2.2 Evidence from Human Studies 
 
Opiates exert their effects not only in the higher areas of the brain but also 
within the spinal cord and receptors are also present in the periphery. Human 
brain imaging studies have demonstrated a role for opiate receptors within 
the thalamus, basal ganglia and cortex to be directly related to the perception 
of both acute and acute painful stimulus (Zubieta et al., 2003, Zubieta et al., 
2002) and the chronic pain of FM (Harris et al., 2007). 
 
2.2.2.3 Supraspinal Regulation of Chronic Pain – Pain Memory 
 
As intimated above, the cortex does not simply represent the activity of the 
spinal cord in pain; it plays an active role in the processing and regulation of 
it. Cortical modulations in both animal and human models can modulate pain 
behaviour (Baliki et al., 2003, Han and Neugebauer, 2005, Jasmin et al., 
2003, Johansen and Fields, 2004).  
 
The IASP definition of chronic pain as discussed earlier, “Pain that persists 
beyond normal tissue healing time, which is assumed to be 3 months”, and 
later proposed definitions such as that of Merskey and Bogduk (Merskey and 
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Bogduk, 1994), “Chronic pain is a state of continued suffering sustained long 
after the initial injury has healed”, could be described in terms of memory. 
Chronic pain is a “memory” of the initial response to tissue injury which for 
some reason has become more permanent and is maintained by substantial 
reorganisation within the CNS. It has been suggested that fear conditioning 
contributes to this process, where chronic pain is acting as an unconditioned 
stimulus leading to increased negative associations with situations and 
environments as a result of being in near constant pain (Apkarian et al., 
2008). This idea is further supported by the increasing prominence in these 
conditions of the mPFC, an area of the brain that has, in rodents, been 
demonstrated to play a key role in Pavlovian fear conditioning and emotional 
and cognitive processes (Millecamps et al., 2007). 
 
Recently, attempts have been made to test this “memory hypothesis” 
pharmacologically using D-cycloserine (DCS), a partial agonist of the N-
Methyl-D-aspartic acid (NMDA) receptor (Furukawa and Gouaux, 2003), 
which has previously been demonstrated to enhance learning and memory 
and facilitate the extinction of acquired fear responses through the 
development of new memories via NMDA receptor regulation. Millecamps et 
al (Millecamps et al., 2007) found that oral administration of DCS to rats with 
spared nerve injury resulted in a dose-dependent decrease in mechanical 
sensitivity which continued for weeks after cessation of treatment. Acute 
antinociception could be induced by direct infusion of DCS into the mPFC or 
amygdala by an NMDA dependant process, furthermore, DCS treatment 
significantly reduced fear avoidance behaviours in SNL animals. In the mPFC 
of SNL rats, expression of the NMDA receptor NR2B was down-regulated; 
however, this effect was reversed with repeated oral administration DCS. 
Taken together these results clearly demonstrate a role for plasticity in the 
brain in the regulation of pain behaviour and suggest that NMDA receptor 
modulation may be a key target for development of drug therapies. 
 
Recent studies have increasingly demonstrated a key role for the limbic 
system in the modulation of pain behaviour and maintenance, in particular 
the anterior cingulate, insula and media-prefrontal cortices and the amygdala. 
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These limbic areas are all strongly interconnected and key in emotional and 
social processing. In a notable study Johansen and Fields (2004) 
demonstrated that the ACC is both necessary and sufficient to develop an 
aversive memory to a painful stimulus in a glutamate dependant fashion. This 
leads to the suggestion that pain processing may lead to an LTP like process 
in the brain, a hypothesis further supported by the up-regulation of the NR2B 
component of the NMDA receptor within the ACC following inflammatory 
injury (Wu et al., 2005).  
 
In a rat model of inflammatory arthritis, Bird et al (Bird et al., 2005) found that 
synaptic plasticity of neurons from the central nucleus of the amygdala was 
inhibited in arthritic animals when the antagonist had no significant effect on 
normal transmission of control neurons. Furthermore the ACC, hippocampus 
and amygdala have been implicated in fear memory acquisition in a process 
that also specifically requires NMDA within the ACC (Malin and McGaugh, 
2006, Zhao et al., 2005). 
 
These results demonstrate that NMDA receptors regulate pain transmission 
and undergo plastic changes to contribute to and perpetuate the persistent 
pain state by altering neuronal activity.  
 
2.2.2.4 Long Term Potentiation 
 
Long term potentiation (LTP) has been widely studied in the hippocampus as 
the cellular basis of learning and memory and cytokines are implicated in the 
regulation of this process. LTP is the strengthening of signalling at a synapse 
(i.e. the potentiation of the signal), it is measured electrophysiologically as an 
increase in excitatory post-synaptic potential (EPSP), which lasts for at least 
one hour. There are considered to be two phases or forms of LTP, the 
shorter term ‘early phase’ LTP which is protein independent and lasts for one 
to five hours and the longer term ‘late phase’ LTP. This latter phase results in 
a more permanent strengthening of the synapses by increased gene and 
protein expression whereas in the early phase the strengthening of signalling 
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is thought to be due to increased release of transmitters such as glutamate 
and the increased activity of these receptors. 
 
Interleukin 1 (IL-1) has been implicated in the regulation of LTP, Ross et al 
(Ross et al., 2003) investigated the role of endogenous and exogenous IL-1 
in LTP in the mouse hippocampus. There are several members of the IL-1 
family IL-1α, IL-1β and IL-1 receptor antagonist (IL-1ra) these cytokines 
interact with two receptors IL-1 receptor 1 (IL-1RI) and IL-1 receptor 2 (IL-
1RII) but signalling only occurs following binding with IL-1RI which results in 
the subsequent activation of a signalling cascade via association with IL-1 
accessory protein (IL-1AcP). The inhibitory cytokine IL-1ra competitively 
binds IL-1RI but does not associate with IL-1Acp therefore not activating the 
cascade. These cytokines and their related factors are all known to be 
expressed within the hippocampus and other brain areas where IL-1 
administration has been demonstrated to both stimulate and inhibit synaptic 
activity (Wang et al., 2000, Zeise et al., 1992). 
 
Levels of endogenous interleukins were measured in mouse hippocampal 
slices at room (21-24ºC) and physiological (34-36 ºC) temperatures with 
significantly higher levels of both IL-1α and IL-1β being expressed at the 
higher temperature. It is also interesting to note that IL-1α was by far the 
more abundant of the two cytokines at physiological temperature. In order to 
stimulate LTP in the slices high frequency tetanic stimulation was used in a 
‘theta-burst stimulation’ (TBS) paradigm, with five trains of fifteen 100Hz 
quadruple bursts. This resulted in significant potentiation of the EPSP, which 
lasted for over one hour. At room temperature, application of IL-1β prevented 
TBS-induced LTP, and this effect was abolished by co-administration with IL-
1ra. When IL-1ra was administered alone LTP induction was not affected 
however at physiological temperatures IL-1ra inhibited LTP development in a 
concentration dependant manner. These results demonstrate a dual role for 
IL-1 in LTP, low levels being necessary and higher levels inhibitory.  
 
In an effort to understand some of the processes behind this alteration in 
LTP, Hellstrom et al (Hellstrom et al., 2005) investigated the membrane 
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properties of hippocampal neurons exposed to LPS in organotypic slice 
culture. Neurons exposed to LPS for seven days demonstrated similar 
resting membrane potentials and action potential properties to control 
cultures. LPS exposed neurons however, did show a significantly lower 
membrane resistance and while the action potential threshold was elevated, 
the frequency was decreased leading to a decreased probability of action 
potential firing. These authors also demonstrated a significant increase in IL-
1β release at two days following the LPS exposure with levels returning to 
baseline after four days. A similar effect was seen with IL-6 expression; IL-6 
expression is thought to be induced by increases in IL-1β however 
application of IL-1ra did not entirely abolish the LPS-induced increase 
suggesting another mechanism by which IL-6 release is stimulated. 
Interestingly, IL-1ra also decreased action potential frequency and when 
applied with LPS an additive effect was seen, suggesting LPS is altering 
action potential properties via an IL-1β-independent mechanism. 
 
Using pharmacological inhibitors, it is possible to specifically measure either 
the Inhibitory post synaptic potentials (IPSPs) or EPSPs. No significant 
difference was seen in the EPSPs of previously LPS exposed versus 
unexposed neurons although there was a trend towards an increase. IPSPs, 
however, were significantly potentiated in treated neurons, an effect that was 
reversed when they were co-incubated with LPS and IL-1ra. This finding that 
GABAergic inhibition is enhanced in an IL-1ra-dependant manner, several 
days after LPS treatment, suggests that IL-1β may have a long term 
inhibitory effect on overall synaptic activity. 
 
Initially this research appears to contradict the previously suggested role for 
IL-1β in regulating LTP as it demonstrates no significant difference in EPSP. 
However, as discussed earlier different concentrations of the cytokine have 
differing effects with a U-shaped dose response curve. A role of IL-6, 
independent of IL-1β, has also been suggested. It seems likely that time 
scales play an important role as Ross et al (2003) looked at the effects of one 
or two hours as opposed to several days. Prolonged chronic cytokine 
exposure may have longer-term effects on LTP production and memory, 
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whereas acute increases have transient reversible effects. It seems likely 
therefore, that longer-term exposure is changing the mechanisms of long-
term LTP by altering gene and protein expression leading to overall inhibition 
of activity, whereas in the shorter-term, more temporary effects are occurring 
via modulation of ion channels and changes in neurotransmitter release. 
 
2.3 Psychological Symptoms 
 
2.3.1 Emotional Decision Making 
 
Apkarian et al (2004a) examined emotional decision making capability in 
CRPS and CLBP and found both of these groups to be significantly impaired 
in this area when compared with healthy controls. Interestingly, although 
performance in CLBP was correlated with reported levels of pain at the time 
and modulated by sympathetic block, this was not seen in CRPS indicating 
that different brain mechanisms are involved in these two conditions. 
 
2.4 In vivo Experiments 
 
As discussed above, cytokines have many effects at the cellular level and 
animal studies have also demonstrated significant behavioural effects. IL-1 
plays a significant role in both spatial memory and passive avoidance 
conditioning but has no effect on non-spatial navigation as demonstrated by 
Yirmiya et al (2002) using two experimental paradigms, the Morris water 
maze (MWM) and the passive avoidance test (PAT). In the water maze, the 
rat’s natural dislike of water and swimming ability are exploited to make it 
search for a hidden platform in a pool of water. In the spatial test, rats are 
given visual cues or landmarks and they must find and then remember the 
location of the platform in relation to these landmarks. In the non-spatial form 
of the test the platform is clearly marked and the animal merely learns that 
the mark represents the location of the platform.  
 
In the PAT animals were given limited access to drinking water (30 minutes 
per day) and then placed in a cage where the water spout was slightly 
electrified. Following training and acclimatisation, the rats were given a shock 
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when they went to drink. The latency to return to the drinking spout on a 
following occasion was measured to see if the animal had ‘learnt’ to avoid the 
shock. 
 
To test the effect of IL-1 on these learning paradigms rats were infused i.c.v. 
with either IL-1β, IL-1ra or saline immediately after each test. IL-1ra 
significantly inhibited learning in the spatial MWM but had no significant effect 
in the non-spatial version. In the PAT, IL-1ra-injected animals had 
significantly decreased latencies compared with controls and IL-1β treated 
animals significantly increased, both of these effects increased over time. 
These results demonstrate a significant role for IL-1 in memory processing 
and learning of both spatial and fear-conditioned events, a theory further 
supported using IL-1r knock out (IL-1 KO) mice. 
 
Using the MWM along with a cage that provided a foot shock, spatial memory 
and fear conditioning were shown to be significantly attenuated in IL-1 k.o. 
mice (Avital et al., 2003).  Performance in the non-spatial MWM and an 
auditory conditioning task were, however, unaffected. In vivo recording in the 
dentate gyrus of IL-1 k.o. animals demonstrated increased paired pulse 
inhibition and LTP could not be generated in CA1 of the hippocampus in slice 
preparations. Together with the previous results this provides evidence for 
cytokine mediated changes in processing at the cellular level leading to 
changes in behavioural responses and specific forms of memory 
development. 
 
2.5 Chapter Discussion 
 
While identifying the areas of the brain that are activated in certain 
circumstances is of great importance, it is also becoming apparent that the 
temporal organisation of activation is of great significance. For example, in 
CLBP patients show an abnormal activation pattern in the resting state (Baliki 
et al., 2008) and in post-hepatic neuralgia (PHN) a change in the temporal 
activation of specific brain areas in allodynia has been linked to the 
magnitude of pain (Geha et al., 2007). 
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Unravelling the role of individual networks is further complicated by the fact 
that descending and ascending pathways commonly act in parallel and/or 
converge on the same areas making teasing out the role of one specific 
network all the more difficult (Bee and Dickenson, 2007). 
 
From the brief discussion of research presented here, it is evident that 
cytokines play a significant role in the regulation of the CNS and that these 
CNS effects are closely correlated with physical and behavioural symptoms 
in both humans and animals. The experiments discussed here tend to 
concentrate on the effects of IL-1 and TNF and these are indeed the 
mostly widely studied cytokines in this context. Although such work provides 
invaluable insight into the role of cytokines it is important to remember that 
the immune response involves a complex interplay between a huge number 
of such molecules with both inhibitory and stimulatory effects. Further work 
into the role of other cytokines is clearly needed to further support and 
understand the results presented here. The evidence for a precise role for 
altered cytokine expression in CRPS and other chronic pain states is far from 
conclusive. It is certain however, that sufferers of such conditions do have 
abnormal cytokine expression with a trend towards an increase in 
inflammatory cytokines and a decrease in the inflammatory molecules, this 
coupled with altered regulation of the HPA and endocrine axes could lead to 
many of the physical and cognitive symptoms described. It is also likely that 
the cytokine profile changes over the course of a disease ultimately 
predicting the severity and chronicity of the condition 
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Chapter 3 
 
3 Introduction: Methods 
 
3.1 Animal Models of Chronic Pain 
 
The use of animals in the study of pain is controversial, it is not possible to 
replicate the human experience of these conditions precisely and as such the 
use of such models has been called into question, however, they can be 
considered a good starting point to improve understanding of pain 
mechanisms at the cellular and systems level. Many models exist that have 
been developed to represent the different types of pain experienced in 
human conditions as closely as possible. Pain can broadly be classified by its 
origin, either inflammatory or neuropathic, and its persistence, acute or 
chronic. As such animal models have been developed to reproduce these 
types of pain; recently elaborate models of lesser studied types of pain such 
as bone and cancer pain have also been developed. 
 
3.1.1 Inflammatory Pain Models 
 
The most common cause of pain is inflammation which can occur as a result 
of tissue injury either by physical or chemical insult, many diseases that 
cause pain are also the result of inflammation e.g. rheumatoid arthritis. 
Inflammatory pain in animal models is usually induced by the injection of an 
inflammogen, the most common injection site in rodents is the hind paw 
which has several benefits over other areas in that it is easily accessible for 
measurements, can be easily seen in behavioural tests and can also be 
compared with a non-injected paw in the same animal (Morris, 2003, Larson 
et al., 1986, Hargreaves et al., 1988, Iadarola et al., 1988) (see Figure 5). 
Other injection sites include i.p. injection as a model of visceral pain, injection 
into a joint to simulate arthritis or direct injection into a muscle for example 
the masseter muscle as a model of orofacial inflammation.  
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Figure 5 An example of the footpad model of inflammatory pain. The right 
hindpaw is noticeably swollen following intradermal injection of an inflammogen, in 
this case 0.1% CFA. The non-injected left paw remains unaffected and can be used 
as a within group control. 
 
As well as location of injection, the choice of inflammogen is important when 
designing a pain model. Formalin is commonly used to induce an acute 
response lasting about one hour, there are two stages to the formalin 
response, in the initial stage, which results from direct activation of peripheral 
nociceptors, the animal keeps the injected paw lifted and does not use it to 
bear weight (Puig and Sorkin, 1996). This first phase lasts around five 
minutes after which the animal will begin to bear weight on the affected paw 
but can be seen to show other pain behaviours such as guarding and licking 
of the injected paw. This second phase is thought to result not only from 
persistent activation of peripheral nociceptors, as in the first phase, but also 
from increased excitability of the dorsal horn fibres (Bruehl et al., 1999, 
Taylor et al., 1995). The TRPV1 agonist, capsaicin, is also commonly used 
since it acts specifically on nociceptors it can be used to model neurogenic 
inflammation. Intradermal capsaicin injection produces hyperalgesia along 
with the classic “wheal and flare” reaction which lasts up to an hour (LaMotte 
et al., 1991). 
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Other substances can be used to induce longer term inflammatory pain, 
some of the most commonly used are carrageenan, mustard oil, zymosan 
and complete Freund’s adjuvant (CFA) (Hargreaves et al., 1988, Iadarola et 
al., 1988, Ma and Woolf, 1996a, Ma and Woolf, 1996b, Neumann et al., 
1996). 
 
CFA is a solution of mycobacterium tuberculosis emulsified in mineral oil, it 
acts as an immunopotentiator, stimulating the cell-mediated immune 
response. In animal models, specific injection of CFA can lead to a localised 
inflammatory response inducing inflammation within two hours of application 
showing an initial peak at six to eight hours with hyperalgesia, oedema and 
inflammation being present for more than three weeks (Raghavendra et al., 
2004, Stein et al., 1988). Although this cannot really be considered a model 
of chronic pain, since it does not persist for many weeks or months, it is 
commonly called a “persistent pain model” and can be used to compare 
mechanisms of longer term pain with those seen in more acute models. The 
degree of oedema in this model has been demonstrated to correlate with 
behavioural symptoms of pain and immunological evidence of a cellular 
inflammatory response (Stein et al., 1988, Nagakura et al., 2003). 
 
Carrageenan (CAR) is a mucopolysaccharide extract of the chondrus crispus 
algae that is commonly used as a food additive. When injected into soft 
tissue CAR induces a rapid, non-immune, highly reproducible response 
which peaks at around three hours and returns to normal within in 24 hours 
unless repeated applications are given (Morris, 2003). As such, the CAR 
model can be considered a model of “sub-acute pain” (Iadarola et al., 1988, 
Morris, 2003). 
 
There are many methods of assessing pain in animal models, one of the 
earliest, and still most commonly used, techniques is the paw withdrawal 
reflex, first reported by Hargreaves et al in 1988 (Hargreaves et al., 1988). In 
this method, a radiant heat stimulus is applied to the paw of the subject and 
the withdrawal time measured. A decrease in withdrawal time at a given 
temperature is considered to be evidence of hyperalgesia. A technique often 
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used alongside the Hargreaves method is the use of Von Frey hairs to 
measure the response to pressure, a decrease in paw withdrawal time in 
response to a given pressure is considered to be evidence of allodynia (Ren 
and Dubner, 1993, Kim and Chung, 1992). 
 
The above measurements of pain response allow the animal to control the 
level of pain in response to a stimulus since they are able to remove their 
paw. Other methods can be used to get some measurement of spontaneous 
pain for example, the writhing response to visceral pain (Ness, 1999, 
Vyklicky, 1979), vocalisation (Wood et al., 2007) and measures of behaviour 
such as lifting or guarding of an injured paw and autotomy (Kauppila, 1998, 
Tjolsen et al., 1992, Olmarker et al., 2002, Stein et al., 1988). 
 
3.1.2 Neuropathic Pain Models 
 
The most common method of inducing neuropathic pain in an animal model 
is through surgery, a specific nerve or group of nerves is damaged or cut and 
then the resultant behaviour compared with that of a sham operated animal. 
The three most common surgical models of neuropathic pain are; chronic 
constriction injury (CCI) where several small ligatures are loosely tied around 
one sciatic nerve (Frank, 1993), partial nerve ligation (PSL) where a single 
tight ligature is tied around a portion of the sciatic nerve (Seltzer et al., 1990) 
and spinal nerve ligation (SNL) where a tight ligature is tied around the spinal 
nerves of one side of the body at L5 and L6 (Kim and Chung, 1992). 
Although these models all produce similar behavioural evidence of on-going 
pain, both evoked and spontaneous, there are subtle differences in the 
behaviours seen (Kim et al., 1997). For example, SNL results in significantly 
higher mechanical allodynia than the other two models, lasting up to 20 
weeks post-surgery, whereas, CCI, which has relatively lower mechanical 
allodynia results in more persistent on-going thermal hyperalgesia (Kim et al., 
1997). These behavioural differences may help contribute to the 
understanding of the mechanisms behind the symptomatology of various 
nerve injuries and neuropathic disorders. 
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3.2 Cell culture 
 
Cell culture is a widely used technique in which isolated eukaryotic cells are 
grown in vitro under controlled conditions, the development and methodology 
of cell culture is closely related to tissue and organ culture where tissue and 
organ explants respectively are maintained in vitro. The correct conditions 
are needed for cell or tissue explants to survive ex vivo, nutrients are 
provided by specific growth media and temperature and humidity maintained 
within tight parameters using an incubator. Incubators are usually filled with a 
specific gas mixture to provide oxygen and help maintain the pH of the 
medium. 
 
Some of the most significant early culture experiments were performed by 
Sydney Ringer in the late 19th century. Ringer demonstrated that it was 
possible to maintain a beating heart ex vivo if it was perfused with a specific 
salt solution; this became known as “Ringer’s Solution” and is still frequently 
used in medicine and research laboratories (Ringer, 1882).  
 
Cell culture is a relatively cheap technique and allows for multiple 
experiments to be repeated under tightly controlled conditions. Experimental 
conditions can be easily manipulated to represent a variety of situations, for 
example, hypoxia or acidosis, and drugs or other reagents can be added at 
varying concentrations. This technique enables the use allows drugs or 
manipulations that would be impossible or unethical in animal or human 
models. Cells can normally be maintained in culture for several weeks 
allowing long term manipulations investigating a variety of time points to be 
carried out. 
 
There are significant issues with cell culture experiments, the conditions in 
which cultures are maintained, no matter how carefully set up and preserved, 
are still far from those in vivo. Cells within an organism are in 3D whereas in 
culture they are often grown on a flat surface. Under culture conditions one 
cell line/type is commonly isolated and grown, in an organism many cell 
types exist synergistically. Depending on the cell type some of these issues 
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can be overcome for example by co-culture of more than one cell type or by 
organotypic slice culture. 
  
3.2.1 Primary Neuronal cell culture 
 
Short term culture of neurons is relatively simple and useful for studying 
growth and development of cells and neurite initiation. In order to study fully 
formed neuronal cells and their function much longer culture times are 
necessary to allow adequate time for a complex network of connections to be 
made, this is somewhat problematic due to the delicate nature of this cell 
type and their highly specific requirements. 
 
Most cell types can be fairly easily harvested from tissue by homogenisation 
and subsequent centrifugation. Obtaining a homogenous aliquot of viable 
neurons from brain tissue is not, however, without its difficulties; it is very 
difficult to separate the cells without damaging them since neurons grow 
together in a tightly knit complex network forming connections with many 
different cells. Brain tissue is not a homogenous mass of neurons, there are 
many other cells present, primarily the microglia and astrocytes, which, as 
well as providing immune protection, release growth factors and provide 
mechanical support for the neurons. Glial cells grow faster than neurons and 
are not so reliant on specific conditions; if the culture is contaminated with a 
significant number of such cells, they can negatively affect neuronal 
development.  
 
The most common starting point for a neuronal culture it to use cells from an 
embryonic or newborn rat or mouse since few connections have been formed 
between cells at this stage meaning they are more easily separated, the 
majority of methods are based on that developed by Banker and Goslin 
(1998). Cultures are usually made from either cortical or hippocampal tissue 
depending on how they are going to be used. Hippocampal cultures allow for 
greater neuronal homogeneity since this area of the brain contains fewer glial 
cells than the cortex. It is, however, more difficult to dissect out this small part 
of the brain and since the amount of tissue it yields is relatively small, other 
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tissue, such as cortical tissue is often used where higher densities of neurons 
are needed, for example in western blotting (Meberg and Miller, 2003). 
 
The need for specific growth factors from a variety of cells means that 
neurons do not grow well in long-term culture using standard media and 
serum. Standard growth media, such as DMEM, also contain substances 
such as cysteine and glutamine which affect neuronal regulation and ferrous 
sulphate, which is toxic to neurons. Serum is also problematic in that it 
encourages glial growth and proliferation, and although cytotoxic inhibitors 
can be used to reduce this problem they also have deleterious effects on 
neuronal growth (Wallace and Johnson, 1989).  
 
In vivo, neurons obtain much of their essential nutrition and growth factors 
from surrounding glial cells, as such, the traditional method to provide these 
nutrients in culture is to either grow the cells on a bed of cultured glial cells or 
inverted over a glial culture or to feed them with glial conditioned medium 
(Banker et al., 1998, Meberg and Miller, 2003, Bekkers and Stevens, 1991). 
The use of glial feeder cells is costly, time consuming, and can lead to 
contamination of cultures. To combat this issue, Brewer et al (Brewer et al., 
1993) developed a culture medium, Neurobasal, and a serum free 
supplement, B27, which contains essential factors to support long term 
growth on primary neuronal cultures while significantly inhibiting glial growth. 
Neurobasal and B27 are now widely available and have been demonstrated 
to support a wide variety of neuronal cultures (Brewer et al., 1993, Brewer, 
1995). 
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3.3 Molecular Biology 
 
Molecular biology is, as the name suggests, the study of biology at the 
molecular level. It is used to break down whole body systems into their 
genetic and protein components and look at how these individual elements 
interact. In recent years molecular biology has taken a massive leap with the 
development of gene-knock-out animals and the mapping of the entire 
genomes of individual species including Homo sapiens in the Human 
Genome Project. Studies of molecular biology in healthy and diseased 
conditions can contribute greatly to the understanding of disease processes 
and often lead to the development of precisely targeted therapies. 
 
3.3.1 RT-PCR 
 
The reverse transcriptase polymerase chain reaction or RT-PCR is one of the 
most frequently used molecular biology techniques, it allows many copies of 
a specific DNA sequence to be generated following the reverse transcription 
of RNA that has been previously isolated from a sample. Reverse 
transcription is the process by which single stranded RNA is transcribed into 
double stranded complementary DNA (cDNA) using a reverse transcriptase 
enzyme. A nucleic sequence of interest within the cDNA can then be targeted 
using specially designed primers. In order for the primers to bind to the cDNA 
a series of temperature changes are used, firstly the double stranded cDNA 
must be denatured at a high temperature into single strands. The 
temperature is then reduced to allow the primers to “anneal” to the DNA, this 
temperature can vary depending on the primer design and concentration as 
well as the cation concentration of the solution. Finally the DNA is extended 
from the primers using a polymerase enzyme the most commonly used being 
Taq polymerase which was named after the Thermus aquaticus bacterium 
from which it was isolated (Chien et al., 1976) (see Figure 6) for a summary 
of the entire PCR reaction. DNA increases exponentially through multiple 
cycles and is ultimately visualised using agarose gel electrophoresis with 
ethidium bromide. 
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Figure 6 Schematic Drawing of the PCR Cycle. cDNA from the RT reaction is first 
denatured at 94-96°C (A) and the subsequently separated strands annealed to 
reaction specific primers at ~60°C (B). The next step is elongation which occurs at 
72°C, the activation temperature of Taq polymerase (C) resulting in two copies of 
the segment of interest (D). The cycle is then repeated multiple times resulting in 
exponential production of the product (E). 
 
3.4 Immunological techniques 
 
Immunology is the study of the immune system including antigens and their 
specific antibodies, this wide area of biomedical science has been harnessed 
for use in research and diagnostic laboratories for decades with new 
techniques utilising antibodies being frequently introduced. 
 
3.4.1 Immunohistochemistry and Immunocytochemistry 
 
Immunochemistry is widely used to locate specific protein antigens within 
tissues and cells populations. One of the primary benefits of this technique is 
that it allows the location of antigens to precise areas within the sample, by 
using a mixture of two or more primary antibodies it is also possible to show 
colocalisation of different proteins. 
 
The simplest method of Immunohistochemistry is the direct method using an 
antibody that is conjugated to a dye to show up the labelled regions. This 
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method is not commonly used, however, as it does not allow for any 
significant amplification of the signal and has little opportunity for 
optimisation. The more common indirect method was used here where a 
primary antibody, raised in a species other than the species of interest, is first 
applied to the sample. This is followed by a secondary antibody which is 
raised against the IgG of the species that the primary antibody was 
developed in (see figure 7).  
 
 
Figure 7 The two basic methods of immunological staining. The Direct Method 
(top) in which the primary antibody to the antigen of interest is conjugated to a dye 
or fluorescent molecule. In the Indirect Method (bottom) the primary antibody binds 
to the antigen of interest and a secondary antibody raised against the IgG of the 
species the primary was raised in is added. The secondary antibody is conjugated to 
a dye and since multiple secondary antibodies can bind one primary molecule the 
single can be amplified. 
 
Two common methods of visualisation were used in this work, the first being 
immunofluorescence where the secondary antibody is conjugated with a 
fluorescent dye such as fluorescein isothiocyanate (FITC) and viewed under 
a fluorescence microscope. Fluorescent staining was typically used when 
more than one antigen was studied in the same sample as colocalisation can 
be very clearly seen in this method. 
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The second detection method used is the “Avidin: Biotinylated enzyme 
Complex” (ABC) method where the secondary antibody is labelled with a 
biotin molecule which had four binding sites for the vitamin avidin. Avidin has 
an incredibly high affinity for biotin and as such binding between these 
molecules is essentially irreversible. Following binding of the secondary 
antibody the ABC complex mixture is added which contains an enzyme for 
detection of product (see Figure 8). 
 
 
Figure 8 The ABC Staining Technique. The primary antibody binds to the antigen 
of interest and a biotinylated secondary antibody is added. Following binding of the 
secondary antibody the ABC complex is added, each avidin molecule binds up to 
four biotin which in turn bind to enzyme reporter molecules. The complex is then 
visualised by addition of a substrate resulting in a coloured precipitate. 
 
3.4.2 Hypoxyprobe 
 
Hypoxyprobe or, Pimonidazole hydrochloride, is a bioreductive compound 
used to label hypoxic areas in tissue or cells. Under hypoxic conditions such 
compounds generate reactive metabolites which bind to cellular 
macromolecules permanently labelling them even if the area is subsequently 
re-oxygenated. Hypoxyprobe is a nitroaromatic compound, such compounds 
have been widely studied and extensively used as markers of hypoxia. In 
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1976 Varghese et al (Varghese et al., 1976) used 14C-labelled misonidazole 
to target hypoxic areas in Chinese hamster ovary cells and KHT tumour cells. 
 
Adducts form with thiol groups in proteins, peptides and amino acids under 
hypoxic conditions, i.e. where pO2 is less than 10mmHg. It has been 
demonstrated that this irreversible binding is dependant only on the degree of 
hypoxia and is not mediated by redox enzymes, NADH or NADPH levels. 
The oxygen dependence of misonidazole binding is close to that of radiation 
resistance and, as such, it can be used as a hypoxia marker in solid tumours. 
 
The use of radioisotopes has limited clinical utility, particularly with the 
commonplace use of radiotherapy in cancer treatment and this led to the 
development of non-invasive assays using 2-nitromidazoles using PET, 
nuclear medicine analysis and magnetic resonance spectroscopy. 
 
Following the success of in vivo techniques it became apparent that some 
form of marker at the cellular level would be highly desirable and an 
immunological method was developed using these compounds to pinpoint 
hypoxic regions within tissues and individual cells. 
 
Antibodies were raised against protein adducts of reductively activated 2-
nitromidazoles. A variety of markers have enabled the precise labelling and 
localisation of hypoxic regions as well as allowing for the investigation of 
colocalisation with other markers. 
 
3.4.3 ELISA 
 
The enzyme-linked immunosorbent assay (ELISA) is an alternative method 
of utilising an antibody to detect as specific antigen. Unlike immunological 
staining techniques, they can give accurate measurements of the amount of 
antigen present and are therefore useful for quantifying responses to 
experimental manipulations. In order to visualise the ELISA reaction 
antibodies are bound to an enzyme which will result in some form of 
quantifiable signal such as fluorescence or colometric dyes. ELISAs are 
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usually performed in 96-well plates, to which the sample or cells of interest 
have been attached.  
 
Prior to the development of ELISA, radioactivity was used to quantify the 
amount of bound antibody, these radioimmunoassays (Yalow and Berson, 
1960) were both dangerous and time consuming so an alternative, 
quantifiable, marker of antibody binding was sought. Stratis Arameas and 
G.B. Pierce individually developed a method by which enzymes, such as 
peroxidise, could be linked to an antibody resulting in a measurable colour 
change on addition of a relevant substrate (Lequin, 2005). Since the ELISA 
relies on the antigen of interest being attached to a surface, the vessel being 
used must be rendered “immunosorbent” a method first demonstrated by 
Wide and Porath (1966) using the dextran gel “Sephadex”. 
 
There are two forms of ELISA, the first is indirect where the sample is 
immobilised on the plate by adsorption to the surface. The plates are blocked 
using a non-specific protein to prevent any irrelevant binding of the antibody. 
Following blocking, the specific antibody is added and then visualised either 
directly if it is conjugated to an enzyme or indirectly via a secondary antibody. 
This form of ELISA is expensive and can be problematic for samples 
containing very small amounts of antigen as all proteins in the sample will 
bind to the plate potentially masking the antigen of interest. 
 
In a sandwich ELISA the plate is pre-coated with an antibody against the 
antigen of interest, a blocking solution is applied to prevent non-specific 
binding and the sample is added. The plate must then be washed to remove 
any unbound antigen and a second antibody is added, sandwiching the 
antigen between two specific antibodies. This second antibody can be 
conjugated to an enzyme for detection or a secondary enzyme-linked 
antibody added. Sandwich ELISAs allow for detection of smaller amounts of 
antigen as only the protein of interest is bound to the plate. 
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Chapter 4 
 
4 Experimental: Questionnaire-Based 
Clinical Study 
 
4.1 Introduction 
 
Over time it has become apparent that as well as the myriad physical 
symptoms characteristic of CRPS there are also a significant number of 
bizarre phenomena which appear to be psychological or non-organic in 
origin. Many sufferers report increased pain in response to visual and audio 
stimuli and altered visuo-spatial awareness (Birklein, 2005, Sunderland, 
1976). They also demonstrate emotional labiality, referred sensations and an 
altered perception of their affected limb (Maihofner et al., 2006, McCabe et 
al., 2003a, McCabe et al., 2003b). Until recently these disturbing symptoms 
went largely unnoticed with sufferers and healthcare professionals alike 
considering them to be unrelated to the condition. In consultations many 
patients were afraid to mention such symptoms due to fear that they would 
not be believed.  Recent work however has shown these symptoms to play a 
significant role in this condition and they are now being considered as 
important areas in research, treatment and diagnosis.  
 
As a great deal of evidence in this area is anecdotal from clinics and 
consultations the number of sufferers experiencing these symptoms is not 
clear. To this end, a questionnaire was developed to further investigate their 
prevalence within a population of CRPS sufferers. The questionnaire 
included questions on a wide range of symptoms and was completed by 
CRPS sufferers attending a national symposium of the support group RSD 
UK. Some of the more significant findings are reported here.  These findings 
were also presented at the IASP ‘Pain in Europe VI’ conference 2006. 
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4.2 Materials and Methods 
 
4.2.1 Methods 
 
A questionnaire was developed to investigate the prevalence of a number of 
unusual symptoms seen in CRPS. The questionnaire was distributed at a 
patient support symposium (RSD-UK annual conference 2005) 52 
questionnaires were considered suitable for further analysis, the majority of 
which were completed by the patients themselves although some were 
assisted by their carer. All of the subjects had been previously diagnosed 
with CRPS type I or II using the accepted IASP criteria. The questionnaire 
was developed and administered, by Professor David Blake of the RNHRD 
Bath, prior to the start of this work. All subsequent analysis was performed by 
the author of this thesis. 
 
Data were collated using an Excel spread sheet and in most cases answers 
interpreted as ‘Yes’, ‘No’ or ‘Sometimes’ by the analyst to allow for 
comparison. Specific questions asked are detailed in the following sections. 
Not all subjects answered every question. 
 
4.2.2 Subject Demographics 
 
N = 52 
Age: range 13-78 (median 41) 
Sex: 45 female, 7 male 
Duration of disease: 0.5 – 32 years (median 5 years)  
This is representative of a typical CRPS population with the majority of 
sufferers being post-menopausal women. Due to the nature of the support 
group a large proportion of the subjects were chronic sufferers who had lived 
with CRPS for many years. 
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4.3. Limb Perception 
 
4.3.1. Introduction 
 
One of the most striking observations in CRPS is that sufferers often feel 
removed or separated from their affected limb, sometimes to the extent that 
they do not feel it belongs to them and, in extreme cases, they want to have it 
removed. All too often, severe cases of chronic CRPS result in the 
amputation of the affected limb due to a combination of unbearable physical 
symptoms and the disownership or alienation of the limb. These symptoms 
are not unlike neglect and alien hand syndrome (AHS) sometimes seen 
victims of stroke and brain damage. Neglect patients have an impaired or lost 
ability to react to or process sensory stimuli presented in one hemispace 
following damage to the cerebral cortex (Farne et al., 2004, Kikkert et al., 
2006). This can manifest itself in several ways including disownership of 
parts of the body contralateral to the damaged hemisphere and an inability to 
see or recognise objects presented in the corresponding visual field. 
 
The questions asked (in reference to the CRPS limb) were: 
1) Is it yours? 
2) Is it alien? 
3) Do you want to get rid of it? 
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4.3.2. Results 
 
The results are summarised below. A remarkably large proportion of CRPS 
sufferers experience altered perception of their affected limb, indeed 89% of 
those questioned would like to “get rid of it” altogether, some persistently 
(67%), others intermittently (22%). 45% of respondents did not consider the 
limb to belong to them and 69% considered it to be ‘alien’ (see table 2 and 
figure 9). 
 
 Is it yours? Is it alien? Do you want to get rid of it? 
No 18 (45) 6 (15) 5 (11) 
Yes 16 (40) 27 (70) 30 (67) 
Sometimes 6 (15) 6 (15) 10 (22) 
Total 40 (100) 39 (100) 45 (100) 
 
Table 2 Results of Limb Perception Questions. The percentage of people giving 
each response is given in brackets. 
 
 
Figure 9 Results of Limb Perception Questions The majority of respondents 
reported some feelings of alienation or disownership towards their affected limb. 
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4.3.3. Discussion 
 
In many ways these results are exactly as one might expect, if a part of the 
body is causing such pain and discomfort then to remove that part would 
provide some relief. What is perhaps of greater interest is that almost half of 
respondents did not consider the limb to be their own and over two thirds 
considered it ‘alien’ to them. Some of the comments made in response to the 
above questions show how strongly sufferers feel about their CRPS limb: 
 
“It belongs to a freak” 
 
“It doesn't feel like mine, despite the constant and extensive pain it can feel 
disconnected and alien. I have wanted to get rid of it repeatedly…” 
 
“Doesn't feel like it's my limb somebody else’s. Wanted to cut it off in the bath 
so I wouldn't make a mess.” 
 
Neglect and alien hand syndrome (AHS) patients often have similar reactions 
to a limb following damage to the cerebral hemisphere contra-lateral to that 
limb. Pain can cause an altered perception of body image in humans and as 
discussed below previous work has shown CRPS patients to have altered 
mapping of the affected limb within S1 (Forderreuther et al., 2004, Maihofner 
et al., 2003).  
 
Impaired perception of the hand has previously been demonstrated in 
patients with upper limb CPRS, Forderreuther et al (2004) examined 114 
patients and found 54.4% described their affected hand has foreign. The 
majority of these patients (35%) voluntarily gave up this information and the 
remainder selected terms suggesting foreignness from a variety of suggested 
words. Although 88.9% of patients with chronic CRPS (duration of more than 
1 year) reported such feelings  45% of acute sufferers (duration less than 90 
days) also had feelings of foreignness. This suggests that such symptoms 
either increase over time or are indicative of the severity and prognosis of the 
disease. 48% of patients were unable to identify individual fingers following 
 91 
tactile stimulation on the affected side compared to only 6.5% on the 
unaffected side suggesting altered representation of the affected hand within 
the sensory cortex. 
 
As a measure of neglect these authors used the line bisection task. Subjects 
are required to centrally bisect a line on a piece of paper that is placed either 
straight in front of them or to their left or right hand side. Deviations from the 
centre of the line are measured in millimetres. No significant difference was 
found between controls and patients with CRPS of the left limb, patients 
suffering with right sided CRPS demonstrated some rightward deviation 
when using the left hand in the centre and right condition. These results do 
not fully support the ‘neglect-like’ hypothesis since they were not seen in all 
patients, also classic neglect is more commonly associated with lesions of 
the right hemisphere and so affects the left side of the body (Farne et al., 
2004), the results reported here only show problems with the right hand. Also 
neglect patients tend to be unaware or in denial of their symptoms, the 
patients studied here were fully aware of their feelings towards their affected 
limb. Cleary there are some similarities with neglect and the symptoms 
described here and it is likely that altered sensorimotor processing is at the 
root of both problems and similar techniques may be beneficial in treating 
both cases. 
 
Taken together with the results reported here it can be suggested that in 
CRPS changes within the central nervous system result in an altered 
perception of the body, perhaps due to plasticity of the cerebral cortex. 
Further work is necessary to identify the root cause of these changes and 
improve current treatment methods. 
 
4.4 Referred Sensations 
 
4.4.1 Introduction 
 
Referred sensations (RS) are defined as stimulation in one part of the body 
resulting in a sensation in another (unstimulated) area, perhaps the most 
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well-known occurrence of this phenomenon is phantom limb pain where 
sensations (often pain) are ‘felt’ in a limb that has been amputated. Over time 
these sensations tend to diminish in such a way as the limb appears to 
‘telescope’, in the case of an amputated arm most of the arm disappears and 
amputees are often left with the feeling of a hand or fingers on the end of the 
stump (Harris, 1999, Moore et al., 2000, Whyte and Niven, 2001). RS have 
been reported in chronic pain and specifically in CRPS (McCabe et al., 
2003a). 
 
The basis of RS appears to be some form of cortical remapping, this has 
been demonstrated in many conditions including CRPS, repetitive strain 
injury and post amputation (Byl et al., 1997, Flor, 2003). The sensory cortex 
is made up of a ‘map’ of the body (see Figure 10 below), with specific areas 
being activated when a specific part of the body is stimulated. RS appear to 
be the result of alterations to the organisation of this map whereby areas 
overlap, shrink or become ‘smeared’ and stimulation of one area causes 
activation of the area of the cortex representing another part of the body. 
 
Alterations in S1 have been demonstrated in many imaging and 
magnetoencephalographic studies. In both humans and monkeys, 
amputation results in a shrinking of the area representing the amputated 
body part which is ‘invaded’ by adjacent cells representing other body parts. 
For example, following amputation of the hand or fingers, the area 
representing the face extends into the S1 area of the amputated hand (Flor et 
al., 1995, Flor, 2003, Merzenich et al., 1984, Weiss et al., 1998). This 
alteration has been shown to correlate to the intensity of phantom limb pain 
felt by the amputee. In contrast to this, when a part of the body is used 
frequently for fine work its representative area in the somatosensory cortex 
increases, this has been demonstrated in string musicians who have a 
significantly increased representation of the fingers of the left hand and 
Braille readers whose index fingers are over represented (Halligan et al., 
1999). 
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Figure 10 The Human S1 somatosensory cortex. The ‘Homunculus’ shows the 
extent of representation of each body part. Regions of intense innervation such as 
the fingers and lips cover a much greater area than those providing less sensory 
input. In many conditions this map is altered resulting in blurring of the areas and 
misrepresentation of the stimulated body part. 
 
The questions asked in relation to referred sensations are: 
1. Does touching any part of your body cause pain in another part of your 
body?  
2. Does touching any other part of your body cause pain in the affected 
area? 
3. Is sensation referred between perineum and foot? 
4. Is sensation referred between hand and face? 
 
4.4.2. Results 
 
Two thirds of patients questioned have experienced RS at some time, more 
than half experienced sensations hand to face and/or foot to perineum (see 
table 3 and figure 11). 
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 Question 1 Question 2 Question 3 Question 4 
No  14 (36) 16 (40) 11 (35) 11 (41) 
Yes 24 (61) 23 (57) 19 (62) 15 (55) 
Sometimes 1 (3) 1 (3) 1 (3) 1 (4) 
Total  39 (100) 40 (100) 31 (100) 30 (100) 
 
Table 3 Results of Referred Sensation Questions. The percentage of people 
giving each response is given in brackets. 
 
 
Figure 11 Results of Referred Sensation Questions. The majority of respondents 
reported referred sensations both directly involving the effected limb and in other 
parts of the body. 
 
 
4.4.3. Discussion 
 
The results reported here support previous work demonstrating a degree of 
reorganisation of the cerebral cortex in CRPS. Along with RS this 
reorganisation may also play a role in the development of other unusual 
symptoms such as altered limb perception and changes in spatial 
awareness. In the present study two thirds of patients reported experience of 
RS compared with only one third  in previous work (Maihofner et al., 2006, 
McCabe et al., 2003a). There are several possible reasons for this but the 
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most likely is that the questions here were of a more general nature whereas 
the two previous studies were looking at specific locations on the body. False 
positives are also more likely in this study as the questions due to the 
environment in which the questions were answered and the reliance on the 
memory of the subjects, it therefore seems likely that the real figure is 
somewhere between one and two thirds. 
 
Both acute and chronic pain have been demonstrated to alter cortical 
organisation. In chronic back pain patients magnetic fields in the cerebral 
cortex contralateral to the site of painful stimulation were increased in 
response to painful stimulation compared to healthy controls (Flor et al., 
1997). There was also a significant increase in the distance between the area 
representing the index finger and that representing the back in these 
patients. These differences were positively correlated with chronicity (Flor et 
al., 1995, Flor, 2003). Acute pain has been demonstrated to generate RS in 
healthy subjects Knecht et al (1998) reported sensations referred from lip to 
hand during innocuous stimulation following a period of painful stimulation to 
the finger. This coupled with evidence of RS just ten days after finger 
amputation in one patient (Weiss et al., 1998) indicates that cortical changes 
may occur rapidly and evolve over time to become more permanent. 
 
Cortical reorganisation has also been demonstrated in CRPS, Maihofner et al 
(2003) found a significant shift in the representation of the CPRS affected 
hand to the cortical representation of the lip as measured by MRI. This affect 
was positively correlated to the extent of spontaneous pain and hyperalgesia 
experienced by the subjects.  This is supported by the work of McCabe et al 
(McCabe et al., 2003a) who demonstrated RS felt in the area of the body 
adjacent to the stimulated area in S1 in CRPS patients. Subjects with chronic 
CRPS (> 1year) demonstrated much stronger RS which were not attenuated 
with treatment, acute sufferers (< 1 year) had much weaker RS which 
recovered with treatment indicating a role for chronic pain in the development 
of RS. 
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Taken together these results suggest that RS and related symptoms increase 
with time and may be correlated with increased pain in CRPS and other 
chronic pain conditions. As well as providing further evidence for pathology of 
the central nervous system in the development and progression of CRPS, 
this work also demonstrates the need to consider symptoms such as RS in 
diagnosis and treatment. Many of the patients questioned here had had 
inappropriate investigations into the origin of these sensations, for example 
pain in the face had led to a dental opinion and that in the perineum a 
urological consultation; such consultations are time consuming and may 
cause unnecessary worry for the patient. Further work is necessary to 
identify the underlying mechanisms of these symptoms and develop better 
methods of treatment. 
 
4.5. Chapter Discussion 
 
Care must be taken when interpreting these results and drawing conclusions 
from them since the subject group all being CRPS patients at a conference 
relating to the condition may be considered somewhat biased. It is however 
possible to draw some conclusions from these results and they certainly 
warrant further investigation. 
 
Cortical remapping is a significant issue in chronic pain conditions and may 
be the cause of many distressing symptoms such as those described here. 
However, Forderreuther et al (2004) reported no significant link between 
feeling of foreignness, pain intensity and ability to identify a specific finger 
suggesting that they may not all be the direct result of remapping. It is likely 
that these symptoms are the result of alterations in many parts of the brain 
and that remapping is one major part of the process. 
 
These results suggest that plastic changes in the CNS are in some way 
involved in the development and maintenance of chronic pain and that this 
can lead to alterations in processing of information within the brain. Whether 
these changes are causative factors or symptoms of the condition is not 
clear. However many neuromodulatory factors such as cytokines, 
chemokines and steroid hormones are known to increase in response to 
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chronic pain. Cytokines have been demonstrated to alter gene expression in 
neurons and related cells (Ledeboer et al., 2005, Marsh et al., 1993) and can 
change their sensitivity and responsiveness. Steroid hormones are known to 
have both stimulatory and inhibitory effects on synaptic processing in the 
hippocampus (McEwen, 2001, Yankova et al., 2001) and have also been 
demonstrated to affect cell growth and differentiation in this area (McEwen, 
2001, McKittrick et al., 2000, Yankova et al., 2001), an over reactive HPA 
axis or a decrease in oestrogen following the menopause may therefore 
contribute to cortical changes. 
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Chapter 5 
 
5 Experimental: Development of a Rat 
Inflammatory Pain Model. 
 
5.1 Introduction 
 
The following experiments were carried out in accordance with UK 
legislation, Animals (Scientific Procedures) Act, 1986 Project Licence: PPL 
30/2195 and Personal Licence: PIL 30/7926. Supervision was provided by 
the project licence holder, Dr Vivienne Winrow and assistance with animal 
husbandry and euthanasia received from the technical staff of the 
Biosciences Services Unit at the University of Bath. 
 
Although there is growing evidence for plastic changes within the CNS as a 
result of neuropathic pain the effect of persistent peripheral inflammatory pain 
on the CNS has not been examined in great detail to date and existing 
results vary. In order to investigate the effects of peripheral inflammatory pain 
on the brain a model is required that will produce persistent (> 2 weeks) 
inflammatory pain that is confined to a specific region. Two inflammatory 
models were tested both involving injection of an inflammogen into one hind 
paw of the rat, the inflammogens tested were: a) 1% Carrageenan and b) 
0.01%, 0.1% and 1% CFA (see Chapter 3 for further information). These 
models were compared in order to find the optimum inflammogen and 
concentration that would provide a persistent painful response with minimum 
systemic involvement and distress to the animals. 
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5.2 Materials and Methods 
 
5.2.1. Materials 
 
5.2.1.1 Animals 
 
Adult Male Wistar rats with initial weights of 200-230g were used in all 
experiments (Charles River UK Ltd., Margate, UK). 
 
5.2.1.2 Reagents 
 
Incomplete Freund’s adjuvant, Carrageenan, and sterile physiological saline 
(0.9% w/v) (Sigma-Aldrich CO Ltd., Poole, UK). Mycobacterium tuberculosis, 
freeze dried human strains C, DT and PN mixed (Central Veterinary 
Laboratories, Surrey, UK). Isofluorane, Oxygen and Liquid Nitrogen (BOC, 
Surrey, UK). Isopentane (Fisher Scientific, Leics, UK). Hypoxyprobe (HPI 
Inc., Burlington, MA, USA). 
 
5.2.1.3 Equipment and Consumables 
 
Sterile needles and syringes (Becton Dickinson, UK). 
Pestle and Mortar (Mason & Cook, Stoke-on-Trent, UK).  
Plethysmometer (Ugo Basile, Comerio, Italy). 
 
5.2.2 Animal Model 
 
All experiments were carried out under Home Office licence, project number 
PPL 30/2195 and personal licence number PIL 30/7926. 
 
5.2.2.1 Animal Husbandry 
 
Rats were housed in groups of 3 or 4 to a cage and exposed to a 12 hour 
light/dark cycle and an average temperature of 20 ± 2ºC.  Sawdust was used 
as bedding and each cage contained a plastic tube to provide environmental 
enrichment for the animals.  Animals were given access to tap water and 
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standard rat diet ad libitum.  Animals were weighed regularly as part of 
monitoring their general health. 
 
On arrival in the facility rats were separated into groups of four and given a 
minimum of five days to rest and acclimatise to their surroundings prior to 
commencement of the experiment. The experimenter was blinded to the 
grouping procedure. 
 
5.2.2.2 Induction of Footpad Inflammation 
 
Animals were lightly anaesthetised by inhalation of 3-4% isofluorane in 
oxygen and given an intraplantar injection of 100μl of 0.01%, 0.1%, 1% CFA 
in 1:1 saline emulsion, 1% carrageenan or physiological saline into the right 
hind-paw.  Non-injected controls were also anaesthetised. Animals were 
allowed to recover under supervision. 
 
5.2.2.3 Measurement of Paw Volume  
 
The volume of both hind paws was measured by liquid displacement 
plethysmometry using the Ugo Basile plethysmometer (see figure 12). This 
device consists of two chambers containing electrodes and filled with saline 
solution, the animal is gently restrained and the paw lowered into the larger 
chamber, saline of equivalent volume to the paw is displaced into the second 
chamber and the subsequent change in conductance measured and 
converted into a volume measurement on the electronic display. In order to 
ensure consistency measurements were all carried out by the same 
experimenter and paws were immersed up to the ankle joint until the 
calcaneum was fully submerged. 
 
5.2.2.4 Termination and Tissue Harvest 
 
One hour prior to termination animals were lightly anaesthetised with 3-4% 
isofluorane in oxygen and 60 mg/kg Hypoxyprobe was administered via 
intraperitoneal injection. At the end of the experiment, animals were killed by 
cervical dislocation and immediately decapitated using a guillotine.  Brains 
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were rapidly removed and frozen in freezing/melting isopentane over liquid 
nitrogen.  Frozen brains were kept in liquid nitrogen for transportation prior to 
longer term storage at -70ºC. 
 
Figure 12 The Ugo Basile Plethysmometer. The rat paw is placed into  the larger 
saline containing chamber and the difference in conductance between it and the 
smaller chamber is measured and converted into volume. Image Ugo Basile, Italy. 
 
5.2.2.5 Statistical Analysis 
 
Treatment groups were compared using analysis of variance (ANOVA) 
followed by Tukey’s honestly significant difference test (Tukey’s HSD) for 
post-hoc analysis. Within group analysis to compare left and right feet was 
performed using a paired sample t-test. All analyses were performed using 
SPSS and p<0.05 was considered significant. Graphs display mean values 
and error bars represent +/- the standard error of the mean (SE). 
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5.3 Results 
 
5.3.1 Paw Volume Measurements from Pilot Experiments 
 
5.3.1.1 Comparison of paw volume in CAR and CFA models 
 
 
Figure 13 Right (injected) hind paw volumes comparing treatments and 
controls. CAR injected paw volume peaks at 3 hours and then declines to 7 days 
where it returns to normal. 1% CFA injected paws rapidly swelled until 72 hours at 
which point the experiment was terminated due to severe discomfort of the animals. 
0.1% injected paw volume peaked at 24 hours dropping to 48 and then steadily 
rising, 0.01% volumes did not show such a significant peak and were similar to 
those of CAR, as such 0.1%CFA was chosen for experimentation. There were no 
significant differences between saline and non-injected controls. For further 
information see text below, n=8 for all groups other than CAR and saline where n=6. 
 
Carrageenan 
CAR injection resulted in rapid swelling of the injected hind paw which 
peaked at three hours post injection and then proceeded to decrease back to 
baseline. At the three hour time point CAR injected paws were significantly 
larger than all other groups (p<0.05), from 24 hours onwards their volume 
was less than that of other treatment groups and by five days there was no 
longer a significant difference compared with either of the two controls.  
When injected paws were compared with non-injected left hind paws in the 
same group similar results were found as compared with right hind paws of 
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control animals. There was a highly significant difference in paw volume from 
days 3-5 (p<0.01) which decreased by day 5 (p<0.05) and was no longer 
significant at days 6 and 7 (see figure 14). 
 
 
 
Figure 14 Hind paw volumes of 1% CAR injected animals. The volume of the 
right (injected) paws increased rapidly, peaking at 3 hours where the difference from 
left paws was highly significant. Right paw volume then decreased but remained 
significant from 24 hours to four days) and five days returning to baseline at 6 and 7 
days. *** p<0.001 ** p<0.01 * <0.05 n=6 
 
Complete Freund’s Adjuvant 
0.01% CFA resulted in a gradual increase in volume of the injected paw with 
minor peaks at 24 and 72 hours. This increase was significant versus both 
controls from 3 hours onwards (p<0.01) and also versus CAR at both days 6 
and 7 (see figure 13). 
 
There was a more rapid increase in right paw volume in animals injected with 
0.1% CFA leading to a more pronounced peak at 24 hours. Volume then 
increased steadily from 48 hours with a minor peak at 5 days. From three 
hours onwards, injected paw volume was significantly greater than that of 
both control groups (p<0.05), differences were also significant when 
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compared with CAR injected paws from 24 hours and 0.01%CFA injected 
paws from 4 days, (see figure 13). 
 
Animals injected with 1% CFA had the highest increase in right paw volume, 
unfortunately this resulted in significant distress to the animals by day 3 and it 
was decided to terminate the use of this concentration at that time point. 
Intravenous injection of CFA is known to induce systemic arthritis and these 
animals showed early symptoms of this disease. As with other concentrations 
of CFA, right paw volume was significantly increased compared with both 
control groups from the three hour time point. At 24 hours the difference was 
significant between 1% and CAR or 0.01%CFA and at 48 and 72 hours the 
1%CFA injected animals had significantly larger right paws than all other 
groups. As mentioned above there was also a significant difference between 
right paw volume of this group and the CAR injected animals at baseline, 
(see figure 13). 
 
When comparing right (treated) and left hind paws (untreated) in the same 
animals the same pattern of significance as when compared with controls 
was seen in both 0.01% and 0.1% CFA groups with the right paw being 
significantly larger than the left from 3 hours to 7 days (p<0.01) (see figures 
15 and 16). 
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Figure 15 Hind paw volumes of 0.01%CFA injected animals. A gradual increase 
in right (injected) paw volume was seen with minor peaks at 24 and 72 hours, the 
difference between paws was significant at all time points post injection. *** p<0.001 
** p<0.01 n=8. 
 
 
Figure 16 Hind paw volumes of 0.1%CFA injected animals. Right paw volume 
gradually increases post-injection peaking initially at 24 hours and then dropping 
slightly prior to increasing gradually up to 7 days the difference between right 
(injected) and left (non-injected) paws was highly significant at all post-injection time 
points. *** p<0.001 n=8. 
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Non-injected Paws 
There were no significant differences in left paw volumes between treatment 
groups and controls other than between CAR treated animals and non-
injected controls at the 48 hour time point (p<0.05). A peak was also seen in 
left paw volume of CAR treated animals at the 3 hour time point although this 
was not significant, this result is interesting as a similar result with 
concomitant cellular inflammation has previously been reported (Roberts et 
al., 2006). The lack of “mirror-image” inflammation seen in the CFA treated 
animals and at the later time points in CAR animals may be explained by the 
differences in the early and late inflammatory responses. Other than this 
there were no significant differences in left paw volumes, a slight increase 
over the 7day period is apparent as would be expected with normal growth of 
the animals, (see figure 17). 
 
 
 
Figure 17 Left (non-injected) hind paw volumes comparing treatments and 
controls. There was a significant difference between the left paws of CAR animals 
when compared with non-injected controls at the 48 hour time point * p<0.05 n=8 for 
all groups other than CAR and saline where n=6. 
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Control Groups 
Although there are some minor variations in the size of the right paws of 
saline injected and non-injected animals there was no significant difference 
between these two groups at any time point. When comparing left and right 
paws within groups of control animals there were no-significant differences in 
paw volume within the saline group (data not shown). There were no 
significant differences in left and right paw volumes of non-injected controls, 
(see figure 18). There was a significant difference in the volume of left and 
right paws at 48 hours and 7 day time points. 
 
 
Figure 18 Hind paw volumes of non-injected controls. The left paws were 
significantly larger than the right in non-injected controls at 48 and 7 day time points. 
*p<0.05 n=4. 
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5.3.1.2 Comparison of weight change in CFA and CAR models 
 
In all models, other than 1%CFA, animals gained weight at approximately the 
same rate suggesting no systemic effects of the treatment. In the 1%CFA 
treated group there is no apparent weight increase between days 1 and 3 
suggesting there is some systemic involvement in these animals, (see figure 
19). Weight loss is a symptom of systemic arthritis and, as discussed above it 
is likely that animals treated with 1% CFA were displaying early signs of this 
disease. 
 
 
 
Figure 19 Effects of treatment on weight gain. In general weights increased at a 
steady rate over time. 1% CFA injected animals did not gain weight at the same 
rate, however, suggesting some systemic involvement in this group. 
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5.3.2 Paw Volume Measurements in Complete Freund’s Adjuvant Model 
 
Following the pilot experiments it was decided to use 0.1% CFA as the 
inflammatory stimulus over several time points up to fourteen days. Eight 
animals were used in each group and compared with non-injected controls. 
The results for each time point are presented here and will be discussed in 
further detail in the later experimental chapters. The time points were chosen 
to represent different stages of the development of persistent pain, 6 hours 
representing the acute stage, 24 and 72 hours the sub-acute stage and 7 and 
14 days the beginning of a persistent pain state. 
 
5.3.2.1 Six Hour Time point 
 
The right hind paws of the injected animals were significantly larger than 
either left or right hind paws of non-injected animals and the non-injected left 
paws of the treatment group at three and six hours post injection 
(p<0.001).(see figure 20).  
 
 
Figure 20 Paw Volumes Non-Injected Control and 0.1% CFA 6 hour time point. 
The volume of the CFA injected paw increased rapidly over six hours and was 
significantly larger than the contralateral non-injected paw and the paws of the 
control group at both three and six hours post injection n=8 *** p<0.001. 
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5.3.2.2  24 Hour Time point 
 
There were no significant differences in paw volume at the start of the 
experiment. There was a rapid increase in injected paw volume and at 3, 6, 
and 24 hours post injection the right paws of the CFA injected group were 
significantly larger than the non-injected contralateral paws and both paws in 
the control group (p<0.001) (see figure 21). 
 
 
 
Figure 21 Rat paw volumes 0.1% CFA versus non-injected controls 24 hour 
time point. Injected paw volume decreases slightly to 24 hours following a relatively 
rapid increase in the first 6 hours post-injection, the difference in volume is still 
highly significant at this time point when compared with the contralateral paw and 
non-injected control animals. n=8 *** p<0.001. 
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5.3.2.3  72 Hour Time point 
 
Following the increase in swelling of the injected paw as described above 
there is a peak at 24 hours after which swelling decreases to 72 hours. The 
injected hind paw of CFA animals was significantly larger than the 
contralateral non-injected paw and both paws of animals in the control group 
at all time points post-injection (p<0.001) (see figure 22). 
 
 
 
Figure 22 Rat paw volume 0.1% CFA versus non-injected controls 72 hour 
time point. Following the peak at 6-24 hours volume of the injected paw decreases 
to 72 hours, the difference between injected paws and contralateral paws and non-
injected control animals is highly significant at all post-injection time points. n=8 *** 
p<0.001 
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5.3.2.4  7 Day Time point 
 
Following a peak at 6-24 hours and a decrease in swelling up until the 72 
hour time point the injected paw steadily increases in volume until the 7 day 
time point. Injected paws were significantly larger than non-injected 
contralateral paws and both paws of control animals at all post injection time 
points (p<0.001) (see figure 23). 
 
 
 
Figure 23 Rat paw volume 0.1% CFA injected vs. non-injected controls over 7 
days. Following a peak in swelling at 6-24 hours the injected paw decreased in 
volume until 72 hours after which there is a steady increase in volume to 7 days. 
Injected paws were significantly larger than contralateral and control non-injected 
paws at all post-injection time points. n=8 *** p<0.001. 
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5.3.2.5  14 Days 
 
Looking at the 14 day time point the overall pattern of paw swelling from the 
acute to the persistent stage can be observed. Following injection there is a 
rapid increase in volume which peaks at 6-24 hours, there is then a decrease 
to 72 hours from which point volume increases gradually until at least 14 
days post-injection (see figure 24). 
 
 
 
Figure 24 Rat paw volume 0.1% CFA injected vs. non-injected controls over 14 
days. The 14 day paw volume profile shows the change in swelling seen in the 
injected paw over the entire experiment, The injected right hind-paw swells fairly 
rapidly over the first 24 hours, peaking at 6-24 hours, the swelling there is a dip in 
volume to 72 hours followed by a gradual increase to at least 14 days. n= 8 
***p<0.001. 
 
5.4 Discussion 
 
The initial aim of this chapter was to identify a suitable animal model for use 
in experiments investigating persistent pain. Consistent with previously 
published results in the CAR model the injected paw volume peaked at 3 
hours and rapidly returned towards baseline in a manner characteristic of an 
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acute inflammatory response. This inflammation is regulated by the 
immediate release of inflammatory mediators such as bradykinin, histamine, 
tachykinins and complement which are released both from local cells and 
infiltrating cells such as neutrophils and subsequently quelled by 
phagocytosis of neutrophils by monocytes (Morris, 2003, Lima and Almeida, 
2002). The significant difference between the CAR injected paw and both the 
contralateral and control group paws decreased towards baseline after the 3 
hour peak and was no longer significant at 6 and 7 days post-injection (see  
Figure 14 and ). Since the time course and persistence of pain, as measured 
by allodynia and hyperalgesia, have previously been demonstrated to follow 
a similar time course to the oedema measured here it was decided that CAR 
injection was not a suitable pain model to investigate chronic pain 
mechanisms (Stein et al., 1988, Raghavendra et al., 2004). 
 
The injection of CFA produced a more persistent response than CAR at all 
concentrations. At the highest concentration of 1% CFA the experiment had 
to be terminated at 72 hours due to the obvious discomfort of the animals 
which, when accompanied by a decrease in weight gain, was indicative that 
the CFA was having a systemic effect possibly due to the early stages of 
systemic arthritis. 
 
Both 0.01% and 0.1% CFA injected paws showed a significant increase in 
volume when compared with contralateral and control group non-injected 
paws and this swelling persisted for at least 7 days post injection (see figures 
15 and 16). A specific profile of swelling was more apparent in the 0.1% 
injected animals, an initial peak was evident at 24 hours and swelling then 
decreased to 72 hours before gradually increasing until at least 7 days. It is 
likely that the initial peak is the result of an acute inflammatory response to a 
foreign substance, as seen in the CAR model, which rapidly subsides 
resulting in a minor decrease in paw volume at 72 hours. From 72 hours  
post-injection swelling increases up until at least 7 days as a result of the cell 
mediated immune response which has been shown to continue for up to one 
month (Stein et al., 1988, Raghavendra et al., 2004, Nagakura et al., 2003). 
Previous work has also shown that the increased swelling seen in the CFA 
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model is paralleled by an increase in pain, as measured by allodynia and 
hyperalgesia (Nagakura et al., 2003, Stein et al., 1988, Raghavendra et al., 
2004). Furthermore, Nagakura et al (2003) also found a significant increase 
in thermal hyperalgesia 24 hours post-injection which decreased at 72 hours 
post-injection before very gradually increasing toward 14 days. Interestingly, 
in this model, mechanical allodynia peaked at 7 days post-injection and 
continued to increase relatively rapidly to 14 days. It is possible, therefore, 
that thermal hyperalgesia is mediated primarily by the initial acute 
inflammatory response and that mechanical allodynia occurs as a result of 
the slower but more persistent immune response. 
 
As a result of the pilot experiments in section 5.3.1 it was decided to use 
0.1% CFA as the inflammogen in all future experiments since this 
concentration gave the best representation of the various stages of the 
inflammatory response without any apparent systemic involvement or 
excessive stress to the animals. The 0.01% CFA treatment was also 
discounted as at the latter time points the volume of the injected paw was not 
significantly different to that of CAR injected paws suggesting that 
inflammation and associated pain may not persist much further than 7 days. 
As no significant difference was seen between saline and non-injected 
control paw volumes it was decided to use one group of non-injected control 
animals throughout the 14 day test period. 
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Chapter 6 
 
6 Experimental: Gene expression of 
inflammatory mediators within the brain in 
peripheral inflammation. 
 
6.1 Introduction and Aims 
 
6.1.1 Introduction 
 
The relationship between pain and inflammation in the periphery is well 
documented, the release of inflammatory mediators in response to tissue 
damage or infection leads to sensitisation of local nerve fibres and 
vasodilation resulting in oedema and flare (Hellstrom et al., 2005, Hoheisel et 
al., 2005). Over recent years the CNS, previously considered to be immune-
privileged, has been found to have its own immune system, which is 
comprised of the astrocytes and microglia. When activated these glial cells 
release are range of inflammatory mediators including cytokines and 
chemokines (McMahon et al., 2005). Much work within the pain research field 
has recently focussed on the role of glial cells and the mediators they release 
in the initiation and maintenance of pain states, particularly within the spinal 
cord (DeLeo and Yezierski, 2001, Watkins et al., 2001, Bee and Dickenson, 
2007). Although earlier work focussed on the role of the spinal cord there is 
increasing evidence that immune responses in the brain may also contribute 
to the development and persistence of pain, changes in the brain are also of 
significant interest as they likely contribute to the affective-motivational 
symptoms of pain which are often intractable.  
 
Apkarian et al (2006) investigated the expression of IL-1β in rats with either 
CCI or SNL induced neuropathic pain. They found that SNL resulted in a 
significant increase in IL-1β expression in the brainstem at 10 days returning 
to baseline 24 days post-injury, within the thalamus, however, a significant 
increase was not seen until 24 days post-injury and was only evident on the 
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right side of the brain, contralateral to the injured nerve. Within the prefrontal 
cortex a significant increase in IL-1β expression was again seen at 10 days 
post-injury again only on the contralateral side of the brain. There was no 
significant difference in IL-1β expression in the CCI model other than then a 
significant decrease within the right side of the thalamus at 10 days if both 
CCI and SNL data were combined, however there was a trend towards an 
increase as seen in the SNL model. These data clearly show not only that 
peripheral injury causes significant changes in the brain, but also that 
different models, even when both represent a neuropathic injury, can 
produce very different results. 
 
In a CCI mouse model it has been shown that there are rapid changes in 
cytokine mRNA expression over the first few hours following injury (Uceyler 
et al., 2008), within the spinal cord TNFα expression decreased significantly 
at 6-9 hours post-injury returning to baseline at 12 hours, in the 
hypothalamus however, there was a drop in expression from 3-24 hours 
reaching a significant minimum at 24 hours post-injection before returning to 
baseline. Within the hippocampus and thalamus levels remained low from 6-
72 hours and 1-24 hours respectively apart from minor increases in both 
areas at 9 hours. In the same model IL-1β mRNA expression was show to be 
decreased in the hippocampus at 1 hour and 24 hours post-injury while in the 
thalamus there was an increase in expression at 3 hours. The only change 
seen in the spinal cord was a decrease in expression 3 hours post-injection. 
Interestingly these results are contrary to what is commonly seen in the 
periphery and the CNS following a neuropathic injury since they primarily 
show a decrease in cytokine expression, this may be because this study 
concentrates on early time points and very specific brain areas as opposed to 
the whole brain. Furthermore the use of mice in this work might also explain 
the differences as most published work is from rat models. 
 
The majority of work investigating the expression of inflammatory mediators 
in the CNS in pain states has focussed on neuropathic models, Raghavendra 
et al (2004) used the CFA footpad model to build on this work with an 
inflammatory model. They found an increase in mRNA and protein of IL-1β, 
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IL-6 and TNFα in the brains of CFA injected rats at 4 hour, 4 days and two 
weeks post-injection. There was an increase in the glial marker, GFAP, at 4 
and 14 days post-injection. Hyperalgesia and allodynia were present in the 
injected foot at all time points and, interestingly, thermal hyperalgesia 
developed in the left foot at 14 days post-injection. These authors suggest 
that the hyperalgesia is a result of glial activation in the brain perhaps due to 
glial cross talk from the left (contralateral to injected paw) to the right 
(ipsilateral) hemispheres, however since no comparisons were made 
between left and right brain regions this can only be speculative. 
 
The chemokines are small inflammatory molecules that derive their name 
from their activity as chemotactic cytokines, they are largely promiscuous 
ligands which act on multiple receptors. The chemokine fractalkine, also 
known as CX3CL1 and neurotactin, binds to only one receptor, CX3CR1, and 
as such is a much stronger potential drug target than other chemokines. 
Fractalkine is also of significant interest as it is expressed within the CNS 
where it is released from neurons and the receptor is expressed on glial cells. 
These features have prompted research into the potential role of fractalkine 
in pain; for a review see Abbadie et al (2003). 
 
Intrathecal injection of fractalkine results in allodynia and hyperalgesia in rats 
and this is inhibited by administration of either the glial antagonist, 
minocycline, or anti-IL1β demonstrating that the effects of fractalkine are, in 
part, regulated by other inflammatory mediators (Milligan et al., 2005, Han 
and Neugebauer, 2005). Furthermore, fractalkine over-expression results in 
the development of hyperalgesia and allodynia in rats with a concomitant 
increase in IL-1β in the CSF indicating that there may be a positive feedback 
loop of glial activation and neuronal release of fractalkine contributing to the 
increased pain response (Langer et al., 2006). 
 
In animal pain models fractalkine has been shown to increase in the spinal 
cord and DRG in rats in the neuropathic CCI and SNL models but not the 
inflammatory CFA model (Han and Neugebauer, 2005, Milligan et al., 2005, 
Axen and Porath, 1966). Interestingly the fractalkine receptor has been 
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shown to increase in the ipsilateral spinal cord in an inflammatory model of 
CFA induced mono-arthritis and this increase was associated with glial 
activation. The activation of glial cells was attenuated by administration of a 
CX3CR1 neutralising antibody as was the increased hyperalgesia and 
allodynia, however, the behavioural changes were only reversed for three 
days while the glia remained inactivated.  
 
The regulation of fractalkine release is controlled by microglial release of the 
protease, cathepsin-s, which cleaves the mucin stalk holding the chemokine 
to the cell membrane Inhibition of cathepsin-s reverses symptoms of 
neuropathic pain (Wu et al., 2005, Clark et al., 2009, Clark et al., 2007). 
 
Another chemokine that has sparked interest in the field of chronic pain is 
CXCL1, also known as growth-related oncogene or GRO. CXCL1, best 
known for its role in cancer, is up regulated in paw tissue in a model of the 
adaptive immune response where it was shown to be upregulated in 
response to increased TNFα expression. CXCL1 release also regulated 
hypernociception in immunised animals in a prostanoid and amide dependant 
manner (Cunha et al., 2008). CXCL1 is also upregulated in the DRG 
following in both neuropathic and inflammatory pain models and overnight 
incubation of small diameter sensory neurons with this chemokine resulted in 
protein dependant increase Na currents and increased expression of Na1.1, 
1.7 and 1.8 subunits. Taken together, these results point to a key regulatory 
role for CXCL1 in nociception. 
 
There is a known link between inflammation and hypoxia, for example in 
stroke many inflammatory mediators are released following ischaemic attack. 
Both the cytokines (IL-1β and TNFα) and chemokines (CXCL1 and CX3CL1) 
have been implicated in stroke (Wang et al., 2007) and hypoxia in the 
periphery has been associated with inflammatory pain conditions such as 
rheumatoid arthritis, CRPS and FM (Peters et al., 2004, Koban et al., 2003, 
Jeschonneck et al., 2000). 
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6.1.2 Aims 
 
As discussed above there is a significant role for inflammation in the 
development and maintenance of pain states which has been demonstrated 
in the periphery and the spinal cord of the CNS. There is limited information 
about the role of inflammation in the brain although it is evident that changes 
do occur in higher brain centres in chronic pain conditions (see Chapters 2 
and 4). 
 
The aims of this chapter were to measure the gene expression of various 
inflammatory mediators throughout the rat brain in response to the persistent 
inflammatory pain model used in Chapter 5 and to see if there is any 
evidence of hypoxia in response to inflammation by measuring hypoxia 
inducible factor 1α (HIF1α). The brain was divided into 6 sections (see figure 
25) to allow comparisons of regions on both the left (contralateral to inflamed 
paw) and right (ipsilateral to inflamed paw) sides of the brain. mRNA 
expression of cytokines (IL-1β, TNFα) and chemokines (CX3CL1, CXCL1) 
along with the chemokine receptor CX3CR1 and HIF1α were measured at 
acute (6 hours) subacute (24 and 72 hours) and persistent (7 and 14 days) 
timepoints as well as in non-injected control animals. 
 
6.2 Materials and Methods 
 
6.2.1 RNA extraction 
 
6.2.1.1 Materials 
 
DEPC, chloroform, ethanol and isopropanol (Fisher Scientific, Leics, UK). 
TRIzol reagent and DEPC treated water (Invitrogen Ltd, Paisley, UK). 
 
6.2.1.2 Methods 
 
All procedures were carried out using DEPC treated apparatus and 
containers in order to prevent contamination by RNAses and DNA. The 
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protocol used is adapted from the TRIzol manufacturer’s instructions and 
based on that of Chomczynski and Sacchi (1987). 
 
 
Figure 25 Rat Brain Sections for PCR analysis. Brains were separated into left 
and right sections and each section divided into anterior, mid and posterior using a 
brain atlas and matrix as a guide. 
 
Prior to RNA extraction brains were cut into six blocks, firstly they were 
separated in to left and right hemisphere and then each hemisphere divided 
into three blocks, (see figure 25). Sections were stored in individual 
eppendorf tubes at -70ºC until further analysis. 
 
Brain blocks were allowed to fully defrost on wet ice and then homogenised 
with 1ml TRIzol per 100mg tissue using a hand held glass homogeniser and 
the resultant solution transferred to 1ml eppendorf tubes. 200µl chloroform 
per 1ml TRIzol used was added to each tube and the solution shaken hard 
for 15 seconds then incubated at room temperature for three minutes. The 
solution was then centrifuged for 15 minutes at 12,000g and 4ºC separating 
the homogenate into three layers, the aqueous phase from each tube was 
transferred into individual fresh tubes taking great care not to disturb the 
layers underneath. The remaining fractions, which contain DNA and protein, 
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were stored at -70ºC for potential future use. 0.6ml of isopropanol per 1ml of 
TRIzol used was added to the aqueous fractions which were mixed and then 
incubated at room temperature for ten minutes to allow precipitation of RNA 
which was then separated by centrifugation at 12,000g and 4ºC for ten 
minutes. After centrifugation a pellet was usually visible at the bottom of the 
tube, the supernatant was decanted and the pellet washed twice with 1ml of 
cold 75% ethanol by vortexing and then centrifuging for five minutes at 
7,500g and 4ºC. The ethanol was decanted and the pellet air dried at room 
temperature for ten minutes and then resuspended in 20µl DEPC-treated 
water per 1ml trizol used. To ensure the RNA was fully dissolved the solution 
was vortexed and then heated at 60ºC for ten minutes before being 
immediately cooled on wet ice. RNA was quantified by measuring adsorption 
at A260 and purity measured by the A260/A280 ratio prior to being stored at -
70ºC for future use. 
 
6.2.2 Reverse Transcription 
 
6.2.2.1 Materials 
 
In-Prom II RT kit and DEPC treated water (Promega UK, Southampton, UK) 
DNase I amplification grade kit (Invitrogen Ltd, Paisley, UK). 
 
6.2.2.2 Methods 
 
This protocol is based on the manufacturer’s suggested method for using the 
In Prom II RT kit (Promega) and modified to enable addition of Invitrogen 
DNase I (Invitrogen). Briefly, for one reaction 1.6µg RNA (isolated as in 6.2.1 
RNA extraction), 1.6µl 10X DNase buffer solution, 1.6µl DNase and DEPC-
water to make a total volume of 16µl were added to a 200µl PCR tube. A 
water control was also set up containing water instead of RNA. The tubes 
were incubated at room temperature for fifteen minutes and then 1.6µl 25mM 
EDTA added and the tubes heated at 65ºC to stop the DNase reaction, the 
tubes were then placed on ice prior to use in the RT reaction. 
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For the RT reaction the relevant volume of mastermixes were made up as 
per the amounts in table 4 and divided between reaction tubes (10.2µl per 
tube) to which 9.8µl of DNase treated RNA had been added. 
 
 Experimental RT negative 
H2O 1.3µl 2.3µl 
Buffer 4.0µl 4.0µl 
MgCl2 2.4µl 2.4µl 
dNTPs 1.0µl 1.0µl 
RNasin 0.5µl 0.5µl 
Reverse Transcriptase 1µl X 
 
Table 4 Volumes of reagents required for each RT reaction. The “RT negative” 
column is for the negative controls which contain no enzyme and the “Experimental” 
column for the regular samples and the water control. 
 
Samples were then placed in a thermocycler and the following cycle run: 
 
Anneal: 25oC 5min 
Extend: 42oC 1 hour 
Inactivate: 70oC 15min 
Hold: 4oC 
 
The resultant product was then placed on ice prior to use in a PCR reaction 
or stored at -70ºC until future use. 
 
6.2.3 Primer Design and Optimisation 
 
6.2.3.1 Primer Design 
 
The mRNA FASTA sequence of interest was identified by searching Entrez 
Gene, the Primer 3 program was then used to generate primer sequences 
using the following constraints: 
 
Product size ranges: 301-400bp, 401-500bp 
Primer TM: opt 60ºC 
Primer length: opt 20 
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A BLAT search or the mRNA sequence was used to ensure specificity and 
identify exon/intron boundaries. This information was cross-referenced with 
the primer 3 output and primers were chosen that spanned to different introns 
to ensure that any contamination from genomic DNA would be apparent in 
the PCR product. A final check on specificity was made using the UCSC in-
silico PCR facility. 
 
Name Genebank # Sequence TM TA 
PCR 
Cycles 
Product 
Size 
(KDa) 
βactin F 
NM_031144 
TGTCACCAACTGGGACGATA 60 61 30 392 
βactin R TCTCAGCTGTGGTGGTGAAG 60 61 30 
Hif 1α F 
NM_024359 
TGCTCATCAGTTGCCACTTC 60 61 30 305 
Hif 1α R CATGGTCACATGGATGGGTA 60 61 30 
CXCL1F 
NM_030845 
AGCTCCAGCACTCCAGACTC 60 55 30 364 
CXCL1R GCCATCGGTGCAATCTATCT 60 55 30 
IL1β F 
NM_031512 
CAGCAGCATCTCGACAAGAG 60 55 30 362 
IL1β R GGGATTTTGTCGTTGCTTGT 60 55 30 
TNFα F 
NM_012675 
GAGGTCAACCTGCCCAAGTA 60 55 30 263 
TNFα R CGTGTGTTTCTGAGCATCGT 60 55 30 
CX3CR1F 
NM_133534 
CAGGACCTCACCATGCCTAC 60 55 30 657 
CX3CR1R GATGCGGAAGTAGCAAAAGC 60 55 30 
CX3CL1F 
NM_134455.1 
CTCTGCTGGCGGGTCAGCAC 60 55 35 491 
CX3CL1R GCTCTGAGGCTTGGCGGCAA 60 55 35 
 
Table 5 Primers designed and used in this work. F forward primer, R reverse 
primer TM/TA primer melting/annealing temperature ºC. 
 
6.2.3.2 Primer Optimisation 
 
Although the primer design process includes specific parameters for the PCR 
protocol used it is sometimes necessary to further optimise the protocol for 
individual primer pairs. The two parameters optimised here were number of 
cycles and annealing temperature.  
 
If very little product is visible it is possible to increase the production by 
increasing the number of PCR cycles. Care must be taken as too many 
cycles can result in amplification of non-specific products and over exposure 
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of the gel. Here 30 cycles were used for all primer pairs other than CXCL1 
where this was not sufficient. Initially 40 cycles was tried, however, this 
resulted in amplification of non-specific products. 35 cycles produced a much 
cleaner gel where it was still possible to measure differences between bands. 
 
Gradient PCR was used to optimise the annealing temperature for primer 
pairs where non-specific products or inconsistent results were an issue. For 
most primer pairs an annealing temperature of 5ºC less than the melting 
temperature is used, which in the case of the primers used here is 55ºC. Hif-
1α and β actin primer pairs generated non-specific products at this 
temperature and gradient PCRs were used to optimise an annealing 
temperature from ~50ºC-65ºC, (see figure 26). 
 
 
 
Figure 26 β actin temperature gradient PCR. The same sample was subjected to 
PCR as described below with a variety of annealing temperatures, as indicated 
above each lane (ºC). Non-specific product is apparent in the first 8 lanes but 
disappears at higher temperatures, an annealing temperature of 61ºC was chosen 
for this primer pair. 
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6.2.4 PCR Amplification 
 
6.2.4.1 Materials 
 
GoTaq green mastermix and DEPC treated water (Promega UK, 
Southampton, UK). Custom primers (Sigma-Aldrich co Ltd, Poole, UK).  
 
6.2.4.2 Methods 
 
The Promega GoTaq mastermix was used for all PCR reactions and the 
method was carried out according to the manufacturer’s protocol. Briefly, 
cDNA template was allowed to defrost on ice and then 1µl of each sample 
added to a PCR tube, 1µl of water was added to a final tube to act as a 
control. A mastermix was made containing the following for each sample: 
 
12.5µl GoTaq green  
0.25µl forward primer 
0.25µl reverse primer 
11µl DEPC water  
 
24µl of mastermix was added to each sample tube and mixed resulting in a 
total reaction volume of 25µl. Tubes were then placed in a thermocycler and 
the following cycle run: 
 
Initial Denaturation: 94oC 2 min 
 
Denaturation: 95oC 45 sec 
Annealing*: 55oC 45 sec  
Extension: 72oC 45 sec 
 
Final extension: 72oC 5 min 
Hold: 4oC 
 
30 cycles* 
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Parameters marked with an asterisk were optimised for individual primer 
pairs, see primer section for details. 
 
Following PCR amplification the samples were immediately placed on ice, 
centrifuged briefly to collect any condensate that had formed, and then stored 
at -20ºC until require for further analysis. 
 
6.2.5 Gel Electrophoresis and Semi-Quantitative Analysis 
 
6.2.5.1 Materials 
 
Agarose, tris base, boric acid, 0.5M EDTA (pH 8.0), ethidium bromide 
solution (10mg/ml) and 100 base pair DNA ladder (Fisher Scientific, Leics, 
UK). 
 
6.2.5.2 Methods 
 
A 1.2% agarose gel was made with 0.5X TBE and 8µl ethidium bromide per 
100ml gel. The samples were defrosted on ice, centrifuged briefly to collect 
any condensate, and 10µl loaded per well. A DNA ladder was loaded into the 
first lane of every row for size comparison and βactin (5µl per well) was used 
as a control. The gel was run at 100mV in 0.5X TBE buffer until the dye front 
was level with the base of the gel. Bands were visualised using UV and 
quantified by densitometric analysis using the Scion Image program.  
 
6.2.6 Statistical Analysis 
 
All results were normalised to βactin control measurements and compared 
using analysis of variance (ANOVA) followed by Tukey’s honestly significant 
difference test (Tukey’s HSD) for post-hoc analysis. All analysis was 
performed using SPSS and p<0.05 was considered significant. Graphs 
display mean values and error bars represent +/- the standard error of the 
mean (SE). 
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6.3 Results 
 
6.3.1 IL1β Expression  
 
IL1β mRNA expression was greatly increased in all sections of the brain at 
one week post-injection compared with non-injected controls and 6, 24, and 
72 hour CFA treated animals. This difference was significant in all anterior 
and mid regions of the brain but not in the posterior regions which just failed 
to reach significance. At 14 days post-injection there is an overall drop in 
expression from 7 days although IL1β expression in all sections remained 
higher than normal and 6, 24 and 72 hour time-points. A decrease in 
expression is also seen in the back of the brain at 6 and 24 hours post-
injection (see figure 27). 
 
 
Figure 27 IL1β mRNA expression in CFA treated animals and non-injected 
controls by time point. There is a large increase in IL1 βmRNA expression at 7 
and 14 days post injection. In the anterior and middle of the brain expression 
dropped at 6 hours before increasing at later time points. n=4  * p<0.05 compared 
with all other groups in that section A anterior, M mid, P posterior, L left, R right. 
 
When looking at the pattern of expression throughout the brain by time point 
the IL1β mRNA expression profile remains fairly consistent at each time 
point. There were no significant differences between sections at any time 
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point other than 24 hours where the mid-right section expressed significantly 
higher levels than those in the right posterior. Interestingly at 14 days post-
injection, although the relative expression from posterior to anterior regions of 
the brain is similar to previous time points, the left side of the brain expresses 
more IL1β mRNA than the right in all three regions (see figure 28). 
 
 
Figure 28 IL1β mRNA expression in CFA treated animals and non-injected 
controls by brain region. There are no significant differences according to brain 
region other than at 24 hours where the mid-right section of the brain expressed 
significantly more IL1βmRNA the back right. Expression was higher at 1 and 2 
weeks than non-injected controls and the three earlier injected time points. n=4 * 
p<0.05  for difference between MR and BRF front, A anterior, M mid, P posterior, L 
left, R right 
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6.3.2 Hif1α Expression 
 
There were no significant differences in Hif1α mRNA expression when 
assessed relative to time point or brain region (see figure 29). 
 
 
Figure 29 Hif1α mRNA expression in CFA treated animals and non-injected 
controls by time point. There was no significant difference in Hif1α mRNA 
expression at any time point although there is a trend towards an increase in CFA 
treated animals. n=4 A anterior, M mid, P posterior, L left, R right 
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6.3.3 TNFα Expression 
 
There was a slight decrease in TNFα mRNA expression from control to six 
hours post-injection which became more marked at 24 hours and remained 
low at 72 hours other than in the back right of the brain where there was a 
large increase in expression at 72-hours post-injection. At 7 days expression 
increased to just above baseline in all sections other than the right posterior 
where there was a drop to just below baseline (see figure 30). 
 
 
Figure 30 TNFα mRNA expression in CFA treated animals and non-injected 
controls by time point. In all areas of the brain there was a drop in TNFα mRNA 
expression at 24 hours post-injection, levels remained low at 72 hours in all areas 
except the right posterior region where there was a large increase. At one week 
there was a trend to an increase in the anterior and mid sections of the brain. n=4 A 
anterior, M mid, P posterior, L left, R right 
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Figure 31 TNFα mRNA expression in CFA treated animals and non-injected 
controls by brain region. There is a drop in expression of TNFα mRNA in all areas 
of the brain at 24 and 72 hours other than the posterior right at 72 hours. At 1 and 2 
weeks expression increases to at least baseline. n=4  + A anterior, M mid, P 
posterior, L left, R right. 
 
When TNFα mRNA data are expressed by brain section it can be seen that 
levels vary slightly throughout the control brain, with greater expression in the 
middle of the brain. At six hours there is a slight decrease in expression 
which becomes much more evident by the 24 hour time point; levels remain 
low in all brain areas at 72 hour post injection other than in the posterior right 
region which has much higher expression than all other sections at this time 
point. At one and two weeks post-injection expression returns to roughly the 
levels seen in the control groups other, the front regions showing slightly 
higher levels at 7 days. There was no significant difference between 
expression in the left and right sides of the brain (see figure 31). 
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6.3.4 CXCL1 Expression 
 
CXCL1 expression was greatly increased at 6 hours post-injection in all brain 
regions, the largest increase being in the anterior brain regions and the 
lowest in the middle. At 24 hours post-injection expression in all brain regions 
dropped to below baseline increasing slightly at 72 hours but remaining 
significantly lower than the expression at 6 hours at both time points. At the 
later time points of 1 and 2 weeks CXCL1 expression returned to baseline in 
all brain regions but remained significantly lower than expression at 6 hours 
in the anterior and mid brain regions (see figure 32). 
 
 
Figure 32 CXCL1 mRNA expression in CFA treated animals and non-injected 
controls by time point. There is a large increase in CXCL1 mRNA expression in all 
brain regions at 6 hours post injection this was significantly greater than control in 
anterior regions and in mid-right and posterior-left sections. n=4 * p<0.05 ** p<0.01 
A anterior, M mid, P posterior, L left, R right. 
 
There is a consistent profile of expression throughout the brain sections at all 
time points, other than six hours post-injection, with mid brain regions 
expressing more CXCL1 mRNA than the anterior and posterior regions. This 
difference was significant at 24 hours with the left middle section expressing 
more than the front right and both back sections (p<0.01) and the right 
middle section expressing more than the back right (p<0.01) and left 
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(p<0.05). In CFA treated rats at the 6 hour time point, where CXCL1 
expression is significantly increased (see figure 32), the profile of expression 
changes with higher levels in the anterior regions of the brain, decreasing in 
the middle and lowest in the posterior regions (see figure 33).  
 
 
Figure 33 CXCL1 mRNA expression in CFA treated animals and non-injected 
controls by brain region. Expression peaked at 6 hours post-injection decreasing 
to below baseline at 24 and 72 hours before returning to baseline at 1 and 2 weeks. 
At 2 hours post-injection expression in the middle two sections was significantly 
higher than in anterior and posterior regions, see text for further explanation. n=4 * 
p<0.05 ** p<0.01 A anterior, M mid, P posterior, L left, R right. 
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6.3.5 CX3CL1 Expression 
 
CX3CL1 mRNA expression was decreased in all areas of the brain post-
injection but most significantly in the posterior regions where there was a 
very large drop in expression at 6 hours post-injection which gradually 
increased at each time point returning baseline in the right posterior region 
and exceeding baseline in the left (see figure 34). 
 
 
Figure 34 CX3CL1 mRNA expression in CFA treated animals and non-injected 
controls by time point. In all brain regions there was a drop in CX3CL1 mRNA 
expression post-injection at 6 hours which then increased to baseline or above. This 
was most evident in the posterior regions of the brain the 6 hour time point in the 
back left was significantly lower than control. n=4 * p<0.05 A anterior, M mid, P 
posterior, L left, R right. 
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Across the brain, CX3CL1 mRNA expression decreased from posterior to 
anterior regions in both control and all CFA treated animals. At 6 hours this 
difference is most significant (p<0.001) where both left and right back regions 
of the brain express significantly lower levels than all other areas. No 
significant difference was seen between left and right regions, however at 72 
hours, 1 week and 2 weeks post-injection left brain regions expressed higher 
levels of CX3CL1 mRNA than the corresponding right regions (see figure 35). 
 
 
Figure 35 CX3CL1 mRNA expression in CFA treated animals and non-injected 
controls by brain section. At all time points CX3CL1 expression is lower in the 
posterior regions of the brain compared with the middle and anterior. This difference 
was most evident at six hours where the difference in expression was significantly 
lower in both back regions compared with all other sections. N=4 *** P<0.001 A 
anterior, M mid, P posterior, L left, R right. 
 137 
6.3.6 CX3CR1 Expression 
 
In both anterior sections of the brain and in the middle left region the 
expression of CX3CR1 mRNA tended to decrease over time post-injection 
with the minimum expression seen at 1 week. Conversely in the middle right 
brain section expression increased post injection with the highest expression 
seen at 7 days. In both anterior regions of the brain there was a large 
decrease in expression of CX3CR1 at 6 hours post-injection which remained 
relatively low at 24 hours before returning to (right section) or slightly 
exceeding baseline (left section) this decrease was significant only at the 24 
hour time point in the right anterior region of the brain when compared with 
control (p<0.05) (see figure 36). 
 
 
Figure 36 CX3CR1 mRNA expression in CFA treated animals and non-injected 
controls by time point. Expression was decreased at 6 and 24 hours post-injection 
in the anterior of the brain increasing back to baseline (right section) or above (left 
section). In the right anterior section expression at 24 hours was significantly lower 
than in control (p<0.05). n=4 * p<0.05 A anterior, M mid, P posterior, L left, R right. 
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In non-injected control animals expression does not differ greatly between 
brain regions, however at 6, 24 and 72 hours post-injection there is a larger 
drop in expression, most evident at the earlier time points. At 6 hours this 
difference is significant in both left and right back brain sections when 
compared with left front and middle regions (p<0.01) and right front and 
middle sections (p<0.05). At 24 hours the difference only reached 
significance between the front left and back right sections (p<0.01). The 
profile of receptor gene expression at one and two weeks did not differ 
greatly from control and no significant differences were found between left 
and right regions (see figure 37). 
 
 
Figure 37 CX3CR1 mRNA expression in CFA treated animals and non-injected 
controls by brain section. At 6, 24 and 72 hours post-injection expression is lower 
in the back of the brain when compared with the middle and front regions. At six 
hours this difference is significant in both back regions when compared with all other 
brain regions. N=4 * p<0.05 A anterior, M mid, P posterior, L left, R right. 
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6.4 Discussion 
 
This chapter set out to investigate the expression of a variety of inflammatory 
mediators in a model of persistent inflammatory pain, the expression profile 
identified is discussed below. 
 
6.4.1 IL1β Expression 
 
IL1β expression was increased at 7 and 14 days post-injection in all brain 
regions, although this failed to meet significance in the anterior sections of 
the brain and at 14 days. At 6 and 24 hours post-injection there is a decrease 
in IL1β expression in the anterior of the brain which was significant in several 
areas at 24 hours. These results are not totally in accordance with previously 
published data where an increase in IL1β mRNA was seen at earlier time 
points in both neuropathic and inflammatory models (Raghavendra et al., 
2004, Uceyler et al., 2008). This variation may be due to several factors, 
slightly different time points were used in this study compared with previous 
studies and it is possible that increases in expression at earlier time points 
would have been seen in the current model.  
 
The increase in IL1β expression corresponds with the increased paw 
swelling seen here at 7 and 14 days (see figures 23 and 24) and the 
increased allodynia described in previous work (Stein et al., 1988, 
Raghavendra et al., 2004), however there was no increase in IL1β 
expression at the 6 hour time point where swelling and nociceptive 
responses show an initial peak. This suggests that IL1β may be involved in 
the regulation of brain processes in longer term pain but not at the acute 
stage. 
 
One suggestion might be that the drop in expression in the back of the brain 
at 6 and 24 hours is a form of endogenous analgesia in response to the rapid 
increase in pain and swelling in the acute stages. The increase in expression 
at the other time points may be the result of continued nociceptive input 
stimulation and increase in IL1β expression leading to changes in structure 
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and function within these brain areas. IL1β has been demonstrated to play a 
role in LTP and it, as such, may be establishing a pain “memory” in the brain 
which may increase the potential for chronic pain to develop (Wang et al., 
2000, Zeise et al., 1992). 
 
6.4.2 Hif1α Expression 
 
No significant changes were seen in Hif1α mRNA expression although there 
were some minor increases in CFA treated animals compared with controls 
with 22 out of 30 time points having higher expression than their respective 
non-injected controls. This increase could be due to the increased 
inflammation seen in the brain as Hif1α had been shown to be upregulated 
by inflammation in the absence of hypoxia (Olson and van der Vliet, 2011). It 
is also possible that hypoxia is present, but in discrete areas of the brain 
which were not identified by the methods used here. 
 
6.4.3 TNFα Expression 
 
TNFα mRNA expression decreased from 6-72 hours post-injection in all brain 
areas other than the anterior right section where there was a large peak in 
expression at 72 hours (see figure 31) It is difficult to explain this result since 
any increase that wasn’t present on both sides of the brain would be 
predicted to occur on the contralateral side to the injected paw. One 
suggestion might be that this increase in TNFα is the result of top-down 
regulation, i.e. an increase in activity in a descending modulatory pathway 
which would occur on the ipsilateral side having potential nociceptive or 
indeed analgesic effects (see figure 3). 
 
Further support for a role for TNFα in descending regulatory pathways comes 
from the increase in expression in the front brain regions at 7 and 14 days, 
these regions contain many of the nuclei responsible for top down regulation. 
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6.4.4 CXCL1 
 
This is the first evidence for an increase in CXCL1 expression in the brain in 
chronic pain. The highly significant increase at 6 hours suggests a role for 
this chemokine in the acute response. CXCL1 may play a more significant 
role in the anterior of the brain since the increase in expression is greatest 
here, differing from the pattern of expression seen at other time points where 
the middle brain areas express the highest levels (see Figure 33). 
 
In the periphery, TNFα has been demonstrated to induce CXCL1 expression 
(Cunha et al., 2008) however, this is not the case here where, in agreement 
with results seen in neuropathic pain models, there is a decrease in TNFα 
expression at early time points. 
 
The peak in CXCL1 expression at 6 hours corresponds with the first peak 
seen in paw swelling (see figure 24) and hyperalgesia and allodynia reported 
elsewhere (Stein et al., 1988). However, CXCL1 levels drop massively at the 
24 hour time point, particularly in the most anterior and posterior regions of 
the brain, whereas oedema and nociceptive measurements remain relatively 
high at this time point. As discussed in relation to IL1β expression this may 
be an endogenous analgesic response, perhaps, if these inflammatory 
mediators remained elevated, hyperalgesia and allodynia would be more 
intense than reported levels. The high levels of CXCL1 expression in the 
front of the brain suggest a role for this chemokine in descending modulation. 
 
At 24 hours, expression of CXCL1 mRNA in the middle brain regions was 
significantly higher than in front and back regions. It is possible that, at this 
time point, CXCL1 is mediating activity within the limbic system and memory 
centres where it is contributing to alterations in the motivational-effective pain 
response. Indeed the fact that this chemokine is generally expressed at 
higher levels in these brain regions implies that it may play a key role in these 
processes under normal conditions. 
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6.4.5 CX3CL1 and CX3CR1 Expression 
 
This is the first evidence of alterations in the expression of both 
fractalkine/CX3CL1 and its receptor, CXCR1, in the brain using a pain model. 
Previously both CX3CL1 and CX3CR1 have been shown to be upregulated 
in the DRG of the spinal cord in neuropathic pain models (Milligan et al., 
2005, Han and Neugebauer, 2005, Axen and Porath, 1966) and a rat model 
of mono-arthritis (Sun et al., 2007). Here both receptor and ligand were 
significantly down-regulated in the back regions of the brain at 6, 24 and 72 
hours post-injection. There are several possible explanations for this, firstly 
fractalkine exists on the neuronal cell membrane and is released following 
neuronal activation, if such release is occurring in the back of the brain due to 
nociceptive stimulation this may cause a decrease in mRNA expression of 
the ligand and receptor due to negative feedback from high levels of 
circulating fractalkine. CX3CL1 expression remains significantly lower in the 
back of the brain at 24 and 72 hours before gradually returning to baseline, 
this may be due to reduced neuronal activity at these time points decreasing 
negative feedback at 7 and 14 weeks or as a result of the increase in IL1β 
and TNFα. 
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Chapter 7 
 
7 Experimental: Expression of GFAP and 
Hypoxia in Rat Brain. 
 
7.1 Introduction and Aims 
 
7.1.1 Introduction 
 
Activation of the glial cells, microglia and astrocytes, within the CNS has 
been demonstrated to play a role in the development and maintenance of 
pain. Glia are activated in response to inflammatory mediators and then 
release further inflammatory molecules along with other mediators of 
neuronal activity. The astrocyte marker glial fibrillary acid protein (GFAP) is 
upregulated in pain and has been suggested to mediate the mechanisms 
related to chronic pain. Building on the results of Chapter 6, where altered 
expression of the mRNA of multiple inflammatory chemokines and cytokines 
was demonstrated in the brain during peripheral inflammation, the expression 
of this marker was measured in the brains of CFA footpad treated animals. 
 
As previously discussed, hypoxia and inflammation are closely related; 
hypoxia can lead to inflammation, for example in stroke or following damage 
to a blood vessel. Ischaemia reperfusion models in animals have provided 
evidence of this in both the CNS and the periphery. In turn, inflammation has 
also been demonstrated to cause hypoxia, tissue swelling can cause 
vasoconstriction and release of inflammatory mediators 
 
7.1.2 Aims 
 
To further investigate the inflammatory response in the rat brain in the 
inflammatory footpad model by examining the profile of GFAP expression at 
acute, sub-acute and chronic time points. 
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To investigate the hypothesis that hypoxia may be present in the CNS in 
chronic pain, it was decided to use Hypoxyprobe (see 3.4.2) to investigate 
potential hypoxia in the rat brain in the inflammatory footpad model at acute, 
sub-acute, and chronic time points. 
 
7.2 Materials and Methods 
 
7.2.1 Blocking and Cutting 
 
7.2.1.1 Materials 
 
Superfrost slides, and isopentane, (Fisher Scientific, Leics, UK), 2mm rat. 
Coronal brain matrix (Kent Scientific Corporation, Torrington, Connecticut, 
USA). Optimum cutting temperature compound (OCT). Cork disks and razor 
blades (RA Lamb Ltd, East Sussex, UK). Liquid Nitrogen (BOC, Surrey, UK) 
 
7.2.1.2 Methods 
 
Brains from experiments described in section 5.3.2 were removed from 
storage at -70ºC and warmed to -20ºC for use as follows; To prepare brains 
for cutting they were cut into 2mm blocks and mounted on cork disks in 
optimal cutting temperature compound (OCT) in freezing/melting isopentane. 
A brain matrix was used to cut 2mm blocks and enable consistent and 
precise cutting of sections. Blocks were stored in 50ml centrifuge tubes at -
70ºC until cut for sections. 
 
Section 6 from the middle of the brain was chosen for analysis since this 
brain region contains many regions important in pain regulation including, the 
hippocampus, the thalamus and the area of the somatosensory cortex that 
represents the hind paw. 
 
16µm sections for staining were cut by cryostat at -15ºC and then mounted 
on superfrost slides. Slides were left to air dry overnight at room temperature 
and stored at -20ºC until used in staining protocols. 
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7.2.2 Staining for Hypoxyprobe, and GFAP 
 
7.2.2.1 Materials 
 
PBS, acetone, coverslips and PAP pen (Fisher Scientific, Leics, UK). Rabbit 
polyclonal anti-Hypoxyprobe (PAb 2627), (HPI Inc., Burlington, MA, USA). 
Rabbit anti-GFAP (ab7779) (Abcam Ltd., Cambridge, UK). Vectastain ABC 
kit (alkaline phosphatase rabbit IgG), (Vector Laboratories Ltd, Orton 
Southgate, Peterborough, UK). Mayer’s Haematoxylin, Fast red TR/Napthol 
tablets, (Sigma-Aldrich Co Ltd Poole, UK). Aquamount (VWR International, 
Poole, UK) 
 
7.2.2.2 Methods 
 
Slides prepared as in section 7.2.1 were removed from the freezer and 
warmed to room temperature, tissue was then fixed for ten minutes in 
acetone at 4ºC. Following fixation excess acetone was evaporated from the 
slides and a PAP pen used to provide a hydrophobic barrier around the 
sections. The remainder of the procedure was carried out according to the 
protocol for the Vectastain ABC kit. Briefly, sections were washed three times 
for five minutes in PBS. Following washing, in order to prevent irrelevant 
binding of antibodies, tissue was blocked for one hour at room temperature 
using a blocking solution of 15% serum in PBS. Blocking solution was 
decanted and sections were incubated overnight in a humidified chamber at 
4ºC with primary antibody diluted in blocking solution. Antibody 
concentrations varied, see results section for further details. In each 
experiment two negative controls were also used, a no primary control, 
where sections were incubated with blocking solution only (see figure 38 A) 
and a serum control, where sections were incubated with serum from the 
primary antibody host species diluted in blocking solution (see figure 38 B). 
Following overnight incubation the primary antibody solution was decanted 
and sections washed three times for five minutes in PBS. Sections were then 
incubated at room temperature for one hour with a 1:200 solution of 
biotinylated secondary antibody, washed three times for five minutes in PBS 
 146 
and then incubated for thirty minutes in ABC-AP solution before washing for 
five minutes in PBS. Slides were then incubated in alkaline phosphatase 
solution (Fast Red TR/Napthol made up according to the manufacturer’s 
instructions) for 5-20 minutes depending on the antigen of interest and the 
reaction terminated in tap water. Tissue was counterstained for five minutes 
in Mayer’s haematoxylin and washed in swirling tap water for ten minutes 
prior to mounting in Aquamount. 
 
7.2.3 Analysis of slides 
 
Slides were graded according to the level and intensity of staining and the 
experimenter was blinded to the treatment group during the analysis. The 
grading protocol was based on that of Colburn et al (1997) where each 
section was awarded a score according to the degree of staining, 0 being no 
staining, 1 mild staining, 2 moderate and 3 intense (see Figure 38). Four 
sections were scored from each brain, meaning a total of sixteen for each 
experimental group and scoring was blinded and randomised. 
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Figure 38 Representative micrographs of hypoxyprobe and GFAP staining 
X200 A) Control, no primary antibody. B) Serum control. C) GFAP staining scored 1 
D) GFAP staining scored 2 E) GFAP staining scored 3 F) Hypoxyprobe staining 
scored 1 G) Hypoxybrobe staining scored 2 H) Hypoxyprobe staining scored 3 
 148 
7.3 Results 
 
7.3.1 GFAP Staining 
 
Baseline GFAP staining representative of inactivated astrocytes is present in 
all treatment groups. Higher levels of staining was seen in the brains of all 
treatment groups with three out of four animals in each group showing a 
staining score of two or more (see figure 39 and table 6). Highest levels of 
staining were at the 6 and 24 hour and 14 day timepoints which correlates 
with the highest levels of paw oedema described previously (see figure 24). 
 
 
Figure 39 Scatter diagram of mean GFAP staining score for each rat in the 
right brain of CFA treated rats and non-injected controls. Expression is 
increased at all time points post injection. n =4 for each animal unless otherwise 
indicated (see table 6). 
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Treatment Group Rat 1 Rat 2 Rat 3 Rat 4 
Normal 2.00 x 1.00 0.00 
  1.00 1.00 1.00 2.00 
  1.00 x 2.00 1.00 
  2.00 2.00 2.00 1.00 
Mean 1.50 1.50 1.50 1.00 
6 hour CFA 2.00 2.00 2.00 2.00 
  x 2.00 2.00 2.00 
  1.00 3.00 2.00 2.00 
  2.00 2.00 2.00 2.00 
Mean 1.67 2.25 2.00 2.00 
24 hour CFA 2.00 2.00 2.00 3.00 
  2.00 2.00 2.00 2.00 
  3.00 x 2.00 x 
  2.00 0.00 2.00 2.00 
Mean 2.25 1.33 2.00 2.33 
72 hour CFA x 2.00 2.00 2.00 
  2.00 2.00 2.00 2.00 
  2.00 2.00 1.00 2.00 
  2.00 2.00 x 2.00 
Mean 2.00 2.00 1.67 2.00 
7 day CFA x 2.00 2.00 2.00 
  2.00 2.00 2.00 2.00 
  0.00 x 2.00 2.00 
  0.00 2.00 2.00 2.00 
Mean 0.67 2.00 2.00 2.00 
14 day CFA 2.00 3.00 2.00 2.00 
  3.00 2.00 2.00 x 
  3.00 2.00 x 1.00 
  2.00 2.00 2.00 1.00 
Mean 2.50 2.25 2.00 1.33 
 
Table 6 Individual GFAP staining scores for right (ipsilateral) brain sections. 
Sections were scored 0-3 according to intensity of staining (see figure 38), x unable 
to score section. 
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A similar pattern of staining was seen in the left side of the brain, 
contralateral to the injected paw. Baseline staining with a score of 1-2 was 
seen in all control animals with the highest scores seen at 6 hours, where all 
sections scored 2 or above and 24 hours, where three out four sections 
scored 2.5-3 (see figure 40 and table 7). These increases correspond with 
the increase in paw swelling described in Chapter 5, interestingly at 72 hours, 
where there is a decrease in paw volume, there is a concurrent decrease in 
GFAP expression. Later timepoints had higher than baseline staining, with an 
increase at 7 and 14 days compared with 72 hours again correlating with the 
increases seen in paw volume. 
 
 
Figure 40 Scatter diagram of mean GFAP staining score for each rat in the left 
brain of CFA treated rats and non-injected controls. Expression is increased at 
all time points post injection. n = 4 for each animal unless otherwise indicated (see 
table 7). 
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Treatment Group Rat 1 Rat 2 Rat 3 Rat 4 
Normal  2.0 x 1.0 1.0 
  1.0 1.0 1.0 2.0 
  1.0 x 2.0 1.0 
  2.0 3.0 2.0 1.0 
Mean 1.5 2.0 1.5 1.3 
6 hour CFA 2.0 2.0 2.0 3.0 
  2.0 2.0 2.0 3.0 
  x 3.0 2.0 3.0 
  2.0 2.0 2.0 3.0 
Mean 2.0 2.3 2.0 3.0 
24 hour CFA 2.0 3.0 3.0 3.0 
  2.0 3.0 2.0 3.0 
  3.0 x 2.0 x 
  2.0 2.0 3.0 3.0 
Mean 2.3 2.7 2.5 3.0 
72 hour CFA x 2.0 2.0 2.0 
  2.0 2.0 2.0 2.0 
  2.0 2.0 1.0 2.0 
  2.0 2.0 x 3.0 
Mean 2.0 2.0 1.7 2.3 
7 day CFA x 3.0 2.0 3.0 
  2.0 2.0 1.0 3.0 
  0.0 x 2.0 3.0 
  2.0 3.0 2.0 2.0 
Mean 1.3 2.7 1.8 2.8 
14 day CFA 2.0 3.0 2.0 2.0 
  3.0 2.0 2.0 x 
  3.0 2.0 2.0 2.0 
  2.0 2.0 2.0 1.0 
Mean 2.5 2.3 2.0 1.7 
 
Table 7 Individual GFAP staining scores for left (contralateral) brain sections. 
Sections were scored 0-3 according to intensity of staining (see figure 38), x unable 
to score section.
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7.3.2 Hypoxyprobe Staining 
 
In the right side of the brain the highest level of Hypoxyprobe staining was 
seen in non-injected animals although scores here still remained low with 
only 2 rats scoring 1 or above (see figure 41 and table 8). At post-injection 
time-points the all sections were scored 1 or below, with most samples 
expressing little or no staining for Hypoxyprobe.  
 
 
 
Figure 41 Scatter diagram of mean Hypoxyprobe staining score for each rat in 
the right brain of CFA treated rats and non-injected controls. n = 4 for each 
animal unless otherwise indicated (see table 8). 
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Treatment Group Rat 1 Rat 2 Rat 3 Rat 4 
Normal 0.0 1.0 2.0 1.0 
  0.0 0.0 1.0 1.0 
  1.0 0.0 2.0 x 
  0.0 0.0 1.0 1.0 
Mean 0.3 0.3 1.5 1.0 
6 hour CFA 0.0 0.0 1.0 x 
  0.0 0.0 1.0 0.0 
  0.0 0.0 0.0 0.0 
  0.0 0.0 0.0 0.0 
Mean 0.0 0.0 0.5 0.0 
24 hour CFA x 0.0 0.0 0.0 
  0.0 0.0 0.0 0.0 
  1.0 0.0 1.0 0.0 
  1.0 0.0 0.0 x 
Mean 0.7 0.0 0.3 0.0 
72 hour CFA 0.0 0.0 0.0 0.0 
  0.0 0.0 0.0 0.0 
  1.0 0.0 0.0 0.0 
  1.0 0.0 0.0 0.0 
Mean 0.5 0.0 0.0 0.0 
7 day CFA 1.0 0.0 0.0 1.0 
  1.0 0.0 0.0 0.0 
  0.0 0.0 0.0 x 
  1.0 0.0 0.0 0.0 
Mean 0.8 0.0 0.0 0.3 
14 day CFA 0.0 0.0 0.0 0.0 
  0.0 1.0 0.0 0.0 
  0.0 0.0 0.0 0.0 
  0.0 0.0 0.0 0.0 
Mean 0.0 0.3 0.0 0.0 
 
Table 8 Individual Hypoxyprobe staining scores for right (ipsilateral) brain 
sections. Sections were scored 0-3 according to intensity of staining (see figure 
38), x unable to score section 
 
 154 
A similar pattern of Hypoxyprobe staining was seen in the left side of the 
brain, contralateral to the injected paw with two of four control animals having 
a moderate level of staining and all remaining groups showing little or no 
staining (see figure 42 and table 9). These data showed a higher variance 
than that seen in the right side of the brain with several more sections from 
injected animals showing some baseline staining. 
 
 
Figure 42 Scatter diagram of mean Hypoxyprobe staining score for each rat in 
the left brain of CFA treated rats and non-injected controls. n = 4 for each 
animal unless otherwise indicated (see table 9). 
 
 155 
 
Treatment Group Rat 1 Rat 2 Rat 3 Rat 4 
Normal 1.0 1.0 2.0 2.0 
  0.0 0.0 1.0 1.0 
  1.0 0.0 2.0 x 
  1.0 0.0 1.0 1.0 
Mean 0.8 0.3 1.5 1.3 
6 hour CFA 0.0 0.0 0.0 x 
  1.0 0.0 0.0 0.0 
  0.0 0.0 0.0 0.0 
  0.0 0.0 0.0 0.0 
Mean 0.3 0.0 0.0 0.0 
24 hour CFA x 1.0 1.0 1.0 
  0.0 1.0 0.0 1.0 
  1.0 0.0 0.0 0.0 
  1.0 0.0 0.0 x 
Mean 0.7 0.5 0.3 0.7 
72 hour CFA 0.0 0.0 1.0 1.0 
  0.0 0.0 0.0 0.0 
  1.0 1.0 0.0 0.0 
  1.0 1.0 1.0 0.0 
Mean 0.5 0.5 0.5 0.3 
7 day CFA 0.0 1.0 1.0 1.0 
  0.0 0.0 1.0 0.0 
  1.0 0.0 1.0 x 
  1.0 0.0 1.0 0.0 
Mean 0.5 0.3 1.0 0.3 
14 day CFA 0.0 0.0 0.0 0.0 
  0.0 1.0 0.0 0.0 
  0.0 0.0 0.0 0.0 
  0.0 0.0 0.0 0.0 
Mean 0.0 0.3 0.0 0.0 
 
Table 9 Individual Hypoxyprobe staining scores for left (contralateral) brain 
sections. Sections were scored 0-1 according to intensity of staining (see figure 
38), x unable to score section.  
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7.4 Discussion 
 
7.4.1 GFAP Expression 
 
The results of GFAP staining are concurrent with those of Chapters 6 and 7, 
increased staining was seen at 6 and 24 hours and 7 and 14 days post-
injection, corresponding with an increase in paw swelling and release of 
inflammatory mediators that has been described at these time points. 
Interestingly, these increases in activation were seen in both sides of the 
brain and not just in the left side, contralateral to the injected paw. The 
increase in GFAP expression in the right side of the brain, particularly at later 
time points, corresponds to the development of hyperalgesia in the left paw 
described by Raghavendra et al (2004), no increase in swelling was evident 
in the left paw of injected rats at this time point but given the evidence it 
seems likely that an increase in hyperalgesia and allodynia would have 
developed which would be followed by an increase in paw volume. This 
supports the hypothesis that glial cell cross talk within the brain contributes to 
the development of referred pain. If inflammatory changes can contribute to 
these sensory changes it is likely that alterations in brain morphology may 
also be contributing to brain changes that lead to the development of the 
motivational-effective symptoms of chronic pain. 
 
It is interesting that some differences were seen between the left and right 
sides of the brain here when no difference was observed in Chapter 6, there 
are several possible explanations for this; Firstly, in these 
immunohistochemical studies a thin section from the middle of the brain was 
used meaning a very specific area of the brain was studied. In the PCR 
experiments of Chapter 6 a larger region was homogenised and finer 
changes may have been lost. Together these results suggest that throughout 
the mid-brain regions there are variations in expression of inflammatory 
markers on both the ipsilateral and contralateral side to the peripheral insult. 
Secondly in this study the activation of astrocytes was measured through the 
expression of GFAP, in Chapter 6 mRNA expression was measured, it is 
possible that mRNA for inflammatory mediators is produced on both sides of 
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the brain in response to painful inflammation in the periphery but transcribed 
and released differentially depending on sensory input and glial activation. 
Finally, as discussed in 2.2.1, astrocytes are not the only cells involved in the 
immune response within the CNS, the microglia are also known to play a key 
role and may be differentially activated to the astrocytes in this model. 
 
7.4.2 Hypoxyprobe Staining 
 
The results of the Hypoxyprobe immunohistochemistry were largely 
unexpected with the highest levels of staining observed in the non-injected 
controls. An explanation for this may be that a mild state of hypoxia is 
induced in the tissues following termination prior to perseveration by freezing, 
which remains evident in non-injected controls. Inflammation can be 
associated with the release of reactive oxygen species (ROS) which can lead 
to oxidative damage, a process which has been demonstrated to play a role 
in neurodegenerative diseases such as Alzheimer’s and Parkinson’s. One 
hypothesis is that ROS are released in the brain during the acute and sub-
acute stages of this pain model reversing the hypoxia that is seen in non-
injected animals. At later stages hypoxia may be seen due to swelling or 
tissue damage within the brain as a result of the longer term inflammatory 
insult. 
 
7.4.3 Conclusions 
 
The results presented in this chapter warrant further investigation. The 
evidence provided here suggests a key role for GFAP in the response to 
inflammatory pain which may vary in different brain areas. The Hypoxyprobe 
results, although slightly inconsistent, indicate that there is variation in 
oxygenation levels within areas of the brain in persistent pain and a role for 
ROS within the CNS in chronic pain has been suggested. 
 
Due to difficulties with staining it was not possible to do in depth statistical 
analysis using these tissues nor was it possible to consistently locate specific 
nuclei within brain regions. It is likely that further experiments would benefit 
 158 
from using perfused wax embedded tissue, a method that would allow for 
finer sections to be cut leading to a clearer result suitable for image analysis. 
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Chapter 8 
 
8 Methodology: The Development of a 
Primary Cell Culture Protocol 
 
8.1 Introduction 
 
In this chapter a method for the culture and characterisation of primary cell 
lines was developed to be used in future experiments. Due to time 
constraints it was not possible to use the protocol further, the development of 
the method is described here. 
 
8.2 Materials and Methods 
 
8.2.1 Materials 
 
Glutamine, poly-l-lysine solution and poly-l-lysine hydrobromide (Sigma-
Aldrich CO Ltd., Poole, UK). Sterile distilled water, Ca2+ and Mg2+ free HBSS, 
10mM HEPES (pH 7.4)Neurobasal, B27 supplement, trypan blue, trypsin 100 
U/ml penicillin and 100 µg/ml streptomycin (Invitrogen Ltd, Paisley. UK).  
 
8.2.2 Optimisation of primary cell culture 
 
The following method is based on that set out by Banker and Goslin (Banker 
& Goslin 1998) and was developed over a series of pilot experiments.  
 
8.2.2.1 Coverslip preparation 
 
To enable the cells to be used in further experiments such as in 
immunohistochemistry they are grown on coverslips within six well plates.  
This allows easy treatment and maintenance and also allows for simple 
transfer of the cells for further experimentation. 
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In order for isolated to cells to grow in vitro they require a substrate to grow 
on to allow them to attach, for neurons poly-L-lysine is the most commonly 
used.  Initial experiments were done using poly-l-lysine hydrobromide in 
1mg/ml solution of distilled water which was then filter sterilised.  Although 
this produced some satisfactory results making up solutions was time 
consuming and the risk of contamination quite high.  It was therefore decided 
to do future work with a pre-prepared and sterilised solution (Sigma), this 
enabled greater consistency and ease of use across experiments and the 
solution is more stable and easier to store than poly-L-lysine hydrobromide. 
 
Coverslips (22mm2) were sterilised by autoclave and then placed in six well 
plates.  Slips were then coated with poly-L-lysine solution (1mg/ml, Sigma), 
approximately 0.5ml was added to each well and the plate rocked to evenly 
cover each slip.  In order to allow the solution to adhere to the slips, plates 
were then incubated at 37˚C overnight. The following day any excess poly-L-
lysine was removed by aspiration and plates were washed three times for 30 
minutes each wash in sterile distilled water (Gibco/Invitrogen), this step is 
essential as excess poly-L-lysine can prove toxic to the cells. If plates were 
not used immediately they were kept under sterile water at 2-8˚C until 
needed. 
 
According to the original method of Banker and Goslin (Banker & Goslin 
1998) the ideal media for culturing neurons is Eagles minimum essential 
medium with hormones and N2 supplements added. The cells then had to be 
plated with an astrocyte ‘feeder layer’ to provide some of the essential growth 
factors they needed. Over recent years media and supplements have been 
developed specifically for the growth of primary cultures of embryonic 
neurons (Brewer et al. 1993; Brewer 1995) which remove the need for a 
feeder layer In this work Neurobasal (Invitrogen) medium was used 
supplemented with the B27 serum free supplement (Invitrogen) containing 
growth factors and nutrients essential for neuronal growth and development. 
The media was also supplemented with 100 U/ml penicillin and 100 µg/ml 
streptomycin (Invitrogen) to help prevent infection and 2mM L-Glutamine as 
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this essential amino acid which is unstable in media and breaks down in 
media kept over long time periods. 
 
On the day of isolation water was removed from the plates by aspiration and 
4ml of plating media (as described above) added to each well. Plates were 
then incubated at 37˚C/5% CO2 until needed (for at least 30 mins), this 
incubation is essential to allow the media to stabilise at the correct pH and 
temperature to maintain the cells. 
 
8.2.2.2 Cell isolation and plating 
 
All animals used were from the University of Bath breeding colonies and 
were kept in the animal house with a twelve hour light dark cycle and free 
access to food and water. 
 
Neuronal culture can be done using cells from adult rats (Brewer 1997) 
however this is a more difficult and time consuming procedure with 
inconsistent results. Neurons in an adult brain have formed a complex matrix 
with many connections to one another and other cells within the brain. 
Disturbing this matrix by dissection causes damage to the delicate cells and 
disrupts extracellular connections therefore, most culture of hippocampal 
neurons is done using foetal cells. Between 17 and 21 days gestation (E17-
E21) has been demonstrated to produce optimum results (Banker & Goslin 
1998) and initial experiments here were done at E18. The dissection proved 
difficult with rats of this age and it was decided to use rats at E19 in future 
work.  
 
A timed pregnant Sprague Dawley rat (E19) was euthanised by CO2. 
Foetuses were removed by caesarean section and decapitated, heads were 
then placed in sterile Ca2+ and Mg2+ free HBSS supplemented with 10mM 
HEPES (pH 7.4) and the brains removed. Brains were placed in a sterile 
Petri dish with fresh HBSS/HEPES and kept on ice (see figure 43). The 
buffer prevents damage to the cells by osmotic and pH challenge, it is 
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essential that this part of the protocol is completed as fast as possible to 
prevent degradation of the tissues. 
 
 
 
Figure 43 An E19 foetal rat brain the ventral view on the left and the dorsal on 
the right. The arrows indicate the circle of Willis, a formation of blood vessels that 
separates each of the cerebral hemispheres from the diencephalon.  
 
 
 
Figure 44 Schematic representation of the dissection process. 1) A ventral view 
of the brain, the cerebral hemispheres are removed by cutting along the circle of 
Wills and down the midline. 2) The location of the hippocampus within the left 
hemisphere viewed from the midline. Following careful removal of the meninges the 
hippocampus is dissected out using Dumont forceps. 3) The free hippocampus. 
 
Using a dissecting microscope hippocampi were dissected out and placed in 
sterile HBSS/HEPES and again kept on ice (see figure 44).  
Olfactory bulb 
Cerebral hemisphere 
Circle of Willis 
Cerebellum 
Diencephalon 
1) 2) 
3) 
Hippocampus 
O.B. 
Olfactory bulb Cerebral hemisphere 
Cerebellum 
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Once all the hippocampi had been removed, they were transferred to a 
centrifuge tube and the volume made up to 4.75ml with HBSS/HEPES.  
 
Trypsin (250µl 5% Invitrogen) was added and hippocampi incubated at 37˚C 
for 10 mins. This allows for enzymatic degradation of the tissue into individual 
cells. Incubating the cells for too long can cause damage and too little time 
causes the cells to grow in clumps where it is impossible for them to develop 
properly (see figure 45). Following incubation the trypsin/buffer solution was 
removed and the hippocampi were washed twice with HBSS/HEPES and 
once with plating medium (5 minutes each wash) to allow all trypsin to diffuse 
from the tissue and prevent further degradation. 
 
 
Figure 45 Cells 7 days in culture after inadequate trypsinisation. Many cells are 
clumped together extending multiple axons between clumps. The cells in the centre 
of the clumps will be starved of nutrients and are unable to form axons and 
dendrites. 
 
The contents of the tube were then made up to ~4ml and triturated using a 
1ml Gilson pipette for approximately 2 mins to mechanically break the tissue 
down into individual cells. Viable cells were counted using an exclusion 
assay. 10µl of trypan blue (Invitrogen) was added to 10µl of the cell 
suspension and incubated for 2 mins. Damaged cells absorb the dye and so 
appear blue, viable cells were then counted using a haemocytometer and 
approximately 50,000-80,000 cells plated in each well depending on the 
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experiment. Plates were briefly swirled to evenly distribute cells and then 
incubated at 37˚C 5% CO2. 
 
Cell growth was monitored and at approximately day three after plating half 
of the media was removed from each well and replaced with media 
supplemented with cytosine arabinoside (to a final concentration of 10µM 
ara-c) to inhibit glial proliferation. Cells were maintained at 37˚C/5% CO2 for 
up to one month with half their media replaced once a week. 
 
In order to ensure the accuracy of the isolation and culture protocol the cells 
must be ‘characterised’, this involves looking at the cell structure and general 
morphology along with identification of certain key proteins or products. In 
this case pyramidal cells are fairly easy to identify by their specific shape of a 
pyramidal shaped body with a single axon and long branching dendrite (see 
figure 4 (bottom) and figure 47). Cells were also stained with neuron specific 
antibodies, the development of the protocol used is described in the following 
section. 
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Figure 46 Individual cells immediately after plating (top) and after five days in 
culture (bottom). 
 
8.3 Optimisation of Immunocytochemistry 
 
Immunohistochemistry is an excellent tool for identifying and characterising 
cell lines. Here the aim was to characterise the cells from primary rat 
hippocampal cultures, as both glial and neuronal cells are found in the 
hippocampus and it is important to know the ratio of each in the culture. 
Characterisation of the cells also serves as a check of the accuracy of the 
dissection process and the success of the culture procedure in general.  
 
Selection of antibodies is key to ensure that they are specific to the individual 
protein and that they are the correct antibody for the method. When using 
multiple antibodies for double or triple staining it is important that they have 
all been raised in different species so as to avoid cross-reactivity. The 
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antibodies used here were all supplied by Abcam and their specificity and the 
rationale for using them is described below: 
 
8.3.1 Materials: Primary antibodies 
 
8.3.1.1 Glial fibrillary acidic protein (GFAP) 
 
GFAP is a component of glial cells, it was identified as being specific to these 
immunological cells and is not found in neurons. It is expressed in astrocytes 
in brain tissue and in the Schwann, satellite and enteric glial cells of the 
peripheral nervous system. Here anti-GFAP is used to identify the purity of 
the culture since for most experiments only neurons are required and to 
identify the best method for achieving pure cultures. 
 
8.3.1.2 Growth associated protein 43 (GAP43) 
 
As its name suggests, GAP43 is expressed in growing and regenerating 
neurons it is expressed within the axonal cytoplasmic surface and the growth 
cones of extending axons. It is sometimes also expressed in reactive glial 
cells. As such its expression is greater during early stages of neuronal 
development and following damage. The aim here is to use it to characterise 
neurons initially and in future experiments it may prove useful when looking 
at growth and development of neurons following treatment. 
 
8.3.1.3 Microtubule associated protein 2 (MAP2) 
 
MAP2 is the major microtubule associated protein of brain tissue. There are 
three forms of MAP2 (MAP2a MAP2b and MAP2c), MAP2b and MAP2c are 
present in the newborn rat brain but MAP2a does not appear until between 
postnatal days 10 and 20. At the same time, the level of MAP2c drops by 10-
fold, this change happens during the period when dendrite growth is 
completed and when neurons have reached their mature morphology. MAP2 
is known to promote microtubule assembly and to form side-arms on 
microtubules. It also interacts with neurofilaments, actin, and other elements 
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of the cytoskeleton. The antibody chosen is known to react with both MAP2a 
and MAP2b making it a good indicator of neuronal differentiation. 
 
8.3.2 Materials: Secondary antibodies 
 
Two secondaries were used since both GFAP and GAP3 were raised in 
rabbit and all double staining was done with the MAP2 antibody (raised in 
mouse) and one or other of these. The antibodies were conjugated to 
fluorescent proteins Rhodamine and FITC. Rhodamine fluoresces red when 
excited at 546nm and FITC green at 450nm. 
 
8.3.3 Development of protocol 
 
In order to obtain the best results it is necessary to identify the ideal antibody 
concentration for any particular cell line and technique. This is done by using 
a gradient of both the primary and secondary antibody concentrations and 
identifying the best end result. Too low a concentration and the protein will 
not be picked up at all and too high a concentration can lead to excessive 
background and nonspecific staining making ‘true’ results difficult to identify. 
 
As well as this other factors such as the fixation, permeabilisation and 
blocking steps all need to be carefully selected to optimise results. It is 
important that these steps do not destroy or lose the protein of interest, 
membrane bound proteins can be lost in permeabilisation and certain fixation 
methods can be damaging to some proteins. The following protocol is the 
basic method used, the results obtained with the different antibodies are then 
described along with the subsequent changes made in the protocol. 
 
8.3.4 General protocol for ICC  
 
8.3.4.1 Fixation 
 
Media was aspirated and cells rinsed twice with Phosphate buffered saline 
(PBS). Cells were then fixed by incubation in ice cold 1:1 methanol/acetone 
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for five minutes. The methanol mixture was aspirated and cells washed twice 
for five minutes each in ice cold PBS. 
 
8.3.4.2 Permeabilisation 
 
PBS was aspirated and cells incubated for ten minutes in PBS with 0.5% 
Triton X-100 (PBST). The PBST was removed and cells washed three times 
in PBS for five minutes each wash. 
 
8.3.4.3 Blocking and incubation with primary antibodies 
 
Single stain 
Cells were incubated with 10% normal serum from the species in which the 
secondary antibody was raised (goat or sheep) in PBST for thirty minutes at 
room temperature. The block was then removed and the primary antibody 
was added made up in blocking solution. Cells were then incubated over 
night at 2-4°C. 
 
Double stain 
Cells were incubated with 1% bovine serum albumin (BSA) in PBST for thirty 
minutes at room temperature. The block was then removed and a mixture of 
the two primary antibodies (raised in different species) in blocking solution 
was added. Cells were incubated overnight at 2-4°C. 
 
8.3.4.4 Secondary antibodies 
 
The primary antibody solution was decanted and the coverslips washed three 
times for five minutes in PBS. Cells were then incubated with the secondary 
antibody (or a mixture of both secondary’s for double staining) made up in 
block for one hour at room temperature, this step must be done in the dark 
when using fluorescent antibodies.  The secondary solution was then 
removed and the coverslips washed three times for five minutes in PBS (also 
in the dark if necessary). 
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8.3.4.5 Counter staining and mounting 
 
Coverslips were mounted onto superfrost slides with vector fluorescence 
hard mount containing 1.5µg/ml DAPI as a counterstain and viewed under a 
fluorescent microscope. 
 
8.3.5 Optimisation of antibodies 
 
8.3.5.1 GAP43 and MAP2 single staining 
 
In order to find the ideal concentration of each antibody a range of 
concentrations was tested based on the concentration suggested by the 
manufacturer. Cells were stained three weeks after plating. The table below 
shows the range tested: 
 
Primary 1/200 1/500 1/1000 
Secondary 1/200 1/200 1/200 
Secondary 1/500 1/500 1/500 
Secondary 1/1000 1/1000 1/1000 
 
Table 10 Antibody concentrations used during antibody optimisation. 
 
The results of the initial experiment were not ideal. No staining was seen with 
the GAP43 antibody and MAP2 results were inconsistent so it was not 
possible to decide on an optimum concentration for each of these antibodies. 
The experiment was repeated with cells two weeks after plating and the 
permeabilisation step was omitted as it may have destroyed some of the 
membrane GAP43 protein.  
 
Again GAP43 staining was unsuccessful, MAP2 was shown to be present in 
the dendrites, axons and cell bodies of the neurons and it was possible to 
compare the different concentrations. The clearest stain with the least 
background was evident with both primary and secondary antibodies at a 
concentration of 1/200 (see  ). 
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Figure 47 MAP2 antibody optimisation. The right hand picture shows the chosen 
concentration (both antibodies 1/200). The left picture shows an example of less 
effective staining (primary 1/1000, secondary 1/200). 
 
8.3.5.2 GAP43 single stain 
 
A third attempt to obtain a result with the GAP43 antibody was made, as it is 
a growth associated protein it was decided to use cells that were only four 
days in culture. High expression of this protein would be expected in the 
growth cones of developing axons at this age. The permeabilisation step was 
again omitted and 100% methanol was used for fixation. Staining was 
observed in the growth cones and developing axons (see figure 14) and an 
optimum concentration of 1/1000 for the primary antibody and 1/500 for the 
secondary was decided on. 
 
This antibody is not ideal for general characterisation as it seems only to be 
expressed at certain stages of neuronal development. It may be useful in 
experiments studying growth, differentiation and recovery of damaged 
neurons since increased expression would be expected in these conditions. 
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Figure 48 GAP43 staining. An example of GAP43 staining in a cell at four days in 
culture. There is expression in the cell body and along the axons. The growth cone 
is brightly stained at the top of the picture. 
 
8.3.5.3 GFAP optimisation 
 
This antibody was also tested at the concentrations listed above. Good 
results were obtained at all concentrations but at the higher end of the 
spectrum a large amount of background was seen. It was therefore decided 
that a concentration of 1/1000 for the primary and 1/500 for the secondary 
antibodies should be used. Figure 49 shows excellent staining of the cell 
body and dendrites of a glial cell at these concentrations. 
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Figure 49 GFAP staining. A glial cell stained for GFAP. The nucleus is stained blue 
with DAPI. 
 
8.3.5.4 Double staining 
 
Following optimisation of the antibodies for single staining they were used in 
a double staining protocol. The results of which are shown in Figure 50. The 
GFAP/MAP2 staining clearly shows the different structure of glial and 
neuronal cells and there is no evidence of these proteins staining the same 
cell type. This suggests that these antibodies are excellent tools for the 
characterisation of these cell types. Again the GAP43 antibody produced 
inconsistent results. 
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Figure 50 Double staining for GFAP and MAP2. Glial cells are stained red and 
neurons green. The difference in structure of the two cell types is also clear with the 
glial cells having a stellate structure and the neurons elongated axons with long 
branching dendrites. 
 
8.4 Discussion 
 
This protocol provides allows for the culture of primary neurons this is 
beneficial compared with cell lines as such neurons express full functionality 
and the features that would be seen in vivo. 
 
The GFAP and MAP2 antibodies tested here provide excellent markers for 
glial and neuronal cells respectively. As such they can be used to investigate 
the purity and viability of hippocampal primary cultures. The GAP43 antibody 
tested produced inconsistent results, this can in part be attributed to the age 
of the cultures tested and another double staining experiment needs to be 
done with ‘younger’ cells. 
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Chapter 9 
 
9 General Discussion and Further Work 
 
9.1 Discussion 
 
The aim of these studies was to investigate the effect of persistent 
inflammatory pain on the brain with a specific focus on inflammatory 
molecules and a potential role for hypoxia. A large body of existing evidence 
has demonstrated a role for inflammatory mediators within the spinal cord in 
both neuropathic and inflammatory pain but only a few studies exist which 
investigate changes within supraspinal regions (Raghavendra et al., 2004, 
Apkarian et al., 2006). 
 
As discussed in the introductory chapters, chronic pain is associated with 
many symptoms which cannot be explained by the physical injury itself, 
indeed, chronic pain can exist without any apparent physical injury. These 
motivational-affective aspects of pain most significant problems to the 
researcher as they are often subjective and related to other conditions such 
as depression, anxiety and neurodegenerative disease. Physical correlates 
of changes in brain chemistry, such as changes in cortical representation, 
have been measured previously in human subjects and animal models but 
many of the molecular mediators of these changes have yet to be identified 
(Apkarian et al., 2004b, Apkarian et al., 2004a, Apkarian et al., 2005, 
Grachev et al., 2000). It has been suggested that chronic pain could be 
described in terms of memory, where the pain felt is a “memory” of the initial 
response to tissue injury which for some reason has become more 
permanent and is maintained by substantial reorganisation within the CNS 
(Apkarian et al, 2008). Inflammatory mediators have been associated with 
learning and memory and as such may contribute to the development of this 
memory and some of the associated physical and psychological symptoms 
(Ross et al., 2003, Wang et al., 2000, Zeise et al., 1992). 
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9.1.1 Questionnaire studies 
 
In chapter 4 data was analysed from questionnaires investigating some of the 
more unusual symptoms seen in CRPS, although the cause of this condition 
is unknown, dysregulation within the CNS has been implicated (Birklein, 
2005). Although the design of the study had some flaws it is still possible to 
conclude that some degree of cortical reorganisation occurs in CRPS due to 
the prevalence of reported referred sensations and related symptoms.  
 
These results also emphasised many of the significant “non-painful” 
symptoms in CRPS which are often overlooked both in this and many other 
conditions. More research into these symptoms, which have many similarities 
to conditions involving neurodegeneration and inflammation within the CNS, 
is vital to provide better insight into the role of the CNS in chronic pain. Such 
research may open up new avenues in treatment strategies for chronic pain 
patients focussing, not only on the “sensory-discriminative” elements of the 
condition, but also on the “motivational-affective” symptoms. 
 
The results of this work prompted the design of an animal model to 
investigate the effect of persistent inflammatory pain on the brain.  
 
9.1.2 Development of an animal model 
 
Two inflammatory models were investigated in Chapter 5 using CAR and 
CFA to induce unilateral footpad inflammation in order to develop a pain 
model that would persist for at least two weeks. CAR and three 
concentrations of CFA were compared. Consistent with previously published 
data CAR swelling peaked at three hours post-injection and rapidly returned 
to baseline, this swelling has been demonstrated to correlate with the 
development and cessation of hyperalgesia and allodynia and as such this 
was not considered a suitable pain model for this study (Morris, 2003, 
Iadarola et al., 1988) since these parameters return to baseline by 7 days 
post-injection (see figure 14).  
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CFA injection produced a more persistent and significant increase in paw 
volume and the 0.1% concentration was chosen as this produced 
significantly different results to CAR, 0.1% and 1%CFA and persisted for 7 
days with no apparent systemic involvement (see figures 13, 15, 16 and 19). 
Also previous work has demonstrated that at this concentration swelling 
correlates with hyperalgesia and allodynia with all parameters measures 
showing an initial peak at 6-24 hours post-injection followed by a decrease to 
72 hours and a gradual increase to 14 days and beyond (Stein et al., 1988). 
It is hypothesised that the initial peak is the result of an acute inflammatory 
response to a foreign substance, as seen in the CAR model, which rapidly 
subsides resulting in a minor decrease in paw volume at 72 hours. From 72 
hours post-injection swelling increases up until at least 7 days as a result of 
the cell mediated immune response which has been shown to continue for up 
to one month (Stein et al., 1988, Raghavendra et al., 2004, Nagakura et al., 
2003). This model was then used to investigate the gene expression of a 
variety of inflammatory mediators using RT-PCR. 
 
9.1.3 Cytokine mRNA Expression 
 
The cytokines IL1β and TNFα were chosen because they have previously 
been demonstrated to play a role in mediating pain responses in the spinal 
cord as well as being up regulated in certain brain regions in both 
neuropathic and inflammatory pain models, they are also known modulators 
of both neuronal and glial function (Ross et al., 2003, Wang et al., 2000, 
Ignatowski et al., 1999, Covey et al., 2000). The profile of IL1β expression 
was not as expected with no increase seen until 7 and 14 days post-injection, 
in fact, there was a drop in expression in the posterior regions of the brain at 
6 -24 hours post-injection (see figures 27 and 28). Interestingly, a similar 
pattern was seen with TNFα expression (see figures 30 and 31), TNFα is 
known to mediate IL1β expression so one potential hypothesis is that the 
drop in TNFα is limiting excessive IL1β release. However, there was one 
significant anomaly in the expression profile of TNFα mRNA; a large increase 
was seen 72 hours post-injection in the right posterior region of the brain 
which had no apparent effect on IL1β expression. The increase in TNFα is 
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unlikely to be due to activation of ascending neurons and subsequent glial 
activation since sensory information from the injected paw is represented on 
the left side of the brain. Therefore it is proposed that this upregulation of 
TNFα mRNA is the result of activation in descending pathways which may 
act to increase or decrease the nociceptive process in the injured paw. The 
overall decrease in IL1β and TNFα mRNA seen in the early time points may 
be some form of endogenous analgesia, or an attempt to protect the brain 
from the increased input from the spinal cord. 
 
The elevated levels of IL1β mRNA seen at 7 and 14 weeks imply that this 
cytokine plays a role in the modulation of longer term pain. As mentioned 
above IL1β is known to have a significant effect on learning and memory, it is 
hypothesised that here the cytokine is contributing to LTP and the 
development of a pain memory which could ultimately result in chronic pain. 
 
It is also possible that persistent low-grade peripheral inflammation has 
gradually decreased the integrity of the blood brain barrier over time so that 
by 7 to 14 days post-injection cytokines circulating within the periphery are 
entering the CNS. 
 
9.1.4 Chemokine mRNA Expression 
 
This work provides the first evidence for a change in the expression of the 
chemokine fractalkine (CX3CL1), its receptor (CX3CR1) and another 
chemokine, growth related oncogene (CXCL1) in the brain in a model of 
persistent pain (see figures 32-37). Both have previously been implicated in 
regulation of pain at the level of the spinal cord and in the periphery and 
altered expression in the brain in neurodegenerative disease has previously 
been reported (Baliki et al., 2003, Axen and Porath, 1966, Cunha et al., 2008, 
Han and Neugebauer, 2005, Milligan et al., 2005). A large increase in CXCL1 
mRNA expression was seen at 6 hours post-injection suggesting this 
chemokine is involved in the acute response to a painful stimulus.  
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CXCL1 release has been associated with an increase in astrocyte activation 
in multiple sclerosis (Omari et al., 2005) and an increase in astrocyte 
activation was indeed seen here at 6 hours, however, although CXCL1 
mRNA expression decreased significantly at 24 hours post-injection GFAP 
staining for astrocyte activity remained high. This may be due to negative 
feedback mechanisms resulting from a large release of CXCL1, it is also 
possible that the protein is still being released from activated astrocytes at 
this time point but that mRNA synthesis has decreased. A third suggestion is 
that the CXCL1 is released as an acute protective response to the initial 
insult since, in multiple sclerosis for example, this chemokine has been 
suggested to have a protective role against neurodegeneration (Omari et al., 
2005). 
 
It should be noted, however, that the incredibly rapid increase in CXCL1 
mRNA expression described here may not be a direct result of the peripheral 
inflammation but a response to the mechanical insult of the injection itself. If 
this were the case then it could not be said this chemokine plays a role in 
inflammatory pain specifically but that it is involved in the CNS response to a 
painful insult. This hypothesis could be investigated with the addition of an 
injected control group. 
 
This is the first evidence of differential expression of CX3CL1 and its receptor 
CX3CR1 in the brain in a persistent pain model. Furthermore, in previous 
models, where alterations in Fractalkine regulation have been demonstrated 
within the spinal cord, there is an increase in both the chemokine and its 
receptor whereas here a significant decrease was seen in the posterior 
regions of the brain at 6 hours post-injection with levels remaining low until 7 
days post-injection. It may be that the decrease in expression seen here is 
due to down regulation of the ligand and receptor due to negative feedback 
as a result of release of fractalkine from stimulated neurons.  
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9.1.5 Hif1α Gene Expression 
 
No significant differences were seen in expression of Hif1α mRNA 
expression (see figure 29). As well as playing a role in inflammation Hif1α 
has been implicated in regulating memory formation in healthy mice and as 
such may contribute to the formation of altered pain pathways (Adamcio et 
al., 2010). Although no real increase was seen here it is possible that in a 
pathological situation the increase would be greater. Hif1α is normally 
expressed in an unstable form under normoxic conditions where it is 
constantly degraded by the enzyme HIF prolyl-hydroxylase which uses 
oxygen as a substrate (Semenza, 2004), under hypoxic conditions Hif1α is 
stabilised due to inactivation of HIF prolyl-hydroxylase. It has recently been 
shown that Hif1α is also modulated by nuclear factor κB under normal 
oxygen pressure and that TNFα can regulate this process (van Uden, 
Kenneth, Rocha 2008), these findings suggest that Hif1α may play role in the 
regulation of pain within the CNS even in the absence of hypoxia. Further 
investigation of the expression of HIF 1 α and related molecules at the 
protein level may provide further evidence of a role in regulating pain and 
inflammation. 
 
9.1.6 GFAP Expression 
 
Within both sides of the brain GFAP expression, as measured by 
immunohistochemistry was upregulated at all time points post-injection other 
than 72 hours with the highest upregulation seen at 24 hours and 14 days 
post-injection (see figures 39 and 40 and tables 6 and 7). This expression 
profile correlates with the profile of paw swelling described in Chapter 5 and 
reported measurements of hyperalgesia and allodynia in previous work.  
 
The increase in activated GFAP on both sides of the brain is evidence to 
suggest that it may be representative of an increase in glial cross-talk within 
the CNS, indeed, Raghavendra et al (2004) reported an increase in 
hyperalgesia in the non-injected/contralateral paw at 14 days post-injections 
suggesting that these CNS alterations are having a behavioural effect. This 
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communication and spreading of activity within the inflammatory cells within 
the CNS is likely to be a key component in the plasticity seen in chronic pain 
within this region, increasing glial activation has a significant effect on 
neuronal activity and the release of inflammatory mediators may contributed 
to LTP. 
 
9.1.7 Hypoxyprobe Expression 
 
Although the results of Hypoxyprobe immunohistochemistry were 
unexpected, with the highest levels of hypoxia observed in the non-injected 
controls, they provide evidence towards an interesting hypothesis. If hypoxia 
is induced in non-injected controls, but not CFA treated animals, as a result 
of the experimental method something must be reversing this hypoxia in 
CFA-treated animals. Inflammation can be associated with the release of 
reactive oxygen species (ROS) which can lead to oxidative damage, a 
process which has been demonstrated to play a role in neurodegenerative 
diseases such as Alzheimer’s and Parkinson’s (Higgins et al., 2010).  
 
One hypothesis is that ROS are released in the brain during the acute and 
sub-acute stages of this pain model, in response to the increase in 
inflammatory mediators from activated astrocytes and potentially microglia, 
reversing the hypoxia that is seen in non-injected animals. At later stages 
hypoxia may be seen due to swelling or tissue damage within the brain as a 
result of the longer term inflammatory insult. The release of ROS may also 
contribute to the early stages inflammation and provides a potential 
mechanism for the neurodegeneration described by previous authors 
(Apkarian and Scholz, 2006, Apkarian et al., 2004b). 
 
9.1.8 Conclusions 
 
The results presented here provide some interesting insights into changes in 
the brain seen as a result of peripheral inflammatory pain and certainly 
warrant further investigation. The first evidence for differential regulation of 
the chemokines CXCL1 and CX3CL1 is presented providing a potential 
 181 
mechanism for neuronal-glial communication with the brain. A role for 
differential regulation of oxygenation is also discussed due to changes seen 
in expression of a cellular hypoxia marker, Hypoxyprobe.  
 
Although these and related results provide an insight into the process of pain 
regulation it is important to note that any processes observed here and in 
similar publications are models of the pain response in normal animals. 
Although they are excellent models to identify potential biomarkers of pain, it 
is likely that, in the chronic condition, the processes described here are 
dysregulated. For example, perhaps in chronic pain CXCL1, seen here to be 
up regulated in the acute phase, remains elevated leading to a persistent 
response even after healing. For this reason it is important to endeavour to 
link animal and cell based studies with clinical trials wherever possible. 
 
9.2 Further Work 
 
To further expand this work it would be interesting to compare and 
inflammatory model (such as asthma/allergy) with an inflammatory pain 
model to ascertain if the effects seen are due to the pain itself or the 
inflammatory response induced by CFA. Adding a control group of saline 
injected animals would make it possible to elucidate whether acute changes 
in brain chemistry, as seen here with CXCL1, are in response to the acute 
painful stimulus of the injection itself or are due to an early inflammatory 
response to the inflammogen. Building on this it would also be of benefit to 
compare a neuropathic pain model with inflammatory pain. 
 
Further immunohistochemical studies, perhaps using perfused wax 
embedded tissue, would allow for more precise identification of specific 
alterations within the brain and better comparisons between the left and right 
hemispheres. In combination with this, real time PCR on specific regions (for 
example, ACC, Insular cortex, thalamus) isolated by microdissection may 
help build on the expression profile of inflammatory mediators described 
here. As well as measuring the cytokines and chemokines discussed in this 
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work it would also be of interest to measure expression of ROS to find out if 
they are indeed increased in pain models as postulated here. 
 
Utilising the cell model described in Chapter 8 several studies could be 
performed to identify some of the mechanistic processes behind the 
differential release of inflammatory mediators. It would be interesting to 
investigate the effects of both CXCL1 and CX3CL1 on the release of IL1β 
and TNFα and HIF1α expression and of these inflammatory mediators on 
ROS expression. To investigate the potential role for hypoxia in regulating 
inflammatory mechanisms within the CNS experiments could be carried out 
in varying oxygen tensions. 
 
Interventional studies need to be performed in order to elucidate the 
regulatory mechanisms behind the changes in CNS chemistry described 
here. Administration of the glial inhibitor minocycline at various time points in 
the animal model described here would identify which, if any, inflammatory 
modulators are released as a result of glial activation. A beneficial role for 
minocycline would be of significant interest in this and related areas of 
research as it is already approved for use as an antibiotic and has excellent 
blood brain barrier penetration making it a potential candidate for the 
treatment of chronic pain. 
 
Finally, when a potential biomarker of a painful condition is described in an 
animal or in vitro model it does not necessarily translate to what is seen in 
the human condition. Wherever possible such models should be combined 
with data from human experiments, of significant benefit here would be 
obtaining profiles of inflammatory mediators form the CSF of chronic pain 
patients. This would provide evidence of circulating biomarkers within the 
CNS in order to identify potential drug targets based on the molecules 
identified through basic science. 
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